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Chapter 1  
Introduction 
 
G Protein-Coupled Receptors (GPCRs) 
The G Protein-Coupled-Receptors comprise a superfamily of integral membrane 
proteins of which there are more than 1,000 known.
1
 GPCRs are essential components of 
cellular communication, conveying extracellular messages through interaction with 
cytokines, hormones, odorants, peptides, small molecules, and neurotransmitters just to 
name a few.
1, 2
 Their multitude and diversity make them highly-desirable targets for the 
pharmaceutical industry, capturing almost 50% of the current therapeutics market.
3, 4
 
However, despite their diversity, all GPCRs are composed of seven transmembrane 
helices that contain an extracellular N-terminal tail and an intracellular C-terminal tail 
and are connected by three extracellular and three intracellular loops. The GPCRs are 
coupled to a heterotrimeric intracellular G protein composed of α, β, and γ subunits. 
Following receptor activation, guanosine diphosphate (GDP) of the inactive G-protein is 
exchanged for guanosine triphosphate (GTP), thus activating the G protein. After 
exchange, the α, and βγ subunits dissociate and interact with their downstream effectors, 
producing a myriad of signaling events resulting in physiological processes such as 
inflammatory response, cellular differentiation, and neurotransmission.
5
  
The downstream effectors activated by a GPCR are dependent on the 
heterotrimeric G protein it is coupled to. The large variety of α, β, and γ subunits provide 
a multitude of possibilities, often leading to a simplified categorization based on the type 
of Gα subunit it couples to.
3
 The G proteins include four subfamilies: Gαs, Gαi, Gαq, and 
Gα12/13
6
 that are classified based on the signaling pathway controlling second messenger 
production and gene expression they activate (or inactivate). Gαs and Gαi affect adenylyl 
cyclase (AC) production, which in turn affects cyclic adenosine 3′,5′-monophosphate 
(cAMP) levels. Gαs stimulates AC production and which increases cAMP levels, whereas 








 ion channels. Gαq activation results in the stimulation of 
phospholipase Cβ (PLCβ), an enzyme that cleaves phosphatidylinositol 4,5-bisphosphate 
(PIP2) to afford messengers inositol 1,4,5-triphospate (IP3) and diacylglycerol (DAG). 
Lastly, the Gα12 protein family, which includes Gα12 and Gα13, regulate the small GTPase 
RhoA subfamily
7
, which includes RhoA, B, and C, and is the focus of the work contained 
in this dissertation. 
At least 25 receptors have been implicated in coupling with the Gα12 family, 
either with Gα12, Gα13, or both. These receptors have also been found to couple with 
other G proteins such as Gαi and Gαq.
8
 This finding, in conjunction with their ubiquity in 
almost all tissues, allows the receptors to regulate multiple biological processes such as 
cellular growth, proliferation, cell-cell adhesion, apoptosis, migration, and invasion, just 
to name a few.
6
 
GPCRs and Cancer 
As G protein Coupled Receptors exert control over a variety of cellular processes, 
especially those related to growth, proliferation, migration, invasion, and apoptosis, 
several have been shown to play a significant role in cancer and metastasis. One such 
example is the protease-activated receptors (PARs), which are activated by thrombin.
4
 
Even-Ram, et al. demonstrated that highly invasive breast cancer carcinoma cell lines 
MDA-435 and MDA 231 correlated with the level of overexpression of thrombin 
receptor, a member of the PAR family.
9
 A study by Chay, et al. confirmed that both 
VCaP, a bone-derived prostate cancer cell line, as well as PC-3 prostate cancer cells, 
maintain increased expression of PAR1.
10
 Additionally, studies have demonstrated that 
increased expression of PAR1 is found in aggressive and metastatic prostate cancers, 
potentially leading to resistance to apoptotic signals, stimulation of angiogenic factors, 




A second GPCR family that has been linked to cancer progression is bombesin, 
which includes receptor types BB1, BB2, and BB3. Findings by Cuttitta, et al. show that 
human small-cell lung cancer (SCLC) produces bombesin-like proteins (BLP) that can 
function as autocrine growth factors for SCLC tumors.
12
 Corral and colleagues observed 




swift induction of Cox-2 as well as enhancement of the invasiveness of Caco-2 cells.
13
 
Bombesin has also been shown to enhance migration and invasion of prostate cancer cells 
in a RhoA-dependent fashion.
14
 Finally, while bombesin has been shown to be a growth 
factor for tumors, it has also been shown to promote angiogenesis in SK-N-SH 
neuroblastoma cells
15
 in addition to metastatic prostate cancer.
16
 
A third GPCR family with a well-established role in cancer is the 
lysophosphatidic acid (LPA) receptors, which include LPA1, LPA2, and LPA3. It has been 
determined that LPA takes on many roles in ovarian cancer, including enhancement of 
the migration of SK-OV3 cells
17
 and as a major tumor-promoting factor in ovarian 
cancer.
4, 18
 Recent evidence using human MDA-B02 breast carcinoma cells points to the 
role of LPA in promoting the secretion of cytokines and growth factors, leading to the 
establishment and progression of bone metastases.
19
 Finally, LPA has also been observed 
to enhance the migration of Caov-3
20
 and invasiveness of  PC-3 prostate cancer cells
21
 
using a RhoA-dependent mechanism.  
Rho GTPases 
The Rho family of GTPases is a subset of the Ras superfamily and is comprised 
of more than 20 signaling proteins.
22-24
 Of these greater than 20 proteins, the most 
thoroughly investigated members are RhoA (consisting of isoforms RhoA, RhoB, and 
RhoC), Cdc42, and Rac.
25
 Rho GTPases are ubiquitously expressed and are responsible 
for the dynamic rearrangement of the actin cytoskeleton. Such rearrangement is necessary 
for biological processes including cell motility, migration, proliferation, etc. RhoA, 
Cdc42, and Rac form stress fibers; filopodia; and lamellipodia in addition to membrane 
ruffling, respectively
22, 26
, which are crucial for these processes. 
Rho GTPases function as molecular switches for signal transduction that originate 
extracellularly through the activation of many processes, including activation of GPCR 






 Their activation is tightly 
controlled using spatio-temporal regulation.
27
 These switches cycle between a guanosine 
diphosphate (GDP)-bound inactive state and a guanosine triphosphate (GTP)-bound 
active state.
28-31
 The tight regulation is afforded through regulator proteins that include 
(1) guanine nucleotide exchange factors (GEFs); (2) GTPase activating proteins 
(GAPs)
24, 26, 32






schematic of the basic RhoGTPase cycle can be found in Figure 1.1.
33
 RhoGEFs catalyze 
the exchange of GDP for GTP, therefore activating the cycle. GAPs enhance the 
hydrolysis of GTP to GDP, thereby accelerating inactivation and terminating the 
signaling pathway. GDIs sequester the GTPases in the cytoplasm to prevent their 
activation and plasma membrane association.     
 
Activation of the RhoGTPase cycle is dependent on RhoGEFs, and greater than 
70 have been identified in humans.
34
 A vast majority of the GEFs are composed of a Dbl 
homology (DH) domain and a plekstrin homology (PH) domain that catalyze GDP/GTP 
exchange and therefore activation. While PH domains boost the catalytic activity of the 
DH domains, additional evidence shows that the PH domain may facilitate localization of 
the DH domain to the plasma membrane.
35
 Aside from the traditional DH and PH 
domains, GEFs that initiate RhoA activation through the Gα12 coupled GPCRs also 
contain regulator of G protein signaling (RGS) domains, known as RGS homology (RH) 
domains. Four members comprise this family, including PDZ-RhoGEF, p115-RhoGEF, 
lymphoid blast crisis (Lbc)-RhoGEF, and leukemia-associated RhoGEF (LARG)
36, 37
, 
which has been the primary focus of the work performed in the Neubig laboratory.
38
 
RhoA Transcriptional Signaling Pathway 
In addition to the well-documented effects on the actin cytoskeleton, RhoGTPases 
also activate signaling pathways that maintain transcriptional regulation.
25
 Figure 1.2 




shows a cartoon depiction of the RhoA-initiated MKL1/SRF transcriptional regulation 
pathway.
39
 The pathway is initiated by the binding of a ligand to its respective GPCR, 
thus activating the Gα12 family of proteins, which continue on to activate GEFs such as 
LARG. LARG catalyzes the exchange of GDP for GTP, thus activating Rho, which acts 
on downstream effectors such as Rho-kinase (ROCK) and mammalian homologue of the 
Drosophila gene Diaphanous1 (mDia1).
40
 These effectors contribute to the 
polymerization of monomeric, free G-actin into polymeric F-actin through inhibition of 
actin disassembly and catalysis of polymerization, respectively. The decrease in free G-
actin due to polymerization releases transcriptional co-activator megakaryoblastic 
leukemia 1 (MKL1, MAL, MRTF-A), which translocates into the nucleus. In concert 
with serum response factor (SRF), MKL1 can induce serum response factor (SRF)-







RhoA Transcriptional Signaling and Cancer 
With the significant effects that members of the RhoA family exert on gene 
expression in addition to dynamic cytoskeletal functions, it is no surprise that they also 
play significant roles in cancer. No cancer-associated mutations have been observed in 
RhoA; however, aberrant regulation (generally through up-regulation/overexpression) 
contributes to cancer progression and metastasis.
41
 Two well-characterized members of 
this family, Cdc42 and Rac, have been implicated in malignant transformation, tumor 







Figure 1.2. RhoA-initiated MKL1/SRF Transcriptional Regulation Pathway. 
Activation of the GPCR by its respective ligand activates RhoGEFs through the Gα12 
family of proteins, which in turn activates Rho signaling. Rho activates Rho kinase 
(ROCK) and mDia1, which facilitate the polymerization of free monomeric G-actin into 
polymeric F-actin. This in turn releases transcriptional co-activator megakaryoblastic 
leukemia 1 (MKL1), which translocates into the nucleus to interact with serum response 




Members of the RhoA subgroup, including RhoA, RhoB, and RhoC, play 
significant roles in multiple cancers. RhoA and RhoC, which are the focus of this 
dissertation, contribute to the progression of a myriad of cancers. Unlike RhoA/C, RhoB 
is often down-regulated
41
 and has been suggested to be a tumor suppressor in several 
cancers
45
 and its overexpression can inhibit migration, invasion, and metastasis
45, 46
. 
RhoA and RhoC were once thought of as functionally identical, but evidence has pointed 
to distinct differences in cellular control
47
 and effects on cellular morphology.
48
 RhoA 
over-expression has been observed in a vast majority of cancers
49
 and at almost every 
stage.
41
 Contrarily, RhoC over-expression is observed in aggressive and metastatic 
tumors
49
, such as prostate cancer, where it’s necessary for invasion
50
; breast cancer, 
where it’s required for metastasis
51
; pancreatic carcinoma cells, where it’s needed to 
promote motility and invasion
47
; and in melanoma, where it’s essential for metastasis.
52
 It 
is obvious that RhoA and RhoC, are crucial for cancer progression, and are therefore 
highly desirable drug targets. 
Rho-associated Kinase (ROCK) 
Following activation, Rho GTPases have the ability to bind more than 60 
proteins.
53
 Rho-associated kinase (ROCK) is a well-documented effector of RhoA/C that 
enhances motility through formation of stress fibers and focal adhesions and stabilizes F-
actin via inhibition of LIM-kinases that promote breakdown of actin filaments.
54
 Due to 
ROCK’s significant effects on motility and cytoskeletal functions, it has also been 
implicated in multiple malignancies, including invasion of rat ascites hepatoma (MM1)
55
, 
high tumor grade in renal cell carcinoma
56
, high tumor grade in testicular cancer
44
, and 
invasion and metastasis of bladder cancer.
57
 Despite their significant effects on the 
cytoskeleton and thus cancer, only one ROCK inhibitor (Fasudil, Figure 1.3)
58
 has been 
clinically approved. Approval occurred in Japan in 1995; however, it has not been 








MKL1/SRF Transcriptional Regulation 
While much has been documented regarding RhoGTPases and their effects on the 
actin cytoskeleton, the regulation of gene transcription via MKL1 and SRF, as well as 
their roles in cancer, are poorly understood. MKL1 is a co-activator of the transcription 
factor SRF, which in concert activates the serum response element (SRE) that modulates 
gene transcription of several genes necessary for cellular growth, migration, and 
differentiation.
60
 Medjkane and colleagues demonstrated that signaling through 
MKL1/SRF was critical for invasion and metastasis in both breast cancer and 
melanoma.
61
 A recent study by Muehlich, et al. found that MKL1/2 is necessary for cell 
motility upon the loss of tumor suppressor Deleted in Liver Cancer 1 (DLC1).
60
  
Targeting the RhoA Transcriptional Signaling Pathway 
Due to the lack of specific and direct inhibitors of Rho GTPases and the Rho 
pathway, the Neubig lab implemented a high-throughput screen to identify novel small 
molecule inhibitors of the RhoA signaling pathway. As described in Evelyn, et al.
62
,  
human embryonic kidney (HEK)293 cells were transiently transfected with Rho-specific 
serum response element luciferase (SRE.L) and thymidine kinase (TK) Renilla luciferase 
reporter plasmids, and the dual-luciferase assay was used to identify two structurally 
similar compounds. The more potent compound, 1423 (Figure 1.4), was shown to block 
RhoA and RhoC-dependent gene transcription with an IC50 of ~1 µM (Figure 1.5). 
Additionally, 1423 was found to inhibit the proliferation of cancer cell lines showing 
increased RhoA/C expression, as well as inhibiting Matrigel matrix invasion by PC-3 
(Table 2.7), a highly invasive human prostate cancer line. A xenograft study was also 
carried out using 1423 to inhibit the growth and/or metastasis of A375M2 melanoma 




cells in vivo. While a reduction in tumor size was observed, the toxicity of the compound 




This leads me to the work presented here, which aims to synthesize and identify 
novel modulators of the RhoA transcriptional signaling pathway. These small molecules 
will serve as potential lead compounds for further development into anti-metastatic 
therapeutics, as well as to further probe the pathway to determine the macromolecular 
target(s) of our compounds. We undertook four general approaches toward the 
identification of such modulators that included: (1) traditional medicinal chemistry 
approaches to lead compound 1423, including modifications to the linker and aromatic 
regions; (2) development of 2D and 3D pharmacophore models; (3) an expanded high-
throughput screen to identify new leads; and (4) development of affinity reagents to 
identify the macromolecular target(s) in the signaling pathway. New compounds were 




Figure 1.4. High-throughput Lead 1423 





Through modifications of lead 1423, we were able to develop several analogs 
with low micromolar potencies and improved selectivity and toxicity profiles. 
Furthermore, we identified analog 203971, a modestly active compound (IC50 of 6.7 µM, 
Table 3.2), that has nevertheless shown exciting results in PC-3 prostate cancer cells as 
well as several melanoma cell lines and has reduced acute toxicity relative to 1423. 
Finally, through the use of an affinity reagent containing a benzophenone moiety, we 
were able to photolabel a 24kD protein of interest for further identification as a potential 
target within the signaling pathway. Identification of this protein would provide vital 
information that would allow us to prepare improved cancer therapies targeting the RhoA 




Chapter 2  
Linker Modifications 
 
Although 1423 (Figure 1.4) is a potent inhibitor of SRE-Luciferase gene 
transcription, it exhibits modest acute cellular toxicity toward PC-3 prostate cancer cells 
at 24 h, as non-specific inhibition of gene expression (Thymidine kinase (TK)-Renilla) 
with a concomitant decrease in WST-1 cell viability were noted (data not shown). 
Therefore, we set out to improve the potency and/or selectivity of lead 1423 while 
mitigating its cytotoxicity through modifications of three structural features contained in 
the “tether” region between the two aromatic rings. First, the N-O bond between the two 
carboxamides can allow 1423 to non-selectively modify proteins that contain cysteine or 
to be cleaved by glutathione. Second, the two carboxamides can create a barrier to 
passive diffusion across the apical and basal membranes into the cell, thereby limiting 
potency.
64,65
 Finally, the flexible acyclic tether region may not be optimal for potency and 
selectivity.
66
 Furthermore, molecular rigidity has been correlated with increased oral 
availability.
67
 Our initial structure-activity relationship (SAR) analysis focused on (1) 
removal of the N-O bond; (2) bioisosteric replacement of the carboxamides
68
; and (3) 
conformational restriction
66
 of the tether region.  
Preliminary Data 
Jenny Ryu executed the synthesis of initial analogs exploring the composition and 
length of the tether region between the two aromatic rings. Scheme 2.1 depicts the 
synthetic route used and shows a general procedure for a variety of amino acids 1. Initial 
acylation using 3,5-bis(trifluoromethyl)benzoyl chloride was performed under basic or 
anhydrous conditions to afford mono(amides) 2. The carboxylic acids of 2 were coupled 
with 4-chloroaniline via N-(3-dimethlaminopropyl)-N′-ethylcarbodiimide hydrochloride 





The effects of the synthesized analogs on Rho-mediated gene transcription, non-
specific gene expression, and cytotoxicity were determined in transiently transfected PC-
3 cells.
63
 Data were collected for both potency and maximal efficacy, as it was observed 
that compounds could maintain equivalent potencies against SRE.L but differ in their 
maximal responses (efficacies) as shown in subsequent tables. This could be due to 
several reasons, including differences in maximum cellular permeability, degree of efflux 
from cells, or different profiles of Rho-pathway target(s) being affected. Because such 
effects contribute to in vivo activity, we considered both potency and efficacy when 
selecting lead compounds in our SAR analysis. The effects on TK-Renilla and WST-1 at 
10 and 100 µM concentrations are included to illustrate selectivity and cytotoxicity. 
Analogs with low potency prevented IC50 values from being calculated and are therefore 
designated as >100 µM. 
Table 2.1 summarizes the impact of modifications to the composition and linker 
length of the tether region between the aromatic rings, as synthesized by Jenny Ryu. For 
compounds in which IC50s are greater than 100 µM and efficacy and cytotoxicity were 
calculated, dashes are used. For compounds in which data were not determined, ND is 
used. Our compounds typically show errors that fall between 1.5- to 2.0-fold the IC50. 
Removing the methyl group (100596) causes only a small decrease in potency and 
selectivity. Replacing the oxygen with a carbon (100594) significantly diminishes 
cytotoxicity and increases selectivity, but also reduces efficacy and reduces potency 20-
fold. Shortening or lengthening the carbon chain of the tether by one or two carbons 
(100600 and 100597, respectively) affects minor changes in activity and selectivity. 
However, extending to a four-carbon chain (100686) abolishes all activity.  
  






























100596 -OCH2- 4.7 71, 100 53, 89 42, 91 
100594 -CH2CH2- 38 38, 64 0, 22 0, 10 
100600 -CH2- 33 45, 85 15, 25 0, 30 
100597 -CH2CH2CH2- 21 37, 79 5, 42 0, 12 
100686 -CH2CH2CH2CH2- >100 0, 12 0, 10 0, 0 
a




Inhibition of Rho-pathway selective serum response element-luciferase reporter   
c
Inhibition of control pRL-thymidine kinase Renilla luciferase reporter   
d
Inhibition of mitochondrial metabolism of WST-1 
e
Not determined 
Bioisosteric Replacement of the Carboxamides 
Due to its moderate decrease in potency and significant reduction in cytotoxicity, 
compound 100594 was utilized as a template for further exploration of the tether region. 
Analogs aimed at increasing permeability through the removal of hydrogen bond donors 
and acceptors using bioisosteric replacement of the carboxamide moieties can be found in 
Table 2.2. Scheme 2.2-Scheme 2.5 summarize the synthetic routes for bioisosteric 
replacement analogs. 
Synthesis of N-methylanilide 101435 and benzylamide 203009 followed similar 
conditions as depicted in Scheme 2.1 using N-methyl-4-chloroaniline and 4-
chlorobenzylamine, respectively, in the final amidation step. Preparation of thiazole 
102445 and ether 102447 occurred by acylation of commercially available starting 
amines with 3,5-bis(trifluoromethyl)benzoyl chloride. Condensation of 3-
bromopropylamine 4 with excess 4-chloroaniline
69
 followed by simple acylation using 
3,5-bis(trifluoromethyl)benzoyl chloride provided monoamine 101425 (Scheme 2.2). 
Construction of regioisomeric amine 102585 took place through acylation of 4-
chloroaniline using 3-bromopropionyl chloride 6 to afford 7 which was further utilized in 
the alkylation of 3,5-bis(trifluoro)benzylamine (Scheme 2.3). Refluxing Borane-THF 
complex reduced 100594 to provide diamine analog 102532 (Table 2.2). 
Table 2.1. Effects of Tether Composition and Length on Transcription and 









Finally, we explored cyclic bioisosteres. Cycloaddition of the nitrile-oxide formed 
from oxime 9
70
 in combination with N-(4-chlorophenyl)but-3-enamide
71
 afforded 
isoxazoline 203003 as shown in Scheme 2.4. We attempted further oxidation to the 









. However, the 
isoxazole could not be generated. Diazotization/azidation of 3,5-
bis(trifluoromethyl)aniline (14) and 4-chloroaniline (16) followed by copper-catalyzed 
Click chemistry
76
 with alkynes 11 and 13, respectively, yielded triazoles 203011 and 






Scheme 2.2. Synthesis of Monoamine 101425 
Scheme 2.3.  Synthesis of Regioisomeric Monoamine 102585 






Table 2.2 summarizes bioisosteric modifications of the secondary amides. The 
simplest bioisosteric replacement of a secondary amide with a tertiary amide by N-
methylation of the 4-chloroaniline (101435), resulted in a complete loss of activity. 
Similarly, replacement of one anilide with a benzyl amide (203009) was detrimental to 
activity. Reduction of one or both of the amide moieties significantly increased potency 
and efficacy against Rho-dependent gene transcription. Analog 101425 exhibited potency 
similar to that of aminoxyacetic acid 100596 and maintained the modest selectivity and 
cytotoxicity of 100594, which made it the most interesting analog of this series. While 
monoamine 102585 and diamine 102532 exhibited increases in potencies, they 
maintained poor selectivity versus non-specific gene expression and introduced 
significant and undesirable cytotoxicity. Further exploration of monoamide replacement 
(102445, 102447, and 203003), while showing increases in potency in comparison with 
100594, reduced selectivity and/or increased cytotoxicity. Disappointingly, triazoles 
203011 and 203017 were completely inactive, which may suggest poor permeability.  
  































>100 - - - 
203009 
 
>100 - - - 
101425 
 
5.1 70, 80 37, 35 0, 11 
102585 
 
8.1 64, 100 13, 91 0, 92 
102532 
 
9.1 65, 100 6, 90 0, 89 
102445 
 
4.1 50, 45 39, 38 0, 0 
102447 
 
8.9 55, 86 28, 65 0, 38 
203003 
 
4.2 70, 84 51, 60 0, 38 
203011 
 
>100 - - - 
203017 
 
>100 - - - 
a
See Table 2.1for assay descriptions 
b
Synthesized by Nicole Harzdorf 
c
Synthesized by Kamali Sripathi 
Table 2.2. Effects of Amide Bioisosteric Replacement on Transcription and 





Passive diffusion is one of the main contributions to oral bioavailability. A study 
by Veber et al. demonstrated that the number of rotatable bonds present in a molecule 
decreases passive diffusion, and therefore limits oral bioavailability.
67
 We wanted to 
incorporate conformational restriction to increase passive permeability and thus oral 
bioavailability. Furthermore, we wanted to examine its effects on affinity and/or 
selectivity of restricted analogs. Binding affinity follows the Gibbs energy of binding,    
Ka  e
  G R ⁄  
with ΔG being comprised of both enthalpic and entropic contributions. Variations of 
these enthalpic and entropic contributions can produce the same ΔG, consequently 
yielding the same binding affinity. While enthalpic optimization can lead to increased 
binding affinity and selectivity versus entropic optimization, it is often more difficult to 
achieve.
77
 We chose to investigate conformational restriction as a means to maintain 
favorable solvation entropy while minimizing conformational degrees of freedom lost 
and hence conformational entropy loss upon binding. Increasing affinity could also result 
in an increase in selectivity of our analogs. 
Again using 100594 as a template, we explored the multiple ways we could 
restrain the molecule in 5- or 6-membered rings, several of which can be found in Figure 
2.1. The numbers within brackets refer to the atoms of 100594 that have been connected, 
and the constraining bonds are denoted with a dashed line.  







Jenny Ryu executed the initial chemistry, using the general synthetic route shown 
in Scheme 2.1, and the results are shown in Table 2.3. She prepared initial analog 
100602, which constrained 100594 in a 6-membered ring by connecting bonds 2 and 4. 
The compound exhibits improved potency and efficacy while maintaining similar 
cytotoxicity to that of 100594. Compound 100690, the isonipecotic isomer, shows similar 
potency and efficacy to nipecotic analog 100602. However, it introduces moderate 
cytotoxicity, which is undesirable. Analog 100692 is a highly-constrained 5-membered 
ring with only one carbon between the two amides. This constraint proved to be 
detrimental to potency. 









































69 23, 83 12, 27 0, 22 
a
See Table 2.1for assay descriptions 
b
Synthesized by Nicole Harzdorf 
c
Synthesized by Jenny Ryu 
   
We synthesized additional analogs to further examine conformational restriction 
with results shown in Table 2.4. First, we explored the tether region containing a benzene 
moiety with the 4-chloroanilide in a para- position (101329) compared to a meta- 
(101343) and ortho- position (101433). Scheme 2.1 depicts the chemistry employed. 
However, the preparation of 101433 did not yield the desired product directly (Scheme 
2.6). Instead, intermediate 20 was isolated and was treated with 4-chloroaniline and 
DMAP to facilitate ring-opening/coupling to the desired analog. 
  
Table 2.3. Preliminary Data on Effects of Conformation Restriction on 






We also synthesized compounds 102443, 102526, and 203001 (Table 2.4) 
utilizing the chemistry shown in Scheme 2.1. Assembly of conformationally restricted 
lactam 203005 required a multi-step synthesis as found in Scheme 2.7. Deprotection of 
commercially available N-(Boc)-4-piperidinone 21 followed by acylation with 3,5-
bis(trifluoromethyl)benzoyl chloride afforded benzamide 22. Generation of the oxime 
(23) followed by Beckmann rearrangement yielded the 7-membered diazepinone 24.
78
 N-
arylation of the lactam using 4-iodochlorobenzene under Buchwald conditions afforded 










Table 2.4 summarizes the impact of conformational restriction of the tether region 
between the two carboxamides of 100594 as a way to improve potency and selectivity. 
We see an increase in potency upon comparison of cyclic 102443 with corresponding 
acyclic analog 101435 (Table 2.2) and cyclic compounds 203001 and 203015 compared 
with 100594. Unfortunately, the restricted analogs did not offer any increase in selectivity 
over their acyclic counterparts. Analogs containing an aromatic ring in the linker with 
substituents in the para- and ortho- positions (101329 and 101433, respectively) were 
inactive. Interestingly, however, the meta- version (101343) was significantly more 
potent and efficacious than 100594. Unfortunately, its cytotoxicity at 10 µM prevented 
further testing at higher concentrations. 
  


























38 38, 64 0, 22 0, 10 
101329 
 





















13 15, 40 0, 1 0, 0 
102526 
 
>100 - - - 
203001 
 
9.5 33, 86 0, 62 0, 14 
203005 
 
>100 - - - 
203015 
 
16 30, 100 8, 78 0, 67 
a
See Table 2.1 for assay descriptions
 
b
Synthesized by Nicole Harzdorf 
c
Not determined    
  
Table 2.4. Effects of Conformational Restriction on Transcription and Cytotoxicity 




Stable Cell Line Development 
The Neubig lab attempted to establish an optimized HEK293 cell line stably 
expressing the SRE and Renilla Luciferase reporter vectors. This line was intended to 
decrease labor-intensiveness and reduce cell assay variability. Unfortunately, 
incorporation of the Renilla Luciferase vector could not be achieved. However, several of 
the previously synthesized compounds were tested in the HEK293 cell line stably 
expressing SRE.Luc for comparison (Table 2.5). Several newly synthesized compounds 
were also tested in the stable line assay, as shown in Table 2.6. The IC50 values are also 
























1.5 6.0 66, 98 56, 79 
101425 
 
5.1 10 30, 73 22, 38 
100692 
 





9.8 11 9, 55 5, 34 
101329 
 
>100 >100 - - 
101343 
 
1.7 3.2 66, 84 57, 53 
101433 
 
>100 95 0, 42 0, 36 
102443 
 
13 19 0, 13 0, 5 
102526 
 
>100 >100 - - 
203001 
 
9.5 15 7, 65 0, 41 
203005 
 
>100 30 0, 23 0, 6 
203015 
 
16 19 13, 96 0, 71 
a
See Table 2.1 for assay descriptions 
b
Synthesized by Jenny Ryu 





The older analogs proved to have increased cytotoxicity in the HEK cell line 
when compared to previous testing in the transiently transfected PC-3 cell line. Potencies 
were similar in comparison, with the exceptions of 100692 and 203005, which showed 
increased potency in the HEK line. Finally, efficacies were reduced in a majority of the 
compounds in the stable transfection. Analog 100602 demonstrated more comparable 
potency to 1423 in HEK cells than in the PC-3 cells with a modest decrease in efficacy 
and a significant reduction in cytotoxicity at both concentrations, further indicating its 
promise for optimization. 
 Exploration of additional conformationally restricted analogs continued with the 
synthesis of pyrrolidone analog 203606 and related compounds, shown in Scheme 2.8. 
Itaconic acid (25) was heated with 4-chloroaniline neat to afford intermediate acid 26, 
which was treated with diphenylphosphoryl azide (DPPA) to induce Curtius 
rearrangement to the corresponding isocyanate. The isocyanate was trapped with various 
substituted alcohols to afford carbamates 203007, 203065, and 203604. In the case of 
amide 203606, the isocyanate was trapped with tert-butanol to afford Boc-protected 
amine 27.
81
 The amine was deprotected and acylated to afford the final 5-membered rigid 
structure 203606. Preparation of 203846 followed similar conditions using 3,5-
difluorobenzoyl chloride to acylate intermediate 28. Compound 203848 examined the 
reverse amide of 203606 and was prepared using 3,5-bis(trifluoromethyl)aniline and 







Analogs 203845, 203850, and 203851 explored additional conformational 
restriction of 100594 as depicted in Figure 2.1. Scheme 2.9 shows the chemistry used to 
prepare cyclic analog 203845. Starting 5-chloro-2-nitrobenzaldehyde (29) was converted 
to the aminopropionic acid 30
82
, which was acylated using 3,5-
bis(trifluoromethyl)benzoyl chloride to afford intermediate acid 31. Reduction of the 
nitro group to the amine and concomitant cyclization was achieved using iron(II) sulfate 
heptahydrate
83,84
 to afford final compound 203845.
 
Scheme 2.10 provides the synthesis of analog 203850. Cyclopropyl cyano ester 
32 was heated directly with 4-chloroaniline neat and underwent a ring-
opening/recyclization to afford nitrile 33.
85
 Reduction of the nitrile was achieved using 
Raney Nickel in a Parr reactor
86
 to afford intermediate amine 34, which was then 
acylated with 3,5-bis(trifluoromethyl)benzoyl chloride to afford 203850. 
Scheme 2.8. Synthesis of Cyclic Analog 203606 






Compound 203851 was synthesized as shown in Scheme 2.11. 5-Chloroindolin-2-
one (35) underwent Vilsmeier formylation in DMF. Following completion of the first 
step, the reaction was cooled and quenched with aqueous ammonia to yield enamine 36.
87
 
Acylation of the enamine afforded 203851. Several attempts to reduce the double bond 
were undertaken, including hydrogenation with 5% Pd/C in ethanol; reduction using 
sodium cyanoborohydride
88
; reduction employing triethylsilane and trifluoroacetic 
acid
89,90
; and atmospheric hydrogenation utilizing 10% Pd/C in ethyl acetate. However, 
none of the attempts proved successful. 
 
Scheme 2.10. Synthesis of Cyclic Analog 203850 




Analogs 203059 and 203063 incorporated a solubilizing pyridine moiety with the 
nitrogen in the 3- or 2-position, respectively, into the 101425 template. Compound 
203061 replaced the bis(trifluoromethyl) moieties with fluorines. The chemistry followed 
the preparation of 101425 (Scheme 2.2) and proceeded by condensation of 3-
bromopropylamine 4 with excess of the desired pyridyl aniline or 4-chloroaniline 
followed by simple acylation using 3,5-bis(trifluoromethyl)benzoyl chloride or 3,5-
difluorobenzoyl chloride. 
Analogs 203853 and 203855 explored replacing one of the amides with an amine 
in the 6- and 5-membered conformationally restricted analogs (Scheme 2.12 and Scheme 
2.13, respectively) similar to that of 101425. Compound 203853 was synthesized by 
EDC/HOBt mediated amidation of piperidin-3-yl-methanol (37) with 3,5-
bis(trifluoromethyl)benzoic acid followed by a Parikh-Doering oxidation
91,92
 to afford 
aldehyde 39. Reductive amination
93
 of 39 with 4-chloroaniline afforded the final 
compound. Compound 203855 (Scheme 2.13) was prepared via arylation
94
 of 3-(tert-
butoxycarbonylamino)pyrrolidine with 1-chloro-4-iodobenzene to afford intermediate 
203854, which was also submitted for testing. Deprotection followed by acylation 
afforded final compound 203855. Analog 203847 (Table 2.6) evaluated reduction of both 
amides of 100602 to the conformationally restricted diamine, which was achieved using 
LAH reduction. 
 






Table 2.6 summarizes the effects of newly synthesized analogs on Rho-mediated 
gene transcription and cytotoxicity in the HEK293 stably transfected cell line. 
Examination of the 5-membered conformationally restricted lactams shows that 
carbamate analogs with no substitution (203007) or difluoro substitution (203604) on the 
benzyl are inactive. The same trend is seen with the corresponding amide series. 
Carbamate 203065 and amide 203606, both containing bis(trifluoromethyl) substituents, 
show similar potencies and efficacies. Differences in potencies based on the substitution 
pattern may indicate that a minimum level of lipophilicity is necessary for activity (see 
Chapter 3). Analog 203848 reverses the amide bond position of 203606. While the 
compound maintains potency and demonstrates excellent efficacy, it is significantly more 
cytotoxic. 
While conformational restriction has shown success, compounds 203845, 203850, 
and 203851 were completely inactive.  Upon further exploration of acyclic analogs of 
101425, we find that compounds 203061, with difluoro-substitution, and 203059, with a 
pyridyl nitrogen in the 3-position, show slight decreases in potency with a significant 
increase in efficacy, perhaps due to better solubility at the higher concentrations. 
Unfortunately, the compounds also show a significant increase in cytotoxicity. 
Compound 203063, with the pyridyl nitrogen in the 2-position, was completely inactive.  
Compounds 203853 and 203855 explore monoamines of the 6- and 5-membered 
conformationally restricted analogs, respectively. Unfortunately, both molecules, in 




addition to intermediate 203854, show complete loss of activity. Conversely, diamine 
203847 demonstrates similar activity and cytotoxicity in comparison with 100602 (Table 

















>100 - - 
203065 
 
16 16, 62 17, 29 
203604 
 
>100 - - 
203606 
 
17 17, 54 4, 14 
203846 
 
>100 - - 
203848 
 
8.6 65, 99 55, 75 
203845 
 
>100 - - 
203850 
 
>100 - - 
203851 
 
>100 - - 
203061 
 
35 0, 96 0, 73 
203059 
 
24 0, 95 0, 65 





















>100 - - 
203853 
 
>100 - - 
203847 
 
19 1, 70 21, 32 
203854 
 
>100 - - 
203855 
 
>100 - - 
                    a
Refer to Table 2.1 for assay descriptions 
The progression of 100594 to 100602 demonstrates that an increase in activity 
and efficacy with retention of modest selectivity and cytotoxicity is possible by 
employing conformational restriction. Compound 100602 remained the best performing 
analog in this series. The more rigid 5-membered analog (203606) showed similar 
potency and efficacy with reduced cytotoxicity. Disappointingly, it demonstrated 
solubility issues as evidenced by visible precipitation in the cellular assays. The 3,5-
bis(trifluoromethyl)benzyl ester 203065 maintains similar activity and potency with 
modest cytotoxicity and does not appear to precipitate in the assays. Analogs 203606 and 
203065 hold potential as new scaffolds for optimization. 
PC-3 Prostate Cancer Cell Invasion 
In their original publication, the Neubig lab showed that 1423 selectively 
inhibited spontaneous PC-3 prostate cancer cell invasion through a Matrigel matrix, but 
had no effect on Gαi-dependent SKOV-3 ovarian cancer cell invasion in vitro.
62
 
Consequently, we screened several of the newly synthesized analogs for their ability to 
inhibit PC-3 prostate cancer cell invasion. We compared the selectivity for invasion 
versus cytotoxicity (measured using WST-1) with that of 1423. Table 2.7 presents the 
results
63
 for our selected compounds. In general, we observed a correlation between 




analogs 100602, 100690, and 100692 demonstrated roughly equivalent efficacies against 
SRE.L at 10 and 100 µM. Their activities in the Matrigel followed a similar trend. 
Compound 100602 lacked cytotoxicity at 10 µM and showed 72% inhibition of invasion 
with modest cytotoxicity at 100 µM. While 1423 maintained 71% invasion at 10 µM, it 
was significantly cytotoxic. Analog 100602 maintains a more favorable efficacy:toxicity 
profile at 100 µM when compared with 1423 at just 10 µM. We also found a correlation 
between selectivity for SRE.L:cytotoxicity and invasion:cytotoxicity in monoamines 
101425 and 102585 and diamine 102532. Although monoamine 101425 shows lower 
efficacy than 1423 at 10 µM in the invasion assay, it does so without any cytotoxicity. At 
100 µM, 101425 exceeds the efficacy of 1423 with half of the cytotoxicity. Analogs 
102585 and 101532 demonstrate no cytotoxicity at the lower concentration. However, we 
see no selectivity in invasion:cytotoxicity at the higher concentration, a trend that is also 












% inh WST-1 
(100 M) 





100594 13 0 62 28 
100600 14 0 75 38 
100597 6 0 15 1 
100686 15 0 25 1 
100602 20 0 72 23 
100690 14 0 79 36 
100692 12 0 78 44 
101343 63 31 86 70 
101329 2 0 0 1 
102443 0 0 0 0 
100596 50 14 88 78 
101425 54 0 84 27 
102585 47 0 96 95 
102532 30 0 86 97 
102445 18 0 8 0 
102447 3 0 26 0 
102441 18 0 56 0 
    
a
Refer to Table 2.1 for assay descriptions
 








Figure 2.2 presents correlation graphs between the average inhibition in the PC-3 
Matrigel invasion assay versus the average inhibition of SRE.L expression in transiently 
transfected PC-3 cells at both 10 and 100 µM concentrations. Data show a positive 
correlation at both concentrations. However, outliers are present that strongly inhibit 
SRE.L without significant effects on invasion. The data also suggest that a threshold of 
approximately 50% of inhibition of SRE.L must be reached before inhibition of invasion 
is detectable.    
Invasion vs. SRE.L - 10uM






























Invasion vs. SRE.L - 100uM
































(A) shows the correlation of % inhibition of Matrigel invasion versus the inhibition of SRE.L at 10 µM 
(B) shows the correlation % inhibition of Matrigel invasion versus the inhibition of SRE.L at 100 µM 
 
In summary, we executed an expanded SAR survey of an inhibitor of Rho-
mediated gene transcription (1423) aimed at improving potency and/or selectivity while 
minimizing cytotoxicity.  To this end, we employed three strategies: (1) removal of the 
labile N-O bond; (2) bioisosteric replacement of the secondary carboxamides to improve 
cell permeability; and (3) conformational restriction to improve activity and/or 
selectivity. These strategies generated analogs with improved selectivity and cytotoxicity 
profiles. Unfortunately our best compounds show a 5- to 10-fold reduction in potency. 
Our most interesting compounds include nipecotic amide 100602, monoamine 101425, 
and 5-membered ring analogs 203606 and the presumably more soluble 203065. These 
compounds inhibit SRE.L expression with similar efficacies to 1423 with significant 
reductions in cytotoxicity. Additionally, for the first time, we have demonstrated a clear 





correlation between inhibition of Rho-mediated gene transcription and cell invasion using 




Chapter 3  
Aromatic Modifications 
 
Through replacement of the potentially labile N-O bond and conformational 
restriction of the flexible tether region between the two aromatic rings, we arrived at our 
lead compound, nipecotic amide 100602, which offered an improved biological profile 
over compound 1423.
63
 Although there was a 10-fold decrease in activity, it maintained 
inhibition of G12QL-stimulated SRE.L-luciferase expression with similar efficacy to 
1423, but with greatly reduced cytotoxicity. Unfortunately, despite the improved 
biological profile, compound 100602 exhibits poor physicochemical properties, including 
low solubility and low permeability (Table 3.6).  
One of the main issues we’ve continuously encountered in our SAR campaign is 
solubility. Lead compound 100602 displays low solubility (Table 3.6), and precipitation 
is visible in our cellular assays. However, we selected 100602 due to its equivalent 
efficacy and diminished toxicity to further explore diversity at each of the terminal 
aromatic rings with the additional goal of improving solubility.  
Preliminary Data 
Our initial survey of aromatic substitution was conducted on the more potent 
aminoacetic acid template to magnify the changes in activity, as shown in Table 3.1. 
Compounds were synthesized using simple acylation of 2-(aminooxy)acetic acid 
followed by EDC/HOBt mediated amidation (Scheme 2.1). Table 3.1 summarizes the 
brief preliminary survey of aromatic substitution. Moving the chloro group from the 
para- (100596) to the meta-position (101200) has no effect. Contrarily, completely 
removing it (100703) negatively affects potency as well as efficacy. Removing one of the 
trifluoromethyl groups (101202 and 100723) also negatively affects potency and efficacy, 
and removing both completely abolishes all activity (100701). Swapping the position of 
the two aromatic rings in 100691 affords a compound with similar potency and overall 




certain level of lipophilicity provided by aromatic substitution is essential for activity, 
perhaps due to differences in cellular permeability. We utilized 100602 as a template for 























4.7 71, 100 53, 89 42, 91 
101200 
 





36 13, 65 33, 59 0, 37 
101202 
 















8.6 58, 100 19, 87 0, 39 
a
Refer to Table 2.1for assay descriptions 
b
Synthesized by Jenny Ryu 
Library Selection 
In order to systematically modify the aromatic substituents, we first explored ring 
A of compound 100602, as shown in Figure 3.1. Paul Kirchhoff, a computational chemist 
in the Hans W. Vahlteich Medicinal Chemistry Core (VMCC) at the University of 
Michigan, assisted with monomer selection. We utilized the MScreen program of the 
Center for Chemical Genomics (CCG) at the University of Michigan to screen the Sigma-
Aldrich “Selected Structure Sets” for commercially available meta-substituted benzoic 
acids with desirable physicochemical properties. We chose only meta-substitutions, as we 
Table 3.1. Preliminary Effects of Aromatic Substitution on Transcription and 




expect that they would have greater potential to interact with various areas in the active 
site than would ortho- or para- substituents. We utilized Molecular Operating 
Environment (MOE) software to compute lipophilicity (SLogP) and molecular weight 
properties based on the parent structure with salt removed. We intended to select diverse 
carboxylic acids with a calculated SLogP less than that of our 3,5-
bis(trifluoromethyl)benzoic acid starting material (2.71) and that would result in a final 
compound molecular weight of 550 or less. Similarly, we explored ring B, again using 
MScreen to identify commercially available meta-substituted anilines with SLogP less 
than that of 4-chloroaniline (1.92) and that would result in final compound molecular 
weights of 550 or less. In choosing only starting acids and anilines with lower SLogP, we 
hoped to decrease the overall SLogP of our new analogs to enhance solubility. 
 
The synthetic routes to new analogs of 100602 are presented in Scheme 3.1 and 
Scheme 3.2. For the acid library (ring A, Scheme 3.1), the starting nipecotic acid 42 was 
Boc-protected, and the resulting acid (43) was coupled to 4-chloroaniline using 
EDC/DMAP-mediated amidation. Following deprotection, the resulting piperidine was 
coupled with various commercially available m-substituted benzoic acids.
95
 The resulting 
compounds were purified using Amberlyst-15 resin to remove excess aniline, followed 
by a water wash to remove residual DMF to afford final acid library analogs. This 
synthesis afforded 20 compounds with yields between 39 and 100% with purities greater 
than 90%. For the aniline library (ring B, Scheme 3.2) the starting nipecotate 46 was 
acylated with 3,5-bis(trifluoromethyl)benzoyl chloride followed by saponification to 
afford the free acid 48. The acid was then coupled with the commercially available m-
anilines.
95
 Compounds were purified by either aqueous workup or aqueous workup 
followed by chromatography to afford final aniline library analogs. Synthesized analogs 
afforded yields between 32 and 100% with purities ranging between 81 to  greater than 
95%. 






The effects on Rho-mediated gene transcription and cytotoxicity of all newly 
synthesized analogs were determined in transiently transfected PC-3 cells at an initial 
concentration of 100 M. For compounds showing greater than 50% inhibition at 100 
M, a full dose-response curve (DRC) was generated. Table 3.2 summarizes the effects 
of benzamide analogs of 100602. Replacement of the bis(trifluromethyl) groups with a 
substituent in the meta-position afforded analogs with little to no cytotoxicity, with the 
exception of 206115. A majority of the analogs had  lower potency than the lead 100602. 
Scheme 3.1. Synthesis of Acid Library 




However, analogs 203971 and 203972 show a slight increase in potency and similar 
efficacies.  
Upon comparing similar analogs, we see that adding a carbon between the amide 
bond and the aromatic ring (100602 vs 203960) has little effect on potency and toxicity. 
Analog 203973 adds a nitrogen to the furan ring of 203971, affording a less active 
oxazole. This substitution increases the topological polar surface area (TPSA) of 203973 
to 71Å and decreases the calculated LogP (CLogP) to 3.46 versus a TPSA of 59Å and 
CLogP of 4.88 exhibited by 203971, which may account for the reduced activity. A 
similar trend is observed when examining compounds 203968, 203979, and 203963.  
Double-bond analog 203968 maintains modest potency (33 µM) and good efficacy (84%) 
with a TPSA of 49Å and a CLogP of 4.33. Thioether 203963 has the same TPSA and a 
similar CLogP (4.26) as 203968 and maintains similar potency with a slight decrease in 
efficacy. However, moving from the thioether to an ether (203979) increases TPSA to 
59Å and lowers CLogP to 3.82. The analog lost activity with a significant reduction in 
efficacy. We then explored the relationships between TPSA and activity as well as 
CLogP and activity for the acid library. We found that TPSA and potency have a weak 
correlation (Figure 3.2, r
2
 = 0.32), whereas CLogP has a moderate correlation with 
potency (Figure 3.3, r
2
 = 0.78).  
Benzophenone-containing 203972 is one of the most promising analogs in our 
library. It maintains good activity, confirming that the benzophenone moiety may be 
suitable for future use as a photoaffinity reagent for determining the molecular target(s) 
of our compounds. 203971 shows a two-fold increase in potency and a slight increase in 























9.8 78 14 
203971 
 
6.4 87 0 
203972 
 
9.9 75 0 
203960 
 
13 69 0 
206115 
 
27 92 32 
203966 
 
26 69 0 
203968 
 
33 84 0 
203975 
 
33 81 1 
203977 
 
35 63 0 
203963 
 
35 76 0 
203973 
 
43 72 0 
203967 
 
51 69 0 
203969 
 
67 64 0 
Table 3.2. Effects of Benzamide Substitution on Transcription and Cytotoxicity in 
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           a
Refer to Table 2.1for assay descriptions 
           b
Synthesized by Jenny Ryu 
          c








The effects of aromatic substitution R2 on ring B are summarized in Table 3.3. As 
with the acid-substituted library, most compounds demonstrated low to no cytotoxicity, 
with the exception of amine 206123, which had significant cytotoxicity of 51% at 100 
µM. Our best analogs 206114 and 206108 show a 10-fold increase in potency with a 
slight decrease in efficacy. Pyridine 206124 showed a similar increase in potency while 
maintaining modest efficacy. Analogs 206109, 206244, 206102, 206248, 206243, and 
206241 all show similar or slight increases in potency. 
y = 1.3217x - 34.465 





















y = -40.739x + 216.94 





















Figure 3.2. Acid Library Topological Polar Surface Area versus Potency 




Although there was very weak to no correlation overall between potency and 
TPSA as well as potency versus CLogP (Figure 3.4 and Figure 3.5), trends were observed 
between subsets of similar compounds. Analogs 206105 appends a ketone to 206102, 
which increases TPSA, decreases CLogP, and significantly decreases potency. The 5-
membered amine 206103 is inactive and highly toxic. The 6-membered morpholine, on 
the other hand, demonstrates moderate potency and efficacy without toxicity. Analogs 
206012, 206248, and 206242 show a similar trend as observed in the acid library (Table 
3.2) in that the vinyl (206248) and ethyl (206102), which share similar TPSA and CLogP, 
also have similar potencies and efficacies. However, the ether analog (206242), with 
increased TPSA and decreased CLogP, maintains less activity. This is also observed 
between analogs 206114, 206108, and 206111. Compounds 206114, 206108, and 206124 
were the most potent analogs in this series and are therefore of greatest interest. 
Although we had intended to select only compounds with limited CLogP to 
enhance solubility, we mistakenly purchased starting materials that exceeded our target. 
Therefore, we synthesized analogs with CLogP values as high as 6.68. While this is 
obviously undesirable, it was actually fortuitous, as the compounds with the highest 
CLogP (206114 and 206108) were our most potent analogs. The added lipophilicity 
appeared to increase the permeability of the compounds, as demonstrated in our parallel 

































9.8 78 14 
206114 
 
1.5 59 1 
206108 
 
1.6 59 0 
206124 
 
2.3 82 5 
206109 
 
5.6 70 0 
206244 
 
6.1 73 1 
206102 
 
8.1 66 0 
206248 
 
11 53 1 
206243 
 
12 87 9 
206241 
 
12 60 0 
206110 
 
26 63 0 
206242 
 
30 51 0 
206104 
 
32 77 0 
Table 3.3. Effects of Aniline Substitution on Transcription and Cytotoxicity in 




















32 73 0 
206103 
 
66 65 9 
206105 
 








































 24 0 
   a
Refer to Table 2.1 for assay descriptions 
   b
Synthesized by Jenny Ryu   
   c








Based on the results from the acid- and aniline-substituted libraries, three series of 
follow-up analogs were examined, as found in Table 3.4. First, we examined additional 
substitutions of 100602. Analog 206455 replaced the furan of 203971 with a thiophene, 
which slightly increased potency and maintained low cytotoxicity. Analog 206119 moved 
the furan of 203971 from the meta- to the para-position, which caused a small loss in 
potency with introduction of minimal cytotoxicity. Analog 206122 reversed the furan 
from ring A to ring B, which led to a loss of potency and efficacy. Compounds 208798 
y = 0.9383x - 18.272 





















y = -3.5952x + 63.552 





















Figure 3.4. Aniline Library Topological Polar Surface Area versus Potency 




and 206681 shortened the length between the pyridyl ether of 206124 (Table 3.3) by one 
and two carbons, respectively. Shortening the tether by one carbon reduced potency 3-
fold and introduced modest cytotoxicity. Shortening by two carbons reduced potency 
almost 5-fold with a moderate loss in efficacy without cytotoxicity. Analogs 206101, 
206106, and 206682 looked at pyridyl moieties with the nitrogen in the 2-, 3-, and 4-
positions, respectively, which all showed losses in potency compared with 100602, with 
206106 showing significant cytotoxicity. 
Next, we examined “hybrid” analogs of our most promising compounds, which 
maintained the furan moiety on ring A, as found in 203971 (Table 3.2). Compound 
206683 blended analog 203963 (Table 3.2), which offered little increase in activity. 
Analog 206460 combined 203971 and 206106, which led to a significant decrease in 
potency with a moderate increase in cytotoxicity. Compound 206120 hybridized 203606 
(Table 2.6) with 203971, which led to a decrease in potency and efficacy; however, it did 
not demonstrate cytotoxicity. Compounds 206451 and 206450 combined 203971 with 
206114 and 206108, our most potent analogs of the aniline library (Table 3.3), with IC50s 
of 1.5 and 1.6 µM, respectively. Disappointingly, these “hybrid” compounds resulted in a 

































4.7 81 4 
206119 
 
9.2 80 6 
206122 
 
21 63 0 
206683 
 
10 63 0 
208798 
 
7.4 79 15 
206681 
 
10 60 0 
206101 
 
>100 37 0 
206106 
 
31 88 25 
206682 
 
84 54 0 
206460 
 
45 88 10 
206120 
 
54 49 0 
206451 
 
>100 21 0 
206450 
 
>100 21 0 
   a
Refer to Table 2.1 for assay descriptions 
 
Table 3.4. Effects of Additional Substitutions on Transcription and Cytotoxicity in 





We selected six lead compounds from our completed SAR to examine the effects 
of structural modification on solubility and permeability. Detailed solubility and 
permeability assay conditions can be found in the experimentals described in Chapter 6. 
These six analogs (100594, 203971, 206108, 206114, 206455, and 203606) were 
compared to initial hit 1423 and lead 100602 (Table 3.6). Compound 1423 showed 
moderate solubility (between 18.6 and 11.9 µg/mL). Unfortunately, kinetic solubilities of 
all the remaining analogs, including 100602, were binned as low solubility (<10 µg/mL, 
Table 3.5). We also evaluated the analogs using PAMPA as an estimate of passive 
permeability (Table 3.5) using the PAMPA Explorer Kit (pION). Only analogs 206108, 
206114, and 203606 demonstrate moderate permeability in the assay (Table 3.6). The 
remaining compounds exhibited low permeability. Compounds 206108, 206114, and 
203606 have calculated partition coefficients (CLogP) of 6.0 or greater (as determined by 
ChemBioDraw Ultra 12.0), which reflects lipophilicity. It is possible that the increased 
potency of these lead compounds may be attributed to increased lipophilicity, as higher 
lipophilicity generally correlates with greater cell permeability. When conducting 
experiment utilizing a single pH, the PAMPA software utilizes a “two-way flux 
equation.” While retention in the membrane is not considered using the two-way flux 
equation, the PAMPA analysis software runs a modified version that factors in the 
amount of sample lost to the membrane. While lipophilicity can correlate with greater 
cell permeability, compounds with a LogP greater than 5 are more likely to become 
lodged in the membrane. Several of our compounds returned non-detectable results. It is 
possible that our standard 4 hour incubation period is not long enough to allow the 
compounds to move through the multiple bilayered-membrane. Further investigation and 










LOW <10 <-5 
MODERATE (MOD) 10-60 -5 to -4 
HIGH >60 >-4 
    aKinetic solubility, ranges found in Ref96 
     b
Log of effective permeability,
 
ranges found in Ref
97
 




























-10 ± 0.00 









































-7.6 ± 2.8 
(MOD-LOW) 
        
a
Kinetic solubility 
        
b
Calculated LogP (ChemBioDraw Ultra 12.0) 
            c
Log of effective permeability (cm/s) as determined by PAMPA Explorer. Measurements are at 
minimum N=3. 
Chiral Recognition 
Chirality is a fundamental component of nature. Proteins are composed of 
primarily L-amino acids and exhibit specificity for complex molecules. These complex 
molecules often contain one or more stereocenters.
98,99
 In the early 1930s, Easson and 
Stedman offered the three-point attachment model to describe the stereospecificity of 
drug receptors for their substrates
100
 as depicted in Figure 3.6.
101
 The model describes the 




sterochemical recognition of enantiomers for a simple molecule containing only one 
chiral center
98,102
 and assumes, although not explicitly stated in the original paper, 
approach from only one side of the binding site.
103
   
The diagrams in Figure 3.6 illustrate the surface of the receptor (IV) and the 
possible enantiomers (I and II), as well as an achiral molecule (III). The Easson-Stedman 
model predicts that in order to achieve maximal effect, the enantiomer must interact with 
the receptor so that A, B, and C of the drug molecule bind to A′, B′, and C′ of the 
receptor, respectively. Only enantiomer I can do so in this case. As depicted in Figure 
3.6, enantiomer II can only form 1 interaction between B and B′. Achiral compound III 
contains A, B, and C in the proper configuration to bind with the receptor, and should be 
able to do so with equal activity to I according to the proposed model. The shaded face of 
achiral molecule III also contains points A, B, and C; however they are not aligned to 




Affinities for each enantiomer can be calculated and compared to yield a 
‘eudismic ratio’ to describe the pharmacological activity between two enantiomers of a 
drug. The enantiomer exhibiting highest affinity and therefore the highest level of 
complementarity to the binding site, is known as the ‘eutomer.’  he lowest affinity 
enantiomer with the poorest degree of complementarity is known as the ‘distomer.’
99,104
 
Pfeiffer demonstrated that a decrease in the ratio of activity of eutomer:distomer 
(eudismic ratio) was correlated with a decrease in drug potency and an increase in the 
total dosage of racemate necessary to elicit a response. In summary, Pfeiffer’s Rule states 
Figure 3.6. Easson-Stedman Three-point Attachment Model. Diagram IV provides a 
schematic of the receptor, along with depictions of the possible enantiomers I and II, as 
well as achiral molecule III. The model predicts that to achieve maximal effect, A, B, and 




that in general a greater eudismic ratio is associated with greater potency of drug 




In order to determine if eudismic ratios were detectable in our series, Jenny Ryu 
synthesized enantiomers of 100602 using commercially available (S)- and (R)-nipecotic 
acid affording analogs 100687 and 100688, respectively. Unfortunately, these 







% inh SRE.L 
(100 M)
a 





9.8 78 14 
100687 
 
9.8 78 5 
100688 
 
9.7 90 7 
     aRefer to Table 2.1 for assay descriptions 
Further Exploration of Stereochemical Recognition 
We decided to further explore stereochemical recognition by synthesizing 
enantiomers of the more rigid five-membered ring analog 203606 (Table 2.6). The 
enantiomeric synthesis is summarized in Scheme 3.3. Synthesis began with (R)-
hydroxypyrrolidin-2-one (49) which underwent a modified Goldberg reaction
106
 to afford 
amidation product 50 which was then converted to the tosylate (51) and displaced by 
azide to yield sterochemically inverted azide 52. Conversion to the mesylate followed by 
azide displacement was also explored. However, elimination products were observed 
immediately and were the major products found. The tosylate still afforded an 
approximately 1:1 ratio of eliminated:desired product. However, purification methods 
effected separation of the two materials. Palladium catalyzed hydrogenation at 





atmospheric pressure provided amine 53. Close monitoring of hydrogenation was 
necessary, as lengthy hydrogenation reduced the chloro moeity. Acylation of the free 
amine with 3,5-bis(trifluoromethyl)benzoyl chloride afforded the desired enatiomeric 
product 206684. The other enantiomer was prepared analogously. 
In order to confirm chiral integrity, we prepared Mosher amides
107
 using each 
enantiomer of amine 53 to prepare analogs 208802 and 208805 (Scheme 3.4). We then 
examined each by proton and fluorine NMR, which confirmed only one enantiomer was 
present in each sample. 
 
  





Additionally, we determined the eudismic ratio of enantiomers of 203971. 
Compounds 206116 were synthesized using the same chemistry as used in the 
preparation of the acid libraries (Scheme 3.1) starting with (R)- and (S)-nipecotic acid, 
respectively. Furthermore, pharmacophore modeling (Chapter 5) suggested that due to 
the similarity of the aromatic rings, our compounds have the potential to flip orientation 
in the binding pocket. Therefore, we investigated the enantiomers of the more 
unsymmetrical analog 206114. The synthesis also followed that in Scheme 3.1 using the 
appropriate enantiomer of the starting acid. 
Table 3.8 summarizes the effects of the synthesized enantiomers of 203606, 
203971, and 206114. In each of the comparisons, a very small chiral preference was 
found. For enantiomers of 203606 (206684 and 206685) and 203971 (206116, lots 
380445 and 380439), preference was shown towards the (S)-enantiomer. For enantiomers 
of 206114 (206686 and 206687), slight preference was shown for the (R)-enantiomer. 
However, the eudismic ratios were all well below 10, consistent with the relatively low 
potencies (micromolar) of the racemates, and perhaps indicating that the overall binding 
affinity is poor or that less than three points of attachment are being made with the 
receptor.  










% inh SRE.L 
(100 M)
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11 66 3 
206684 
 








14 83 0 
206686 
 
4.0 46 0 
206687 
 
2.9 60 0 
a
Refer to Table 2.1 for assay descriptions 
Further Exploration of 203971 
Analog 203971, the best performing analog of the acid library series, showed two-
fold activity improvement as well as a slight increase in efficacy with no cytotoxicity in 
PC-3 prostate cancer cells. We examined the effect of 203971 (Table 3.2) on the 
migration of PC-3 prostate cancer cells in comparison to less active analog 100594 
(Table 2.1), with the results shown in Figure 3.7. Detailed scratch assay conditions can be 
found in the experimentals described in Chapter 6. Panel A shows the scratch assay at 
time 0 h and 24 h using DMSO as a control. Compounds 203971 and 100594 were 
applied at 10 µM concentrations. As illustrated by the graph in panel B, significantly 
inhibits migration in PC-3 prostate cancer cells following 24 h treatment. We also intend 
to perform the scratch assay on the remaining compounds found in Table 3.6. 
Table 3.8. Effects of Single Enantiomers on Transcription and Cytotoxicity in 





Upon the initial discovery of 1423, the Neubig laboratory also observed that it had 
an effect on the RhoC-overexpressing melanoma cell lines A375M2 and SK-Mel-147.
62
 
Therefore, we also tested 203971 in the RhoC-SRE.L assay using transiently transfected 
SK-Mel-147 cells. We observed similar results to the PC-3 cell line, with 203971 
displaying an IC50 of 5.3 µM and no WST-1 cytotoxicity (data not shown), exhibiting its 
potential as an inhibitor of metastatic melanoma. The compound has also shown promise 
in other RhoC-overexpressing cancer targets, which will be disclosed in future 
publications. 
Unfortunately, initial compound 1423 displayed significant in vitro and in vivo 
cytotoxicity (Table 2.1) and was therefore too toxic to use in in vivo studies. On the other 
hand, acid library analog 203971 demonstrated single-digit micromolar potency without 
any cytotoxicity up to 100 µM concentration (Table 3.2). Therefore, we conducted 
preliminary toxicity studies using the less toxic compound 203971. A 5-day chronic 
dosing study was conducted with compound administration at 10, 20, 50, and 100 mg/kg 
Figure 3.7. Scratch Assay Using PC-3 Prostate Cancer Cells. Panel (A) shows cells at 
time 0 h and the migration of cells following 24 h incubation using DMSO, 10 µM 
203971, and 10 µM 100594. Panel (B) graphically depicts the migration after 24 h, as 




dissolved in 50 µL of dimethyl sulfoxide (DMSO) per day using 3 mice per dose. 
Following sacrifice on the 8
th
 day, the mice were weighed and blood samples were 
collected. Dissection was performed, and the internal organs were weighed and examined 
for abnormalities. Weight was maintained over the course of the study, with the only 
abnormality observed being a slight increase in liver weight. All mice survived the 5-day 
study without any noted abnormal behavior, indicating tolerability. The serum samples 
were also submitted for determination of drug levels. A single intraperitoneal (IP) dose of 
100 mg/kg provided maximum serum levels 3 to 5 times higher than the in vitro IC50, 
indicating its potential use for further in vivo studies. 
Future Direction for 203971 
Based on the positive tolerability results, we are currently assessing standard 
pharmacokinetic parameters as well as the relative bioavailability of 203971. These 
results will dictate the feasibility of further in vivo exploration such as assessment of 
treatment regimen as well as the optimal method of administration. Our lab has also 
recently established an assay to examine metabolic stability. We intend to examine our 
lead compounds, including 203971, in our metabolic assay. If further in vivo testing is 
viable, we will move into melanoma xenograft studies.  
Future Direction: Third Point of Diversity 
Our investigation of the enantiomers of 100602, 203606, 203971, and 206114 
resulted in compounds with low micromolar potencies and no apparent stereorecognition 
by the macromolecular target. The poor potencies and lack of stereo-differentiation may 
indicate less than three points of attachment are being made with the receptor. Therefore, 
we intend to pursue installation of a third point of diversity to provide the necessary third 
interaction. We intend to use conformationally restricted analog 203971 to further probe 
this third point of diversity. 
We envision the synthesis proposed in Scheme 3.5. Our progress to date is 
summarized here. First, 3,5-pyridinedicarboxylic acid is esterified to provide diester 56
108
 
which is then treated with potassium hydroxide to form monoacid 57.
109
 The acid then 
undergoes Curtius rearrangement to the isocyanate, which is trapped by t-butanol to 






which is then hydrogenated using Rhodium on Alumina to afford a single diastereomer 
(presumably cis-) 60.
111
 Acylation with 3-(furan-2-yl)benzoyl chloride followed by 
amidation with 4-chloroaniline under standard EDC/HOBt-mediated coupling conditions 
provides intermediate 62.  
We anticipate that deprotection of the primary amine will provide key common 
intermediate amine 63, and that various functional groups can then be added via 
acylations, sulfonylations, reductive aminations, etc. Because only one diastereomer is 
afforded using the above hydrogenation conditions (presumably cis-), it will be necessary 










Chapter 4  
Photoaffinity Reagents 
 
In 2007, the Neubig lab identified small molecule 1423 as an inhibitor of RhoA 
transcriptional signaling in HEK293 cells using a high-throughput screening assay.  
Mechanistic analysis demonstrated that 1423 acts downstream of RhoA and targets 
MKL/SRF-dependent transcriptional activation. However, the exact mechanism of action 
has not yet been deciphered. Their findings suggest that 1423 could affect the functions 
of MKL1 in various ways, including preventing its release from actin; blocking 
translocation from the cytoplasm to the nucleus; repressing transcription via increasing 
sumoylation; disrupting the interaction between MKL1 and its transcoactivator SRF, or 
inhibiting its coactivator function.
62
 Due to the multitude of effectors activated by the 
RhoA family, determining the exact role of the signaling cascade in cancer is convoluted. 
However, discovery of 1423 as an inhibitor of Rho-mediated gene transcription and our 
further optimization into more potent and specific analogs with low cytotoxicity may 
allow us to probe its mechanism of action and identify its macromolecular target(s). 
Identification of the macromolecular target(s) of our small bioactive molecules 
would allow us to employ rational and structure-based drug design to create more potent 
and selective therapeutics for the treatment of RhoA-related cancers. There are several 
methodologies one can use to identify target proteins. Our interests focus on three such 
strategies that include affinity matrices, biotinylated reagents, and tag-free photoaffinity 
probes. Each approach has advantages and disadvantages, which will be discussed in 
subsequent sections. Following the isolation and purification of a target protein, its 
identity can be determined using immunohistochemical analysis, peptide 
microsequencing, or modern degradative mass spectrometry.
112
 These techniques will not 






  The preparation of affinity matrices is the simplest method for protein 
identification and is achieved by the attachment of modified lead compounds to a solid 




 beads that can contain 
various functional groups for easy ligand attachment. The support is then incubated with 
cellular lysate to allow protein binding. Following incubation, the resin and bound protein 
are isolated (simple filtration) and are washed repeatedly using aqueous buffer. The 
washing steps remove any nonbinding proteins, affording only proteins that are bound to 
the desired ligand or nonspecifically to the matrix. Binding proteins can then be eluted 
from the resin through incubation with free ligand or under denaturing conditions.
115
 The 
protein can then be isolated via sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and subjected to various techniques for identification.  
Solid supports such as agarose and sepharose are designed to prevent nonspecific 
binding of hydrophobic or charged proteins.
112
 However, such nonspecific interactions 
still occur with the matrix. Therefore control matrices should be used to help determine 
binding specificity. Construction of a control matrix can be executed using a resin-only 
control or an inactive compound control. A resin-only control can be prepared by using a 
resin-appropriate blocking agent to cover any activated sites following ligand loading. 
This leads to charge minimization, which minimizes nonspecific protein interactions.
112
 
An inactive compound control provides a better comparison for specificity and should be 
constructed by immobilizing a compound on the resin that is similar to the active ligand, 
but is inactive itself. The optimal molecule would be an inactive enantiomer of the lead 
compound; however, structurally similar compounds can work.
116
 The gels are then 
compared, and proteins appearing in both would be considered nonspecific binders. 
Another control experiment to determine specificity of binding is a competition 
experiment in which excess free ligand is incubated with the lysates and ligand-bound 
affinity matrix.
117
 The excess free ligand binds the target protein, preventing it from 
interacting with the resin. Therefore, upon comparing gels, certain protein bands would 
no longer be present, indicating a specific interaction with the small molecule. 
There are several limitations to using affinity matrices. One significant limitation 




phase resin. To address this issue, hydrophilic polyethylene glycol (PEG) linkers have 
been utilized to attach the ligand to the resin.
112, 117
 Activity can then be estimated 
following installation of a model PEG linker to ensure binding potential is not lost. 
Additionally, the hydrophilicity of the PEG linker minimizes nonspecific binding, and the 
spacer projects the ligand away from the resin. This spacer distance has been shown to be 




Another limiting factor for affinity matrices is the affinity of the ligand for its 
target. It is best to use a potent molecule with presumably high affinity and selectivity for 
the target.
116,117
 High binding affinity is necessary to preserve protein binding interactions 
during extensive washing steps required for removal of nonbinding proteins.
112
 
Therefore, this is a major consideration when determining the proper isolation method. 
Preliminary Results 
Due to our lack of knowledge regarding the cellular target(s) of the 1423 series 
and their respective binding affinities, we decided to explore all three affinity methods 
previously mentioned, starting with affinity matrices. As previously discussed, a spacer 
unit is necessary to minimize the potential interference of the solid support on binding of 
the ligand. Most importantly, the spacer must be positioned on the small molecule in a 
manner that would permit retention of reasonable biological activity.
112
 Determination of 
these potential positions can be done in one of two ways. One, SAR data can provide 
information regarding the areas that are tolerant to modifications. However, this may 
require a large amount of prior analog synthesis. We employed a second option that 
utilized active analogs to append functionality that mimics the spacer unit at various 
locations on the molecule. Compounds that retained a majority of their activity were then 
to be used as scaffolds for the preparation of affinity reagents. 
In preliminary work, Jenny Ryu synthesized a limited number of analogs of 
100596 (Table 2.1) to determine what potential linking functionality could be appended 
to the chloro-substituted aromatic ring without loss of activity. The groups extending 
from the aromatic ring explored included –NHAc and –COHNEt, –EtSMe, and –




activity. These observations were then incorporated into the design of our affinity 
reagents. 
Affinity Linker SAR 
In order to prepare our active affinity reagent, we selected 100602 to perform 
preliminary SAR exploring methoxy substitution. While 100602 is less potent than 1423, 
it is more selective and less cytotoxic. We observed that placing the methoxy group in the 
para-position on the aromatic ring is superior to the meta- position in terms of selectivity 
over nonspecific gene transcription (pRL-TK Renilla) inhibition (Table 4.1). Therefore, 
our active affinity matrix was based on 101331. 
Following identification of the active ligand, we wanted to select a similar 
“inactive compound” to function as a negative control. While the ideal inactive molecule 
would be the distomer of an enantiomeric pair, 100602 maintained a low eudismic ratio, 
showing no stereochemical recognition. Therefore, we opted to investigate a highly 
similar acyclic compound 100686, which differs only by one bridging methylene unit and 
lacks significant biological activity up to 100 µM (Table 4.1, Figure 4.1). Appending a 
methoxy group in either the para- or meta-position reintroduces a small amount of 
activity. However, we opted to base our affinity reagents on 101339, the least active 





























-Cl -H 9.8 38, 78 20, 34 0, 14 
101331 
 
-OMe -Cl 6 28, 28 4, 6 0, 0 
101341 
 
-Cl -OMe 5 29, 42 15, 15 0, 0 
100686
a
 -NHCH2CH2CH2CH2- -Cl -H - 0, 11 0, 14 0, 0 
101337 -NHCH2CH2CH2CH2- -Cl -OMe 10 18, 46 0, 20 0, 10 
101339 -NHCH2CH2CH2CH2- -OMe -Cl 20 3, 22 0, 14 0, 0 
              a
See Table 2.1 for assay descriptions     
b
Synthesized by Jenny Ryu 
 
   
(A) Active compound 100602 shows good inhibition of SRE.L (Firefly), low cytotoxicity (blue), and modest selectivity of SRE.L versus TK-Renilla (green); (B) 
Inactive compound 100686 shows no activity (SRE.L) up to 100 M; (C) Structures of active analog (100602) and inactive acyclic analog (100686) 
Table 4.1. Affinity Linker SAR 
Figure 4.1. Active and Inactive CCG-1423 Analogs Selected for Use in Affinity Reagents 




Initial affinity matrix experiments were carried out by Andrew Haak in the 
Neubig lab. Agarose beads functionalized with 1,1′-carbonyl diimidazole were coupled 
through a carbamate bond with active ligand amine 203883 (prepared in Scheme 4.1) to 
afford the “active” affinity matrix 64 (Figure 4.2). By a precisely analogous route, 
“inactive” control matrix 65 was prepared starting with 5-aminopentanoic acid instead of 
nipecotic acid (Scheme 4.1).  A third set of blank beads was also used. The remaining 
active sites on each set of beads were blocked using ethanolamine. Approximately 30 
milligrams of total cytosolic and nuclear protein were isolated from roughly 100 million 
prostate cancer cells. Ten milligrams of protein were incubated with approximately 150 
µL of each set of beads. Following incubation, each batch was centrifuged, and the lysate 
was removed. The beads were then washed with a combination of high and low NaCl 
buffered solution to removed nonspecific binding. Proteins were then eluted from the 
solid phase using Laemmli buffer, and samples were run on an SDS page gel. The gel 
was stained using Coomasie for visualization. 
 
The active ligand sample generated a protein band. Unfortunately, this band was 
also observed in both the inactive compound as well as the blank control, indicating a 
nonspecific binding interaction. Due to the modest potency of our compound (9.8 µM, 
Table 4.1) coupled with the extensive washing steps, we do not believe this is the optimal 
technique for target identification. Therefore, we made no additional attempts to optimize 
our affinity matrix experiments.  
Biotinylated Reagents 
The second technique we were interested in is the use of biotinylated reagents for 
target identification. Biotinylated reagents offer one major advantage over matrices – 
they are soluble.  Binding of target proteins to a soluble probe may be more facile than 
binding to a resin-bound probe. Following incubation of reagent with cell lysates, the 
Figure 4.2. Active and Inactive Affinity Matrices Based on 100602 and 100686. Both 




probe containing the binding partner(s) can be isolated using a streptavidin resin. 
Furthermore, incorporation of biotin allows visualization through the use of antibodies 
against biotin or the use of labeled streptavidin.
112
 
Despite significant advantages, there are drawbacks to biotinylated probes. One 
drawback is that incorporation of biotin likely decreases cell permeability, which 
prevents their use in whole cells. Furthermore, their incorporation often requires the use 
of high-boiling solvents due to the poor solubility of biotin in organic solvents. However, 
this can be overcome by attachment late in probe synthesis.
112
 
Based on the previous affinity linker SAR (Table 4.1), we set out to make the 
biotinylated reagents shown in Figure 4.3. We again incorporated the PEG linker for the 
same reasons as described above for the affinity matrices and utilized 100602 and 100686 
to generate “active” (203602) and “inactive” (203600) probes, respectively. 
 
Scheme 4.1 provides the synthesis of active biotinylated reagent 203602. 
Synthesis began with nipecotic acid 42, which was acylated with 3,5-
(bistrifluoromethyl)benzoyl chloride to afford acid 48. Amidation of 48 with 66 was 
achieved using CDI-mediated coupling
119
 to afford amide 67. The phenol of 67 was 
alkylated
120
 using mesylate 68
121
 to install the hydrophilic linker, yielding 69. 
Deprotection followed by biotinylation afforded final affinity reagent 203602. Inactive 
probe 203600 was prepared following the same synthetic scheme starting with 5-
aminopentanoic acid instead of nipecotic acid. 
The final active and inactive probe molecules were submitted to the Neubig lab 
for testing. However, due to the lack of success with the affinity matrices and our 
compounds’ potentially poor affinity, we decided not to pursue this technique for target 
identification at this time. 
 
 













Tag-free Photoaffinity Probes 
As previously mentioned, a high binding affinity of a small molecule ligand for its 
target is vital to achieving isolation following repeated washing procedures. Because we 
do not know the affinities of our compounds for their target(s) and because we were 
unable to successfully isolate specifically bound proteins, we cannot discount loss of 
binding interaction as being responsible. However, maintenance of such interactions can 
be permanently achieved through incorporation of cross-linkable functionality into our 
proposed affinity reagents. Current literature provides multiple examples of successful 
applications of such reagents incorporating photolabile functionalities such as azides, 
diazirines, and benzophenones. 
Figure 4.4 summarizes how tag-free photoprobes can be utilized in whole cells for 
target identification. The colors used in the cartoon correlate with the colors used in the 
molecular structures. First, a photolabile group is appended to a desired active ligand, as 
depicted in blue. Additionally, a low-molecular weight reactive handle is attached to 
complete the photoprobe. In this instance, the handle is an acetylene, as shown in purple. 
After confirming its activity, the photoprobe is incubated with whole cells, allowing the 
small molecule to interact with its target (light green) under physiological conditions. 
Following binding, UV irradiation is applied that converts the photolabile group into a 
highly reactive species that can covalently link the probe to its target. This irreversible 
modification will allow the application of extensive washings without the fear of losing 
the interaction between the small molecule and the target protein.
112
 The cells are lysed, 
and the handle can then be used with Click-chemistry to append biotin for streptavidin-
mediated isolation or to append a fluorophore for visualization. The desired protein can 











The selection of cross-linking functionality and its distance from the small 
molecule ligand are also crucial for the outcome of an affinity isolation experiment. 
Based on their synthetic ease, we initially examined two different photolabile groups, an 
azide and a benzophenone. As previously described for the other affinity reagents, we 
prepared the active reagents based on compound 100602 and inactive reagent based on 
acyclic 100686. Compound 203972 (Table 3.2), as prepared in the acid library, contains a 
modification to 100602 that includes a benzophenone moiety. Analog 203972 was one of 
the most active analogs in our library, confirming its potential as a photoaffinity reagent. 
Benzophenone Probes 
The use of benzophenones for target identification is advantageous for several 
reasons. One advantage is their superior stability that allows their use under ambient 
light, unlike aryl azides and diazirines. Furthermore, activation of benzophenones is 
achieved at around 350 nm. This prevents damage to most proteins, which absorb 
ultraviolet radiation only at wavelengths less than 300 nm.
122,123
 Finally, benzophenones 
insert into unreactive C-H bonds, both in aqueous media and in the presence of 
nucleophiles.
122
 These properties afford efficient labeling
124
 of C-H bonds within 3.1 Å
123
 
that is site specific.
122
 
Figure 4.5 provides the accepted mechanism for benzophenone photochemistry. 
Upon irradiation with ultraviolet light, the benzophenone containing ligand (70) forms a 
diradical species (71) that abstracts a hydrogen from a nearby protein to generate a ketyl 
radical and a protein radical (72). The pair of radicals can then recombine to form a 







In order to determine potential activity of our desired probes, we synthesized 
model molecules that installed a methoxy group to function as a propargyloxy mimic. 
Both the model probes (black) and completed photoaffinity probes (blue) are shown in 
Table 4.2. We utilized 203972 as a template to explore various aspects of our probes. 
First, we examined the optimal position of the chloro group on the aromatic ring by 
preparing para- (206117) and meta-chloro (206118) analogs. Second, we positioned the 
benzophenone on ring B (Figure 3.1) as shown by 206448. Finally, we examined the 
linker length between the low molecular weight reactive propargyl group (206558) to 
provide a spacer region for application of Click chemistry following labeling. 
Scheme 4.2 provides the synthesis of benzophenone precursor probes 206117 and 
206118, which examine the position of the chloro moiety. Synthesis was carried out 
starting with Boc-protected nipecotic acid (43) and the desired aniline isomer (74 or 75), 
which were subjected to standard amidation conditions to afford amides 76 and 77, 
respectively. Deprotection followed by amidation with 3-benzoylbenzoic acid afforded 
final model analogs 206117 and 206118, respectively. 
  
Figure 4.5. Photoaffinity Labeling Steps Using Benzophenone. Probe-containing 
ligand 70 is photolyzed to form a diradical (71) that abstracts a hydrogen from a nearby 
protein to form a ketyl and a protein radical (72). The pair of radicals recombine to form 






Table 4.2 summarizes the data for the benzophenone analogs. Models 206117 and 
206118 both retained activity. Model 206117, with the chloro group in the para-position 
was slightly more potent and efficacious. Therefore we synthesized the benzophenone 
photoaffinity probe 206454 with the chloro moiety in the para-position with the 
propargyl ether in the meta-position as shown in Scheme 4.3. First, 5-amino-2-
chlorophenol was Boc-protected to afford intermediate 81
126
, which was then alkylated 
using propargyl bromide to afford propargyloxy 82. Following deprotection of 82, aniline 
83 was coupled with Boc-protected nipecotic acid 43 to afford intermediate 84. 
Deprotection followed by coupling with 3-benzoylbenzoic acid afforded final probe 
206454. 
  





Additionally, we synthesized a benzophenone photoaffinity probe with a longer 
linker unit (206558) to minimize steric hindrance if the Click chemistry step does not 
afford a good yield. The synthesis can be found in Scheme 4.4, which begins with 
tosylation of 2-(prop-2-yn-1-yloxy)ethanol (86), which was received from Bryan 
Yestrepsky. Alkylation of phenol 81 using 87, followed by TFA deprotection afforded 
intermediate aniline 89, which was then coupled with acid 43. Boc-deprotection followed 
by standard EDC/DMAP-mediated coupling conditions with 3-benzoylbenzophenone 
afforded final compound 206558. Fortuitously, both affinity reagents 206454 and 206558 
were actually more potent than initial benzophenone 203972 and methoxy model analog 
206117 (Table 4.2). 
  





In the aniline library (Chapter 3), we explored benzophenone placement on ring B 
(206111). Despite its inactivity (Table 3.3, Table 4.2), we synthesized precursor molecule 
206448, which placed a methoxy in the meta-position on ring A. The executed route to 
precursor 206448 is shown in Scheme 4.5. Starting aniline 91 was coupled with acid 43 
under standard EDC/DMAP-mediated coupling conditions to afford intermediate 92. 
After Deprotection, amine 93 was coupled with 3-methoxy-5-trifluoromethylbenzoic acid 
(94) to afford 206448. The model analog regained activity, showing an IC50 of 5.3 µM. 
Therefore, we continued with the synthesis of full photoaffinity reagent (206559), which 
can be found in Scheme 4.6. Starting acid 100 was esterified to produce methyl ester 101. 
The phenol was alkylated with propargyl bromide to afford ester 102, which was then 
saponified to afford free acid 103. The acid was then coupled with amine 98 under 
standard amidation conditions to afford final probe molecule 206559. As is reflected in 
Table 4.2, 206559 is also active, allowing the benzophenone placement to be manipulated 






Scheme 4.4. Synthesis of Benzophenone Photoaffinity Probe 206558 Containing an 







Scheme 4.5. Synthesis of Ring B Benzophenone Model Analog 206448 
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6.6 57 0 
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5.0 53 0 
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>100 ND ND 
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2.7 58 0 
  aRefer to Table 2.1 for assay descriptions. Final probes are colored blue. 
Azide Probes 
Next we explored probes containing aryl azides. There are several advantages to 
utilizing azides for labeling. An azide is relatively small and its incorporation provides 
minimal structural change to the starting compound. Furthermore, azides can afford 
greater solubility in comparison to other modifications. On the other hand, while many 
laboratories have exploited aryl azide chemistry, it has been noted that crosslinking 
efficiency is rather low.
112,124
 Complexities and poor efficiency arise from the activation 
of such azides as depicted in Scheme 4.7.
123,124,127,128
 Irradiation at wavelengths shorter 
than 280 nm produces formation of a singlet nitrene (100), which can intersystem cross 
(ISC) to the triplet ground state (103). However, at low temperatures (i.e. 77K), the 
Table 4.2. Effects of Benzophenone Photoaffinity Models and Probes on 




energy barrier necessary for this conversion is high and only the singlet is produced.
124
 
The singlet 100 undergoes rearrangement and ring expansion into ketenimine 101 that 
can be attacked by a nucleophilic nitrogen or oxygen of a protein to afford an azepine-
labeled protein (102).
128
 An additional complexity of utilizing azides for labeling is that 
the activation wavelength can cause damage of biological systems, which is undesirable. 
 
Similar to the preparation of the benzophenone analogs, we synthesized model 
and photoaffinity reagents using aryl azides, and the results can be found in Table 4.3. 
One model compound incorporating a methoxy substituent on ring A was prepared 
(206449). Scheme 4.8 provides the chemistry employed. Due to the sensitivity of aryl 
azides, all chemistry on azide-containing intermediates was executed in the dark. 
Synthesis began with the acylation of 4-chloro-3-nitroaniline (106) to provide 
intermediate 107. The nitro group was then reduced using iron and hydrochloric acid to 
afford aniline 108. The azido group was introduced by diazotization/azidation of 108. 
Deacetylation with potassium hydroxide afforded aniline 110, which was then coupled 
with 43 (Scheme 3.1) using standard amidation conditions. Deprotection of 111 followed 
by coupling with acid 94 afforded 206449. As shown in Table 4.3, 206449 maintained 
activity in PC-3 prostate cancer cells. Therefore, the synthesis of aryl azide photoaffinity 
probe 206569 (Table 4.3) was carried out through coupling azide 112 (Scheme 4.8) with 
acid 98 (Scheme 4.6) under EDC/DMAP-mediated amidation conditions. Additionally, 
we investigated installation of the azide in ring A (206452). The synthetic route can be 
found in Scheme 4.9. Introduction of the azide in 114 was accomplished via 
diazotization/azidation of 113 followed by standard coupling conditions with 85 (Scheme 




4.3) to afford final aryl azide photoprobe 206452. As with aryl azide 206569, 
photoaffinity probe 206452 retained activity (Table 4.3). However, it was the least potent 
of all of the photoaffinity reagents. 
  
  
Scheme 4.8. Synthesis of Aryl Azide Precursor Analog 206449 






















7.0 77 13 
206569 
 
11 75 4 
206452 
 
17 54 2 
        aRefer to Table 2.1 for assay descriptions 
Preliminary Photoaffinity Labeling Experiments 
We selected benzophenone photoaffinity probe 206559 (Table 4.2) to perform 
preliminary photoaffinity labeling (PAL) experiments based on its potency in PC-3 
prostate cancer cells (2.7 µM). Initial PAL experiments were executed in the Neubig lab 
by Yihan Sun as follows. Parental PC-3 cells were grown to confluence in medium 
containing 10% fetal bovine serum (FBS) and 1% Penicillin/Streptomyin. The medium 
was removed, and the cells were washed with phosphate buffered saline (PBS). Cells 
were then incubated in PBS with 0.3 µM 206559 for 30 minutes. A competition 
experiment was also performed by incubating cells in PBS with 0.3 µM 206559 and 10 
µM 203971 (Table 3.2) for 30 minutes. UV irradiation was applied for 30 minutes at 
room temperature. Cells were then lifted, and the cell suspension was transferred and 
centrifuged to recover the cell pellet, which was resuspended in lysis buffer and 





Buffer Kit to attach Cy5.5 dye for visualization, as shown in Figure 4.6. 
 
Table 4.3. Effects of Aryl Azide Photoaffinity Models and Probes on Transcription 















Electrophoresis was performed for both the cross-linked probe as well as the 
competition experiment, using 10 or 20 µg of protein (Figure 4.7). Lane one contains 0.3 
µM 206559 with 30 minute UV treatment. Lane two contains the competition experiment 
using 0.3 µM 206559 with 10 µM 203971 with 30 minute UV treatment. Lane three 
contains 0.3 µM 206559 without UV treatment. 
One band was visualized at approximately 24kD (as indicated by the white box in 
Figure 4.7) that was present with the UV irradiated photoaffinity probe (lane 1). Upon 
treatment with 10 µM 203971 (lane 2), the band appears to be competed off, suggesting it 
is a specific binding interaction. Furthermore, the band is not visible in the non-UV 
treated lane (lane 3). Based on these results, we investigated making an inactive probe for 
comparison.  he “inactive” probe 208797 was synthesized as found in Scheme 4.10. 
Unfortunately, appending the propargyl ether restored its activity, making it unsuitable as 

















Molecular weight marker 
b
Total amount of protein used in experiment 
c
Lane 1 containing 0.3 µM of 206559 with 30 minute UV treatment 
d
Lane 2 containing competition experiment: 0.3 µM of 206559 and 10 µM 203971 with 30 minute 
UV treatment 
e
Lane 3 containing 0.3 µM 206559 with no UV treatment 
Chemical Validation of Photolabeling Experiment 
 We attempted to confirm that our probe molecule retains structural integrity 
during the photolysis process by attempting to capture a generic amino acid. Therefore, 
we employed 206454 (Scheme 4.11) in capture experiments using N-acetyl glycine 
methyl ester (118) to mimic a peptide-bound amino acid residue in the protein. We 
monitored the progress of the photolysis experiments by HPLC and TLC, allowing them 
to run up to 12 hours. The small peaks that grew in were examined by LC/MS. However, 
the molecular weights did not correlate with our desired product (119) or any potential 
side products. 
 
Figure 4.7. SDS-PAGE Gel of Photo Affinity Labeling Experiment 
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Future Direction: Photolabeling 
Identification of the band discovered in the PAL experiment has not yet occurred, 
but we are planning to do so in the future. Because our molecules contain an acetylene 
handle, we can also utilize Click chemistry to append biotin to the cross-linked protein-
containing probes to capture with streptavidin. We can then isolate the desired protein(s) 
for identification and further exploration.




Chapter 5  
Expanded Screening Effort 
 
Introduction to Virtual Screening 
Virtual screening (VS) methods encompass three-dimensional (3D) 
methodologies such as high-throughput docking (HTD) and pharmacophore searching 
(PS), as well as two-dimensional (2D) techniques such as structural similarity searching 
and quantitative structure-activity relationship (QSAR) models. While such predictive 
techniques are not 100% accurate, their predictions can provide an “enrichment” in 




VS techniques can be divided into two main approaches. Structure-based 
techniques require a 3D structure of the macromolecular target and do not necessarily 
require known active ligands. Ligand-based techniques require known active ligands but 
do not necessarily require that the target be known. Furthermore ligand-based techniques 
may use 2D or 3D methods. Given that the macromolecular target is not known for this 
project, ligand-based approaches will have to be employed to conduct virtual screening. 
Ligand-based 2D methods are often simpler and quicker than 3D methods and can 
be employed when little structural information or SAR data is available.
130, 131
 The basis 
for such 2D models is that compounds with similar structures often have similar 
properties and should therefore have similar activities.
132
 Therefore, similarity searching 
at a high level should produce compounds with similar activities. This basic premise is 
also employed in 2D-QSAR analysis, which utilizes molecular properties to evaluate the 
biological activity of a compound. These properties are converted to molecular 
descriptors that are used to predict what analogs are likely to have similar activities based 
on given properties and their overall contribution to activity. 
One 3D ligand-based technique is to generate a pharmacophore model based on 




for other potentially active ligands. A key component of PS is that only a small subset of 
compounds need be tested to generate a computational pharmacophore model.
133
 In the 
situation where the binding conformations for the active ligands are not known, 3D 
overlays of the active ligands are generated. A computer program simultaneously 
minimizes the conformational energies of each of the individual structures while 
maximizing the overlap between the structures based on features like hydrogen bond 
donors/acceptors, aromatic rings, hydrophobic groups, etc. Once the overlays are 




Once a pharmacophore model has been generated, it generally undergoes 
iterations of validation and refinement. After optimization, it can be employed in virtual 
screens to survey chemical databases. The model is used to identify ligands that contain 
similar features in the same spatial alignment to those used to construct the model. This 
search may retrieve compounds of similar structure to the active ligands, or it may supply 
novel scaffold structures, known as “scaffold-hopping,”
134, 135
 which can expand 
medicinal chemistry efforts into novel chemical space. 
Pharmacophore Model Generation 
Because we have not yet identified the macromolecular target(s) of our small 
molecules, we enlisted the help of Paul Kirchhoff to perform virtual screening of a new 
100,000 compound library in the CCG. First, we selected a training set of 11 of our most 
active conformationally restricted analogs (with the exception of 100601) in transfected 
PC-3 prostate cancer cells from a test set of 106 ligands. We chose a conformationally 
restricted training set to minimize the number of conformations the ligands could adopt 
and thus produce less error during minimization. Ligand overlays were created based on 
active structures with IC50 <15 µM that showed low toxicity of <10% inhibition of WST-
1 reduction at 100 µM (Table 5.1). The two most active compounds (102445 and 203971) 
were used to create the initial overlay. MOE defaults for flexible alignment were used 
with the addition of an aromatic center to the scoring function. After inputting the two 
structures into MOE, the program simultaneously minimized the conformational energies 
of each of the individual structures while maximizing the overlap between the structures 




groups, etc. The resulting coordinates were then frozen, and the next most active structure 
was added, and the program was re-executed. The process was repeated with each 
additional structure moving from most potent to least potent, creating the overlay shown 
in Figure 5.1. 
Multiple pharmacophore models were generated from the overlays and tested 
against the 106 test ligands as part of the pharmacophore validation and refinement. The 
goal was to find a pharmacophore model which would select the most potent structures 
while avoiding those which were also toxic. The pharmacophore model chosen is shown 
in Figure 5.1-Figure 5.4 and was named the “Potent and Low  oxicity (PaL )” 
pharmacophore. This model showed some selectivity toward the more potent compounds 















































       aRefer to Table 2.1 for assay descriptions 
 
The model considers the four features shown as essential—the two aromatic rings 
(F1, F3; green), the hydrophobic/aromatic atom (F4; cyan), and the hydrogen bond 
acceptor (F2; red) as shown in the structural overlay in Figure 5.1. Figure 5.2 through 
Figure 5.4 show the distances in Angstroms between each essential feature.  







Figure 5.1. Potent and Low Toxicity Pharmacophore Model with Structural Overlay 
Figure 5.2. Potent and Low Toxicity Pharmacophore Model with Distances from 








Figure 5.3. Potent and Low Toxicity Pharmacophore Model with Distances from 
Hydrogen Bond Acceptor Feature 2 
Figure 5.4. Potent and Low Toxicity Pharmacophore Model with Distances from 




A second pharmacophore model was constructed using 9 active compounds with 
IC50<15 µM that showed significant WST-1 toxicity of >60% inhibition at 100 µM 
(Table 5.2) and was labeled “Potent and  oxic (Pa ).”  he idea here is that this model 
could be used to eliminate toxic compounds identified by a virtual screen with the PaLT 
model. Note that the training set was not restricted to rigid analogs. The PaT model 
considers five features shown as essential for potent and toxic compounds—two aromatic 
rings (F2, F3; green), the hydrophobic atoms (F1, F4; black), and the hydrogen bond 
donor (F5, fuchsia) as shown in the structural overlay in Figure 5.5. The model was 
constructed analogously to the PaLT pharmacophore. The two most toxic compounds 
(101200 and 100691) were used to create the initial high toxicity model parameters using 
MOE. The resulting coordinates were then frozen, and the next most toxic structure was 
added, and the program was re-executed. The iterative process continued moving from 




















































      
a
Refer to Table 2.1 for assay descriptions 
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Figure 5.5. Potent and Toxic Pharmacophore Model with Structural Overlay 
Figure 5.6. Potent and Toxic Pharmacophore Model with Distances from 







We were interested in virtually screening a new 100K library recently added to 
the CCG-collection. Before performing the screen, we needed to determine whether our 
models were capable of enriching the hit rate. Therefore, we tested our pharmacophore 
models retrospectively based on the results from our prior 54K high-throughput screen 
using five methodologies. Table 5.3 summarizes the results of each model using Güner 
and Henry’s metrics for analyzing pharmacophores.
9
 The labels are as follows: hit list 
(Ht) represents the number of compounds that the model identifies as active, and the hit 
Figure 5.7. Potent and Toxic Pharmacophore Model with Distances from 
Hydrophobic Feature 4  
Figure 5.8. Potent and Toxic Pharmacophore Model with Distances from Hydrogen 




list actives (Ha) describes the number of actual actives within the hit list. D represents the 
total number of compounds in the database, in this case 54,161 and A is the number of 
confirmed active compounds in the library, in this case 103 (see Figure 5.9 and 
discussion).  
The calculations found in Table 5.3 are determined as follows
136
: the percent yield 
of actives (%Y) is calculated as:  
    
  
  
     
 and the percent ratio of actives (%A) in the hit list is given by: 
    
  
 
      







     
      
 








We examined each of the models for their ability to enrich the hit rate over the 
actual hit rate of the entire high-throughput screen. The first model employed our potent 
and low toxicity pharmacophore (Pharma PaLT). The model retrieved 7376 compounds it 
considered active, however only 20 of those were actually active, affording a poor 
percent yield of actives. This also afforded a low percent ratio of actives. In the ideal 
situation, these should be maximized and equal to one another. When they are not, the 
goodness of hit list suffers. This score ranges from 1 (best) to 0 (worst), and calculates 
the balance between the maximum yield and maximum percent of actives retrieved. 
Equation 5.1. Percent Yield of Actives (%Y)  
Equation 5.2. Percent Ratio of Actives (%A) 
Equation 5.3. Enrichment (or Enhancement, E) 




Secondly, we utilized our potent and toxic pharmacophore (Pharma PaT) to remove any 
toxic compounds from pharmacophore PaLT (Table 5.3), which afforded a hit list of 
7339. However, while this removed 37 compounds, it did not enhance enrichment over 
the PaLT model, again yielding disappointing results. 
Next, we examined 2D calculations, first using a similarity search of greater than 
65% similarity to the eleven compounds originally used in our potent and low toxicity 
model. Although it only retrieved one active compound, the similarity search afforded the 
best results in terms of enrichment, with 9 times enrichment versus random selection 
from the library. A QSAR model using the same PaLT compounds was also explored, 
with an activity cutoff of 10
-6
 M. A second QSAR model removing compounds with 
toxicity greater than 30% (QSAR PaT (30%)) was also employed. Both yielded slight 
enrichment of around 3 times over random selection. The 2D methods appeared to 
actually outperform the 3D methods. This is likely due to our lack of knowledge of the 
actual binding conformation. We selected our training set from conformationally 
restricted analogs. The forced rigidity in combination with lacking knowledge regarding 
the actual binding pose may have further complicated the use of a 3D pharmacophore. 
Furthermore, the algorithm used for conformational energy minimization may introduce 
additional error into our 3D model. A study conducted by Venkatraman, et al. arrived at a 
similar conclusion and prefaced that virtual screening results are strongly influenced by 
the target family, the structure and conformation of the query, and the types of ligand sets 
used. While 2D models can be more efficient virtual screening methods, they can 
nevertheless be problematic. The overall 3D shape is critical for binding interactions with 
the active site, which cannot be predicted using 2D models. Additionally, only 3D models 
are well-suited for scaffold hopping for exploration of new chemical space.
137
 
Disappointingly, our 3D pharmacophore models did not provide any significant 
enrichment versus random selection. While our 2D similarity search yielded the best 
results, it did not achieve a high enough level of enrichment to be useful, i.e. it would not 
be predicted to select a small enough subset of the CCG collection to make screening 
cost-effective. 
136
 In all of our pharmacophore models, we achieved a poor GH score, 
ranging from 0.02 to 0.05. Therefore, we decided not to perform a virtual screen of the 
























Hit List(Ht) 7376 7339 57 3907 3844 
Hit List 
Actives(Ha) 
20 20 1 22 21 
% Yield 
Actives(%Y) 
0.27 0.27 1.75 0.56 0.55 
% Ratio Actives 
(%A) 
19.42 19.42 0.97 21.36 20.39 
Enrichment (E) 1.43 1.43 9.23 2.96 2.87 
Goodness of Hit 
(GH) 
0.04 0.04 0.02 0.05 0.05 
a
Application of potent and low toxicity pharmacophore, IC50 <15 µM; WST-1 toxicity <10% 
b
Results following subtraction of potent and toxic pharmacophores IC50 <15 µM; WST-1 toxicity >60% 
from potent and low toxicity pharmacophore model  
c
65% Similarity search using potent and low toxicity pharmacophore, IC50 <15 µM; WST-1 toxicity <10% 
d
QSAR model using potent and low toxicity pharmacophore, IC50 <15 µM; WST-1 toxicity <10% with an 




QSAR model subtracting toxic pharmacophores  from potent and low toxicity model with an activity 
cutoff of 10
-6
 M and WST-1 toxicity >30%. 
 
High-throughput Screen 
In 2007, a primary high-throughput screen (HTS) similar to the HTS that 
discovered lead compound 1423
62
 was conducted on a 54,161 compound screening 
collection. The collection was tested at 10 µM concentration in an SRE.L assay 
performed at the CCG at the University of Michigan. Due to testing limitations at the 
time, the primary screening data were not followed up on as completely as is now 
possible. 
Figure 5.9 provides the HTS triage funnel for the 54K screen in our reevaluation 
of the 2007 data. The primary assay conducted at 10 µM in HEK293 cells afforded 2547 
active compounds, which were triaged to eliminate compounds that were luciferase 
inhibitors, promiscuous, or contained structural alerts to afford 1500 compounds for 
confirmation. The primary screen was repeated at 10 µM concentration for the 1500 
active compounds, which yielded 170 confirmed actives (11.3% confirmation rate). Dose 
response confirmation was performed on the 170 confirmed actives (original DMSO 
stock), which provided 107 titrating compounds (62.9% titration rate). Four compounds 
were also eliminated at this step, as they were found to be luciferase inhibitors. This 
provided 103 small molecules for follow up.  




Due to budgetary constraints, we purchased 61 commercially available fresh 
powders from ChemDiv. We selected representative compounds from individual clusters 
to avoid selecting highly similar compounds, maintaining diversity in our analog set. The 
61 fresh powder samples were tested in two assays, each at a single dose of 10 µM and 
100 µM concentrations using SRE.L and WST-1 assays in transiently transfected PC-3 
prostate cancer cells. This secondary assay was performed by Sue Wade in the Neubig 
laboratory. Compounds with > 50% SRE.L inhibition and <20% WST-1 inhibition 
afforded 30 compounds for follow up dose response. Of these 30 compounds, we selected 
3 top compounds with nanomolar potencies for further study. The structures and IC50s of 
the 3 small molecules can be found in Figure 5.10. 
 
 
Figure 5.9. High-throughput Screen Triage Funnel 
Figure 5.10. Structures of the Top 3 Compounds for Follow Up from High-




We were interested in preliminary elucidation of SAR for the three confirmed 
actives of greatest interest. The CCG library contained data on compounds that had 
already been tested in the original HTS SRE.L assay in HEK293 cells at 10 µM with 
greater than 70% similarity to 58146. Table 5.4 illustrates the compounds previously 
tested. Analog 58150 removes the meta-methyl and provides 2,4-dichloro groups, which 
maintains activity. Shortening the tether region 1 carbon, and installing an ester (96396 
and 8610) significantly reduces activity, with a longer ester length corresponding with 
even less activity. Much of the remaining analogs tested are completely inactive and are 
indicative of the narrow SAR of this series.  
Cmpd 
No Structure 
























































































































































The Neubig laboratory obtained samples from the CCG library for a limited 
number of analogs for each of the three small molecules and performed an SRE.L/Renilla 
dual-luciferase assay as well as monitored WST-1 cytotoxicity for each in PC-3 prostate 
cancer cells. These samples were from a new collection that was not included in the 
original high-throughput screen. Preliminary SAR for 58146 (Table 5.5) shows that 
replacing the methyl group with an electron withdrawing, lipophilic chlorine (123851) 
significantly reduces potency and decreases selectivity over TK-Renilla. Replacement of 
the 3-methylphenyl with a benzyl moiety (123857) somewhat reduces potency and 
greatly reduces efficacy. Amazingly, shortening the tether region between the thiol and 
acid moieties by a single carbon (123860) abolishes activity. No cytotoxicity was 



























0.20 56, 91 0, 0 0, 0 
123851 
 
1.3 30, 84 16, 14 0, 0 
123857 
 





 20, 30 6, 4 0, 0 
a
Refer to Table 2.1 for assay descriptions.   
b
N = 2 
c
Could not be calculated 
 
 Table 5.6 compares a single analog (112019) with compound 5677. Replacement 
of the methyl group with the chloro group reduces potency slightly, increases efficacy, 























0.12 40, 55 11, 45 0, 0 
112019 
 
0.30 40, 68 0, 49 0, 0 
a
Refer to Table 2.1 for assay descriptions
  
b
N = 1 
 
Preliminary SAR for remaining compound 86769 can be found in Table 5.7. 
Removal of the methyl group (186414) significantly reduces activity and selectivity. 
Removal of the chloro group (186447) significantly reduces potency, but improves 
selectivity versus TK-Renilla. Moving the sulfonamide from the para-position to the 
meta-position and adding a methyl substituent to the center aromatic ring (186528) is 
Table 5.5. Preliminary SAR for CCG-58146 




detrimental to potency and efficacy. As with the other scaffolds, none of the analogs in 























0.10 40, 62 20, 87 0, 0 
186414 
 
2.4 33, 69 16, 97 0, 0 
186447 
 
3.1 37, 60 0, 50 0, 0 
186528 
 
14 15, 50 39, 88 0, 0 
a
Refer to Table 2.1 for assay descriptions
 
b
N = 1 
Future Direction 
The observed SAR for 58146 indicates that modifications can be made to this 
highly potent structure with retention of activity, but that the SAR is narrow, which can 
be indicative of a well-defined binding site. As a low molecular weight molecule, it is 
ideal for further derivatization. The Neubig lab is currently performing functional assays 
to ensure that the compound is inhibiting Rho-mediated gene transcription and is not a 
luciferase inhibitor. Our triage should have eliminated this possibility; however before 
purchasing additional analogs or executing extensive synthesis, we would like to confirm 
the basis of its activity. 
  








Despite the well-documented role for the RhoA transcriptional signaling pathway 
in the progression and metastasis of multiple cancers, there are few chemical inhibitors of 
the pathway. Much of the effort has focused on modifications of RhoGTPases as well as 
on the downstream effectors of Rho GTPases, such as ROCK. Targeting ROCK, while 
showing great promise, fails to target the RhoA pathway in its entirity, as the effector acts 
through only one portion of the pathway (Figure 1.2). 
Previous work by Chris Evelyn indicates that compound 1423 inhibits 
downstream of RhoA, but distinct from the interaction of the serum response factor 
(SRF) with the serum response element (SRE). Results suggest that the compound 
interferes with SRF/MKL1-dependent transcriptional activation; however, the exact 
mechanism could not be elucidated. Evidence suggests that effects on MKL1/SRF 
function, such as affecting nuclear translocation/efflux, recruitment, posttranslational 




To our knowledge, 1423 and its analogs are uniquely targeting the RhoA 
transcriptional signaling pathway by acting on an aspect of MKL1-related function. 
Furthermore, 1423 and its analogs are the only known compounds specifically targeting 
the RhoA pathway in this manner. A recent paper has further demonstrated the ability of 
1423 to prevent nuclear accumulation of MKL1, and therefore block the stimulation of 
SRF-dependent transcription. The Patti lab has recently demonstrated that patients with 
type 2 diabetes (T2D) as well as insulin-resistant subjects with normal insulin levels and 
a family history (FH
+
) of T2D maintain increased expression levels of MKL1 and SRF 
target genes. Furthermore, upregulation of STriated muscle Activator of Rho Signaling 
(STARS), which activates SRF, was also discovered in these subjects. Upregulation of 




Pharmacological inhibition of MKL1-dependent SRF transcriptional activation using 
1423 led to increased glucose uptake and glucose tolerance in mice. Specifically targeting 




There are three significant goals for moving this project forward. The first goal is 
to identify the protein band discovered using our photoaffinity labeling experiment. 
Identification of the band could provide a novel target(s) which could lead to 
identification of the mechanism of action. Due to the modest potency of our probes and 
the possibility that the target is in low abundance, we will also explore using Stable 
Isotope Labeling by Amino Acids (SILAC)
139
 as a  more global and sensitive method for 
detecting the binding target for our compounds. Discovery of the target and/or 
mechanism of action could allow us to pursue more rational, structure-based drug design.   
Second, we would like to identify and optimize a new scaffold. Synthesis of the 
libraries exploring aromatic modifications provided little improvement in the potency of 
our analogs. Although analog 203971 demonstrated a modest IC50 of 6.4 µM, it has 
shown significant anti-migratory properties in PC-3 prostate cancer cells. Recent 
evidence has shown that efficacy may be more important than potency in determining the 
effects on migration (Haak, Neubig, unpublished). However, after synthesizing our small 
libraries, we feel we have exhausted potential SAR using the current scaffold. We hope 
that one of our newly identified compounds from the recent HTS follow up will provide a 
novel more potent leadfor optimization. 
Finally, we are interested in continued testing of 203971. We are interested in 
determining the pharmacokinetic parameters as well as the relative bioavailability to 
determine the feasibility of further in vivo exploration. If further in vivo testing appears 
viable, we will explore the metabolic stability of the analog, as well as move into 









All starting materials were obtained from commercial suppliers and were used 
without purification. All reactions involving air- or moisture-sensitive compounds were 
performed under an N2 atmosphere. NMR spectra were recorded on a Bruker instrument 
at 500 MHz, Bruker instrument at 300 MHz, or a Varian instrument at 400 MHz for 
1
H. 
Chemical shift values are recorded in  units (ppm). Mass spectra were recorded on a 
Waters Corporation LCT Time-of-Flight mass spectrometer or on an Agilent 
Technologies LC/MS system using a 1200 Series LC and 6130 Quadrupole LC/MS 
(Agilent Technologies, Santa Clara, CA, USA) in positive mode with 5–10 L injection 
volume and a linear gradient of 10% Solvent D (0.02% TFA and 0.1% acetic acid in 
acetonitrile) in Solvent C (0.02% TFA and 0.1% acetic acid in water) to 90% Solvent D 
in Solvent C over 6 min with a hold at 90% for 7 min, as indicated. HPLC retention times 
were recorded using an Agilent 1100 Series employing an Agilent ZORBAX Eclipse Plus 
C18 column (4.6 x 75 mm, 3.5 m). Retention times were collected using Gradient A 
(10-90% Acetonitrile/Water over 13 minutes) or Gradient B (50-90% Acetonitrile/Water 
over 13 minutes) as indicated. 
 
General Procedure for Acylation of Amine (Procedure A). Amine (1.42 mmol) was 
dissolved in 2M NaOH (2.36 mL) and was treated with desired acyl chloride (1.18 
mmol). The reaction was allowed to stir overnight at room temperature. The resulting 
solution was washed with DCM (15 mL), and the aqueous layer was acidified to pH 2 
using 2M HCl. The aqueous layer was extracted with EtOAc (2 x 20 mL). The combined 
extracts were washed with brine (20 mL), dried (MgSO4), and concentrated to afford title 





General Procedure for Acylation of Amine (Procedure B). Dichloromethane (11.2 
mL) was added to a flask containing desired amine (1.18 mmol) and was treated with 
desired acyl chloride (1.18 mmol) and TEA (1.18 mmol). The mixture was allowed to stir 
at room temperature overnight. The mixture was concentrated and then partitioned 
between 2M HCl (10 mL) and EtOAc (10 mL). The aqueous layer was extracted a second 
time with EtOAc (10 mL). The organics were combined, washed with brine (20 mL), 
dried (MgSO4), and concentrated to afford title compounds that were used without further 
purification unless indicated. 
 
General Procedure for Amide Coupling (Procedure C). Anhydrous THF (0.3 M) was 
added to a flask containing starting acid (1.18 mmol), and was treated with corresponding 
amine (1.18 mmol), followed by HOBt (1.42 mmol), EDC (1.42 mmol), and DIPEA 
(1.42 mmol). The solution was allowed to stir overnight at room temperature and was 
then diluted with EtOAc (15 mL) and was washed with saturated NaHCO3 (20 mL), 
followed by 1M HCl (20 mL) and then brine (20 mL). The organics were dried (MgSO4) 
and concentrated to afford crude product. 
 
General Procedure for Amide Coupling (Procedure D). Anhydrous DCM (1.0 mL) 
was added to flask containing aniline (0.10 mmol) and was treated with EDC (0.15 
mmol) followed by DMAP (0.15 mmol), and corresponding acid (0.11 mmol). The 
solution was allowed to stir overnight at room temperature and was then diluted with 
DCM (4 mL) and was washed with 1M HCl (2.5 mL), followed by saturated NaHCO3 
(2.5 mL). The organics were dried (MgSO4) and concentrated to afford crude product. 
Chapter 2 
3-(3,5-bis(trifluoromethyl)benzamido)propanoic acid (2a). Prepared according to 
Procedure A to afford 0.384 g (1.17 mmol, 99% yield) of title compound as a white 




H NMR (500 MHz, DMSO-d6): δ 
12.30 (bs, 1H), 9.09-9.05 (m, 1H), 8.49 (s, 2H), 8.32 (s, 1H), 3.53-3.45 (m, 2H), 2.58-






(203009). Compound was prepared using 2a (0.104 g, 0.316 mmol) and 4-
Chlorobenzylamine (0.049, 0.348 mmol) according to Procedure C. Crude material was 
purified using column chromatography (80-90% EtOAc/Hex) to afford 0.084 g (0.186 
mmol, 59% yield) of title compound as a white solid. TLC Rf: (80% EtOAc/Hex): 0.24. 
TOF MS-ESI m/z [M+H]
+
 453.0; [M+Na] 474.9. HPLC (gradient A): ret time = 7.25 
min; purity = 99%. 
1
H NMR (500 MHz, DMSO) δ 9.12 (t, J = 5.6 Hz, 1H), 8.49 (s, 2H), 
8.33 (s, 1H), 7.26-7.20 (m, 4H), 4.25 (d, J = 5.9 Hz, 2H), 3.54 (q, J = 6.5 Hz, 2H), 2.52-
2.46 (m, 2H). 
 
N-((2-(4-chlorophenyl)thiazol-4-yl)methyl)-3,5-bis(trifluoromethyl)benzamide 
(102445). Prepared according to Procedure B using [2-(4-Chlorophenyl)-1,3-thizol-4-
yl)]methanamine hydrochloride and 2 eq of TEA. Reaction was re-dissolved in EtOAc 
(10 mL) and washed with saturated NaHCO3 (10 mL) followed by brine (10 mL). 
Organic layer was dried (MgSO4) and concentrated to afford 0.153 g (0.329 mmol, 89% 
yield) of title compound as a yellow solid. TOF MS-ESI m/z [M+H]
+
 464.9; [M+Na] 
486.9. HPLC (gradient A): ret time = 8.69 min; purity = 99%. 
1
H NMR (500 MHz, 
DMSO-d6): δ 9.6  (t, J = 5.6 Hz, 1H), 8.58 (s, 2H), 8.35 (s, 1H), 7.95 (d, J = 8.4 Hz, 2H), 
7.64 (s, 1H), 7.57 (d, J = 8.4 Hz, 2H), 4.68 (d, J = 5.6 Hz, 2H). 
 
N-(3-(4-chlorophenoxy)propyl)-3,5-bis(trifluoromethyl)benzamide (102447). 
Prepared according to Procedure B using 3-(4-chlorophenoxy)propan-1-amine 
hydrochloride and 2 eq of TEA to afford 0.471 g (1.11 mmol, 94% yield) of title 
compound as a yellow solid. TOF MS-ESI m/z [M+H]
+
 426.0; [M+Na] 448.0. HPLC 
(gradient A): ret time = 8.51 min; purity = 99%. 
1
H NMR (500 MHz, DMSO-d6): δ 9.05 
(t, J = 5.5 Hz, 1H), 8.49 (s, 2H), 8.32 (s, 1H), 7.32 (d, J = 8.8 Hz, 2H), 6.96 (d, J = 8.8 






 A solution of 4-Chloroaniline (0.536 g, 
4.20 mmol) in toluene (4.2 mL) was treated with 3-Bromopropylamine hydrobromide (4) 




was collected and treated with aqueous 2M NaOH (5 mL), and the aqueous layer was 
extracted with DCM (2 x 20 mL). Combined extracts were washed with water (5 mL), 
dried (MgSO4), and concentrated to afford a light brown oil. Crude material was purified 
by flash chromatography (0-10% Methanolic ammonia/DCM) to afford 0.099 g (0.536 
mmol, 38% yield) of title compound as a yellow oil. TLC Rf (10% Methanolic 
ammonia/DCM): 0.39. 
1
H NMR (500 MHz, DMSO-d6): 7.14-7.10 (m, 2H), 6.56-6.52 (m, 




Prepared using 5 according to Procedure C. Crude material was purified by flash 
chromatography (33% EtOAc/Hex) to afford 0.073 g (0.172 mmol, 45% yield) of title 
compound as a light brown solid. TLC Rf (33% EtOAc/Hex): 0.38. TOF MS-ESI m/z 
[M+H]
+
 425.1; [M+Na] 447.1. HPLC (gradient A): ret time = 7.60 min; purity = 99%. 
1
H 
NMR (500 MHz, CDCl3): δ 8.0  (s, 1H), 7.21-7.11 (m, 2H), 6.74-6.66 (m, 1H), 6.64-
6.56 (m, 2H), 3.67 (q, J = 6.4 Hz, 2H), 3.29 (t, J = 6.3 Hz, 2H), 1.98 (p, J = 6.3 Hz, 2H). 
 
N-(3-((4-chlorophenyl)amino)propyl)-3,5-bis(trifluoromethyl)benzamide 
hydrochloride (101425 B2). Compound 5 (0.104 g, 0.245 mmol) was dissolved in a 1.05 
M methanolic HCl solution (2 mL), and the reaction was allowed to stir at room 
temperature for 4 hours. The solvent was removed in vacuo and the resulting solid was 
sonicated in ether and dried in vacuo to afford 0.111 g (0.241 mmol, 98% yield) of title 
compound as a white solid. Elemental Analysis: C = 46.62%, H = 3.24%, N = 5.94%, 
consistent with desired HCl salt. HPLC (gradient A): ret time = 7.61 min; purity = 97%. 




H NMR (500 MHz, CDCl3): δ 11. 5 (s, 2H), 8.61 (s, 
1H), 8.49 (s, 2H), 8.01 (s, 1H), 7.57 (d, J = 8.0 Hz, 2H), 7.39 (d, J = 7.8 Hz, 2H), 3.67 (s, 







(102532). Compound 100594 (0.050 g, 0.114 mmol) was dissolved in anhydrous THF 




Reaction was then refluxed for 14 h and was then cooled to room temperature and 
quenched by the addition of 1N HCl (15 mL). The mixture was refluxed for 1 h and was 
cooled to 0 °C. The pH was adjusted to 10 using 2M NaOH and was extracted with 
EtOAc (3 x 25 mL). The combined organics were washed with brine (25 mL), dried 
(MgSO4), and concentrated. Crude material was purified using flash chromatography (1-
5% Methanolic ammonia/DCM) to afford 0.027 g (0.066 mmol, 58% yield) of title. TLC 
Rf (1% Methanolic ammonia/DCM): 0.11. TOF MS-ESI m/z [M+H]
+
 410.9. HPLC 
(gradient A): ret time = 6.32 min; purity = 96%. 
1
H NMR (500 MHz, CDCl3): δ 7.81 (s, 
2H), 7.78 (s, 1H), 7.17-7.05 (m, 2H), 6.57-6.45 (m, 2H), 3.92 (s, 2H), 3.20 (t, J = 6.6 Hz, 




 4-Chloroaniline (0.151 g, 1.18 mmol) 
was dissolved in hot acetonitrile (5.60 mL).  The solution was treated with 3-
bromopropionyl chloride (0.183 mL, 1.82 mmol) in acetonitrile (1.0 mL) over several 
minutes. The reaction was heated at reflux for 3h. The reaction was cooled, concentrated, 
and re-dissolved in EtOAc (20 mL). The organic layer was washed with saturated 
NaHCO3 (20 mL) followed by 1N HCl (20 mL) and then brine (20 mL). It was then dried 
(MgSO4) and concentrated to afford 0.291 g (1.11 mmol, 94% yield) of title compound as 
a white solid. 
1
H NMR (500 MHz, DMSO-d6): δ 10.20 (s, 1H), 7.6  (d, J = 8.9 Hz, 2H), 





 Compound 7 was dissolved in acetonitrile (0.65 mL) and was treated with 
3,5-bis(trifluoromethyl)benzyl amine (0.171 g, 0.704 mmol). The solution was heated at 
reflux for 6 hour and 40 minutes. Upon cooling, the solution was diluted with water (5 
mL), and the pH was adjusted to 10. The solution was extracted with DCM (3 x 10 mL), 
and the combined extracts were washed with saturated NaHCO3 (10 mL) followed by 
brine (10 mL). Organics were dried (MgSO4) and concentrated to afford 0.084 g (0.198 
mmol, 104% yield). TOF MS-ESI m/z [M+H]
+
 424.9; [M+Na] 446.9. HPLC (gradient 
A): ret time = 6.18 min; purity = 95%. 
1




7.78 (s, 3H), 7.44 (d, J = 8.7 Hz, 2H), 7.27 (d, J = 8.7 Hz, 2H), 3.96 (s, 2H), 3.11-2.94 




 Hydroxylamine hydrochloride 
(0.073 g, 1.05 mmol) was dissolved in Methanol (1.0 mL) and was treated with 3,5-
Bis(trifluoromethyl)benzaldehyde (0.165 ml, 1.00 mmol) added dropwise. The reaction 
mixture was refluxed for 5 hours, was allowed to cool to room temperature, and was 
poured into ice water. Formed precipitate was filtered and washed with water.  The solid 
was then dried in vacuo to afford 0.176 g (0.684 mmol, 68% yield) of title compound as a 
white solid. Compound was used without further purification. 
1
H NMR (500 MHz, 




 But-3-enoic acid (0.170 ml, 2.00 mmol) was 
dissolved in dichloromethane (3.20 mL) and placed under N2. DMAP (0.008 g, 0.065 
mmol) and 4-chloroaniline (0.510 g, 4.00 mmol) were added, and the mixture was cooled 
to 0-5 °C. EDC (0.383 g, 2.00 mmol) was added and the solution was stirred for 10 
minutes. The solution then stirred at RT for an additional 6 hours. After stirring, DCM 
(10 mL) was added. Organics were washed with 10% HCl (10 mL) followed by saturated 
NaHCO3 (10 mL). Reaction was concentrated to yield 0.343 g (1.75 mmol, 88% yield) of 
title compound as an off-white solid. 
1
H NMR (500 MHz, DMSO-d6): δ 10.11 (s, 1H), 
7.65-7.60 (m, 2H), 7.39-7.30 (m, 2H), 6.03-5.88 (m, 1H), 5.22-5.11 (m, 2H), 3.13 (dd, J 





 Compound 9 (0.075 g, 0.292 mmol) was added to a 
stirring solution of N-(4-chlorophenyl)but-3-enamide (0.039 g, 0.200 mmol) in DCM (2.1 
ml), and the reaction was cooled to 0 °C. Sodium hypochlorite (1.134 g, 0.800 mmol) 
was added dropwise over 20 minutes and the resulting mixture was stirred and allowed to 
warm to ambient temperature. The solution continued to stir overnight. Water (5 mL) was 
added to the solution, and the product was extracted using DCM (3 x 5 mL).  Combined 




yield) of title compound as an off-white solid. No further purification was performed. 
TOF MS-ESI m/z [M+H]
+
 451.0; [M+Na] 473.0. HPLC (gradient B): ret time = 6.37 
min; purity = 82%. 
1
H NMR (500 MHz, DMSO-d6): δ 10.22 (s, 1H), 8.28 (s, 2H), 8.24 
(s, 1H), 7.63 (d, J = 8.7 Hz, 2H), 7.37 (d, J = 8.7 Hz, 2H), 5.25-5.17 (m, 1H), 3.77-3.68 






N-(4-chlorophenyl)pent-4-ynamide (11). Compound was prepared according to 
Procedure C using 1.1 eq of 4-Chloroaniline to afford 0.129 g (0.621 mmol, 83% yield) 
of title compound as a tan solid. TOF MS-ESI m/z [M+Na] 230.0. 
1
H NMR (500 MHz, 
CDCl3): δ 7. 7 (d, J = 8.8 Hz, 2H), 7.42 (s, 1H), 7.28 (d, J = 8.8 Hz, 2H), 2.68-2.55 (m, 





 Compound 15 (0.050 g, 0.196 mmol) and 
compound 11 (0.041 g, 0.197 mmol) were suspended in a 1:1 mixture of t-Butanol (0.392 
mL) and Water (0.392 mL).  L-Ascorbic acid (0.020 ml, 0.020 mmol) was added, 
followed by copper(II) sulfate pentahydrate (6.53 µl, 1.96 µmol). The heterogeneous 
mixture was stirred vigorously overnight and was then diluted with water (2 mL), cooled 
in ice, and the brown solid was collected by filtration. The precipitate was washed with 
cold water (2 x 10 mL) and was dried in vacuo. Crude material was purified using 
column chromatography (35-50% EtOAc/Hex) to afford 0.017 g (0.037 mmol, 19% 
yield) of title compound as a colorless oil. TLC Rf: (50% EtOAc/Hex): 0.30. TOF MS-
ESI m/z [M+H]
+
 463.0; [M+Na] 484.9. 
1
H NMR (500 MHz, CDCl3): δ 8.21 (s, 2H), 7.99 
(s, 1H), 7.93 (bs, 1H), 7.65 (bs, 1H), 7.45 (d, J = 8.8 Hz, 2H), 7.29-7.25 (m, 2H), 3.32-
3.19 (m, 2H), 2.99-2.86 (m, 2H). 
 
N-(but-3-yn-1-yl)-3,5-bis(trifluoromethyl)benzamide (13). 3-Butyn-1-amine 
hydrochloride (12) (0.053 g, 0.500 mmol) was suspended in DCM (5.0 mL) and was 




by triethylamine (0.150 ml, 1.07 mmol).  The reaction was stirred vigorously overnight at 
room temperature. The yellow solution was concentrated in vacuo to afford 0.150 g 
(0.485 mmol, 97% yield) of title compound as a yellow oil.  The compound was used 
without further purification. TOF MS-ESI m/z [M+H]
+
 463.0; [M+Na] 484.9. 
1
H NMR 
(500 MHz, CDCl3): δ 8.2  (s, 2H), 8.02 (s, 1H), 6.67 (s, 1H),  .70-3.63 (m, 2H), 2.62-









 Compound 17 (0.023 g, 0.150 mmol) and 
compound 13 (0.046 g, 0.150 mmol) were suspended in a 1:1 mixture of t-Butanol (0.300 
mL) and Water (0.300 mL).  L-Ascorbic acid (0.015 ml, 0.015 mmol) was added, 
followed by Copper(II) sulfate pentahydrate (0.010 mL, 0.003 mmol). The heterogeneous 
mixture was stirred vigorously for 48 h and was then diluted with water (2 mL), cooled in 
ice, and the brown solid was collected by filtration. The precipitate was washed with cold 
water (2 x 10 mL) and was dissolved in EtOAc. The filtrate was extracted with EtOAc (2 
x 2 mL) and the organics were combined with the dissolved precipitate. Combined 
organics were washed with brine (5 mL), dried (MgSO4) and concentrated in vacuo. 
Crude material was purified using a Biotage (30-60% EtOAc/Hex) to afford 0.006 g 
(0.037 mmol, 28% yield) of title compound as an off-white solid. TLC Rf (50% 
EtOAc/Hex): 0.34. TOF MS-ESI m/z [M+H]
+
 463.0; [M+Na] 485.0. HPLC (gradient A): 
ret time = 7.83 min; purity = 99%. 
1
H NMR (500 MHz, CDCl3): δ 8.29 (s, 2H), 8.00 (s, 
1H), 7.84 (s, 1H), 7.70-7.61 (m, 2H), 7.55 (s, 1H), 7.59-7.44 (m, 3H), 3.96-3.91 (m, 2H), 
3.17-3.12 (m, 2H). 
 
4-(3,5-bis(trifluoromethyl)benzamido)benzoic acid (2b). Prepared according to 
Procedure B to afford 0.432 g (1.15 mmol, 98% yield) of title compound as a white solid. 




H NMR (500 MHz, DMSO-d6): δ 12.81 (s, 1H), 10.91 





(101329). Prepared using 2b according to Procedure C. Crude material was triturated 
with EtOAc to afford 0.201 g (0.413 mmol, 36% yield) of title compound as a light 
yellow solid. TLC Rf (50% EtOAc/Hex): 0.62. TOF MS-ESI m/z [M+H]
+
 487.0; [M+Na] 
509.0. HPLC (gradient A): ret time = 8.46 min; purity = >95%. 
1
H NMR (500 MHz, 
DMSO) δ 10.9  (s, 1H), 10. 5 (s, 1H), 8.65 (s, 2H), 8. 2 (s, 1H), 8.11-8.01 (m, 2H), 
8.01-7.91 (m, 2H), 7.90-7.81 (m, 2H), 7.51-7.37 (m, 2H). 
 
3-(3,5-bis(trifluoromethyl)benzamido)benzoic acid (2c). Prepared according to 
Procedure B to afford 0.429 g (1.14 mmol, 96% yield) of title compound as a white solid. 




H NMR (500 MHz, DMSO-d6): δ 1 .18 (bs, 1H), 10.81 
(s, 1H), 8.66 (s, 2H), 8.39-8.38 (m, 2H), 8.08 (d, J = 7.5 Hz, 1H), 7.73 (d, J = 7.6 Hz, 
1H), 7.55-7.45 (m, 1H). 
N-(3-((4-chlorophenyl)carbamoyl)phenyl)-3,5-bis(trifluoromethyl)benzamide 
(101343). Prepared using 2c according to Procedure C. Crude material was purified using 
Combiflash (33-66% EtOAc/Hex) to afford 0.222 g (0.437 mmol, 38% yield) of title 
compound as a brown solid. TLC Rf (50% EtOAc/Hex): 0.66. TOF MS-ESI m/z [M+H]
+
 
487.0; [M+Na] 509.0. HPLC (gradient A): ret time = 8.44 min; purity = >95%. 
1
H NMR 
(500 MHz, DMSO-d6): δ 10.86 (s, 1H), 10. 6 (s, 1H), 8.67 (s, 2H), 8. 1 (s, 1H), 8.28 (s, 
1H), 8.11 (d, J = 8.1 Hz, 1H), 7.84 (d, J = 8.8 Hz, 2H), 7.77 (d, J = 7.7 Hz, 1H), 7.59 (t, J 
= 7.9 Hz, 1H), 7.44 (d, J = 8.8 Hz, 2H). 
 
2-(3,5-bis(trifluoromethyl)phenyl)-4H-benzo[d][1,3]oxazin-4-one (20). Prepared 
according to Procedure C. Desired product was actually N-(2-((4-
chlorophenyl)carbamoyl)phenyl)-3,5-bis(trifluoromethyl)benzamide. Crude material was 
triturated with DCM to afford 0.103 g of title compound as a white solid. 
1
H NMR (500 
MHz, DMSO-d6): δ 8.78 (s, 2H), 8.31-8.28 (m, 1H), 8.08 (s, 1H), 7.93-7.89 (m, 1H), 








 Compound 20 (0.050 g, 0.139 mmol) and 4-Chloroaniline (0.035 g, 0.278 
mmol) were added to a tube and were treated with DMAP (0.017 g, 0.139 mmol) 
dissolved in Pyridine (1.0 mL) and stirring began. Additional Pyridine (1.0 mL) was 
added, and solution was heated to 80 °C for 34 h. Solution was then acidified to pH ~2 
using conc. HCl. Resulting white solid was filtered and then washed with water. Crude 
material was purified using flash chromatography (33% EtOAc/Hex) to afford 0.036 g 
(0.074 mmol, 53% yield) of title compound as a white solid. TOF MS-ESI m/z [M+Na] 
509.0. HPLC (gradient A): ret time = 9.35 min; purity = >95%. 
1
H NMR (500 MHz, 
DMSO-d6): δ 11.27 (s, 1H), 10.59 (s, 1H), 8.49 (s, 2H), 8.40 (s, 1H), 7.96 (d, J = 7.9 Hz, 




(102443). Prepared using 2a according to Procedure C. Crude material was triturated 
with EtOAc to afford 0.034 g (0.073 mmol, 7% yield) of title compound as a white solid. 
TOF MS-ESI m/z [M+H]
+
 465.0; [M+Na] 487.0. HPLC (gradient A): ret time = 8.10 
min; purity = 99%. 
1
H NMR (500 MHz, DMSO-d6) δ 9.10 (d, J = 5.0 Hz, 1H), 8.51 (s, 
2H), 8.32 (s, 1H), 8.07 (d, J = 8.6 Hz, 1H), 7.30 (s, 1H), 7.23-7.17 (m, 1H), 4.12 (t, J = 
8.5 Hz, 2H), 3.61 (dd, J = 12.4 Hz, 6.5 Hz, 2H), 3.15 (t, J = 8.5 Hz, 2H), 2.80 (t, J = 6.9 
Hz, 2H). 
 
(1S,2R)-2-(3,5-bis(trifluoromethyl)benzamido)cyclopentanecarboxylic acid (2d). 
Prepared according to Procedure A to afford 0.196 g (0.531 mmol, 93% yield) of title 
compound as a white solid. 
1
H NMR (500 MHz, DMSO-d6): δ 12.0  (s, 1H), 8.81 (d, J = 
7.9 Hz, 1H), 8.44 (s, 2H), 8.31 (s, 1H), 4.65-4.52 (m, 1H), 3.02-2.95 (m, 1H), 2.09-1.74 
(m, 5H), 1.62-1.46 (m, 1H). 
 
N-((1R,2S)-2-((4-chlorophenyl)carbamoyl)cyclopentyl)-3,5-
bis(trifluoromethyl)benzamide (102526). Prepared using 2d according to Procedure C. 




title compound as a white solid. MS-ESI m/z [M+Na] 500.0. HPLC (gradient A): ret time 
= 8.16 min; purity = 99%. 
1
H NMR (500 MHz, DMSO-d6): δ 9.96 (s, 1H), 8.8  (d, J = 
8.2 Hz, 1H), 8.21 (s, 1H), 8.21 (s, 1H), 8.19 (s, 2H), 7.50-7.47 (m, 2H), 7.21-7.17 (m, 
2H), 4.76-4.64 (m, 1H), 3.15 (q, J = 7.8 Hz, 1H), 2.12-1.78 (m, 5H), 1.59-1.49 (m, 1H). 
 
2-(1-(3,5-bis(trifluoromethyl)benzoyl)piperidin-2-yl)acetic acid (2e). 2-(piperidin-2-
yl)acetic acid hydrochloride (0.259 g, 1.44 mmol) was added to a flask, followed by 2M 
NaOH (2.4 ml) and dichloromethane (2.4 ml). The reaction mixture was stirred 
vigorously, and 3,5-bis(trifluoromethyl)benzoyl chloride (0.216 ml, 1.20 mmol) was 
added via syringe. The reaction mixture was stirred vigorously overnight. After stirring 
overnight the DCM layer was removed and aqueous layer was acidified to ~pH 2 and was 
extracted using EtOAc (2 x 20 mL). The combined organics were washed with brine (20 
mL), dried (MgSO4), and were concentrated. Crude material was purified by flash 
chromatography (4:6:0.5 EtOAc/Hex/AcOH) to afford 0.091 g (0.237 mmol, 20% yield) 
of title compound as a yellow oil. TLC Rf (4:6:1 EtOAc/Hex/AcOH): 0.30. 
1
H NMR (500 




(203001). Prepared using 2e according to Procedure C. Reaction molarity was 0.24 M, 
and reaction was diluted with EtOAc (10 mL), and washing steps utilized 15 mL each. 
Crude material was purified using flash chromatography (1-1.5% Methanolic 
ammonia/DCM) to afford 0.030 g (0.059 mmol, 25% yield) of title compound as a 
yellow oil. TLC Rf (1.5% Methanolic ammonia/DCM): 0.21. HPLC (gradient A): ret time 
= 8.11 min; purity = 99%. TOF MS-ESI m/z [M+Na] 514.9. 
1
H NMR (500 MHz, 
CDCl3): δ 8.88 (s, 1H), 7.9  (s, 1H), 7.78 (s, 2H), 7.51 (d, J = 7.8 Hz, 2H), 7.23 (d, J = 
8.6 Hz, 2H), 3.48-3.40 (m, 1H), 3.33-3.22 (m, 1H), 3.06-2.94 (m, 1H), 2.80-2.63 (m, 1H), 
1.94-1.44 (m, 6H). 
 
Piperidin-4-one, TFA salt (21a). tert-Butyl 4-oxopiperidine-1-carboxylate (0.448 g, 




mL, 112 mmol). Reaction was allowed to stir overnight and was concentrated to afford 
0.602 g (2.82 mmol, 126% yield) of title compound as a yellow oil. 
1
H NMR (500 MHz, 
DMSO-d6): δ 9.12 (bs, 2H), 3.44 (s, 4H), 2.60-2.53 (m, 4H). 
 
1-(3,5-bis(trifluoromethyl)benzoyl)piperidin-4-one (22). Compound 21a (0.233 g, 1.10 
mmol) was dissolved in DCM (2.2 mL) and was treated with 3,5-
bis(trifluoromethyl)benzoyl chloride (0.242 mL, 1.33 mmol) and TEA (0.460 mL, 3.30 
mmol). The reaction was stirred overnight at room temperature. Mixture was then diluted 
with DCM (2.0 mL) and was washed with saturated NaHCO3 (20 mL) followed by 
aqueous 1N HCl (20 mL) and then brine (20 mL). Organic layer was dried (MgSO4) and 
concentrated. Crude material was purified by flash chromatography (50% EtOAc/Hex) to 
afford 0.109 g (0.321 mmol, 29% yield) of title compound as a yellow oil. TLC Rf (50% 
EtOAc/Hex): 0.36. 
1
H NMR (500 MHz, DMSO-d6): δ 7.99 (s, 1H), 7.69 (s, 2H), 4.13-





To a solution of 22 (0.345 g, 1.02 mmol) in pyridine (2.8 mL) was added molecular 
sieves (3Å, 8-12 mesh, 0.34 g), and the mixture was stirred at room temperature for 10 
minutes, followed by the addition of hydroxylamine hydrochloride (0.177 g, 2.55 mmol). 
The reaction was allowed to stir overnight at room temperature. Reaction mixture was 
filtered through celite and was rinsed with additional pyridine. The filtrate was diluted 
with water (10 mL) and was extracted with EtOAc (30 mL). Organic layer was dried 
(MgSO4) and concentrated to afford 0.190 g (0.536 mmol, 53% yield) of title compound 
as a white solid. 
1
H NMR (500 MHz, CDCl3): δ 7.97 (s, 1H), 7.91 (s, 2H),  .89 (bs, 2H), 
3.53 (bs, 2H), 2.81 (bs, 1H), 2.66 (bs, 1H), 2.56 (bs, 1H), 2.38 (bs, 1H). 
 
1-(3,5-bis(trifluoromethyl)benzoyl)-1,4-diazepan-5-one (24). Compound 23 (0.190 g, 
0.536 mmol) was suspended in acetone (2.3 ml) and was treated with sodium carbonate 
(0.171 g, 1.61 mmol) in water (0.531 ml), and the mixture was stirred for 10 minutes. A 
solution of p-toluenesulfonyl chloride (0.153 g, 0.805 mmol) in acetone (0.574 ml) was 




removed from the mixture, and additional water (10 mL) was added. The aqueous 
mixture was extracted with dichloromethane (3 x 20 mL). Combined organics were dried 
(MgSO4) and concentrated. Crude material was purified by flash chromatography (5% 
Methanolic ammonia/DCM) to afford 0.116 g (0.327 mmol, 61% yield) of title 
compound as a pale yellow solid. TLC Rf: (5% Methanolic ammonia/DCM): 0.21. TOF 
MS-ESI m/z [M+H]
+
 355.0; [M+Na] 377.0. 
1
H NMR (500 MHz, CDCl3) δ 7.98 (s, 1H), 





 1-chloro-4-iodobenzene (0.239 g, 1.00 mmol) was dissolved in dioxane 
(1.0 mL) and was treated with 24 (0.027 g, 0.076 mmol), Copper(I) iodide (3.0 mg, 0.016 
mmol), cesium carbonate (0.048 g, 0.147 mmol), and N,N-dimethylethylenediamine (1.7 
µl, 0.016 mmol). The tube was evacuated and backfilled with nitrogen two times. The 
reaction was then heated to 100 °C and capped. The reaction was allowed to stir at 100 
°C for 24 hours. The mixture was allowed to cool to room temperature and was filtered 
through a 2 x 0.5 cm pad of silica gel eluting with 10 mL of ethyl acetate. The EtOAc 
was evaporated. Crude material was purified using column chromatography (50-66% 
EtOAc/Hex) to afford 0.017 g (0.037 mmol, 48% yield) of title compound as a colorless 
oil. TLC Rf: (66% EtOAc/Hex): 0.29. TOF MS-ESI m/z [M+H]
+
 465.0; [M+Na] 487.0. 
HPLC (gradient A): ret time = 7.40 min; purity = 99%. 
1
H NMR (500 MHz, CDCl3): δ 
7.99 (s, 1H), 7.90 (s, 2H), 7.37 (d, J = 6.2 Hz, 2H), 7.15 (bs, 2H), 4.20-3.55 (m, 6H), 
3.06-2.78 (m, 2H). 
 
tert-butyl 3-((4-chlorophenyl)carbamoyl)pyrrolidine-1-carboxylate. Prepared using 
N-Boc--proline (0.108 g, 0.500 mmol) and 4-chloroaniline (0.070 g, 0.550 mmol) 
according to Procedure C to afford 0.129 g (0.397 mmol, 79% yield) of title compound as 
an amber oil.  Crude material was used without any further purification. TOF MS-ESI 
m/z [M+Na] 347.1.
 1
H NMR (500 MHz, CDCl3): δ 7. 9 (d, J = 8.8 Hz, 2H), 7.28 (d, J = 






chlorophenyl)carbamoyl)pyrrolidine-1-carboxylate (0.129 g, 0.397 mmol) was dissolved 
in dichloromethane (3.45 ml).  The solution was then cooled to 0 °C, and trifluoroacetic 
acid (1.04 ml, 13.50 mmol) was added dropwise. The solution stirred at room 
temperature for 2 hours and then the solvent was removed in vacuo to afford 0.050 g 
(0.223 mmol, 56% yield) of title compound as a sticky brown oil. 
1
H NMR (500 MHz, 
CDCl3): δ 9.37 (s, 1H), 8.53 (s, 1H), 7.84 (s, 1H), 7.45-7.40 (m, 2H), 7.35-7.28 (m, 2H), 
3.75-3.63 (m, 2H), 3.60-3.45 (m, 3H), 2.55-2.42 (m, 1H), 2.40-2.30 (m, 1H). 
  
1-(3,5-bis(trifluoromethyl)benzoyl)-N-(4-chlorophenyl)pyrrolidine-3-carboxamide 
(203015). Compound was prepared using N-(4-chlorophenyl)pyrrolidine-3-carboxamide 
(0.050 g, 0.148 mmol), 3,5-bis(trifluoromethyl)benzoyl chloride (0.029 mL, 0.162 
mmol), and triethylamine (0.046 mL, 0.325 mmol) according to Procedure B. Crude 
material was purified using a Biotage (45% EtOAc/Hex) to afford 0.018 g (0.039 mmol, 
26% yield) of title compound as a clear oil. TOF MS-ESI m/z [M+H]
+
 465.0; [M+Na] 
486.9. HPLC (gradient A): ret time = 7.69 min; purity = 99%. 
1
H NMR (500 MHz, 
CDCl3): δ 8.27-8.08 (m, 1H), 8.03-7.98 (m, 2H), 7.97-7.93 (m, 1H), 7.48 (d, J = 8.6, 1H), 
7.43 (d, J = 8.6, 1H), 7.30-7.20 (m, 2H), 4.03-3.45 (m, 4H), 3.23-3.04 (m, 1H), 2.41-2.28 
(m, 1H), 2.26-2.15 (m, 1H). 
 
1-(4-chlorophenyl)-5-oxopyrrolidine-3-carboxylic acid (26). A neat mixture of 4-
chloroaniline (0.511 g, 4.01 mmol) and itaconic acid (0.521 g, 4.00 mmol) was heated at 
110 °C for 2 h. Crude material was re-crystallized from water/ethanol to yield 0.353 g 




H NMR (500 MHz, DMSO-d6): δ 12.8  (s, 1H), 7.69 (d, J = 9.0 Hz, 2H), 7.43 (d, J = 




 Compound 26 
(0.076 g, 0.317 mmol) was suspended in toluene (5.29 mL) and to the mixture were 
added t-butanol (0.090 mL, 0.951 mmol), triethylamine (0.067 mL, 0.476 mmol), and 




concentrated in vacuo. Crude material was purified using a CombiFlash system (30% 
EtOAc/Hex) to afford 0.038 g (0.122 mmol, 39% yield) of title compound as a white 
solid. TLC Rf (50% EtOAc/Hex): 0.31. 
1
H NMR (500 MHz, DMSO-d6): δ 7.72-7.63 (m, 
2H), 7.50-7.36 (m, 3H), 4.20 (s, 1H), 4.06 (dd, J = 10.0, 7.0 Hz, 1H), 3.59 (dd, J = 10.1, 
3.8 Hz, 1H), 2.83 (dd, J = 17.1, 8.2 Hz, 1H), 2.42 (dd, J = 17.1, 4.6 Hz, 1H), 1.39 (s, 9H). 
 
4-amino-1-(4-chlorophenyl)pyrrolidin-2-one (28). Compound 27 (0.038 g, 0.122 
mmol) was dissolved in DCM (0.815 mL) and was cooled to 0 °C. TFA (0.408 mL) was 
slowly added to the stirring solution, and the reaction continued stirring at 0 °C for 1 hr 
45 min. The solution was slowly added to 10 mL of cooled 1M NaOH. The mixture was 
then extracted with DCM (2 x 5 mL) and was concentrated in vacuo to afford 0.023 g 
(0.071 mmol, 58% yield) of title compound. Compound was used without further 
purification. 
1
H NMR (500 MHz, CDCl3): δ 7.58-7.53 (m, 2H), 7.34-7.29 (m, 2H), 4.01 
(dd, J = 9.6, 6.6 Hz, 1H), 3.86-3.79 (m, 1H), 3.50 (dd, J = 9.8, 4.0 Hz, 1H), 2.88 (dd, J = 
17.1, 7.3 Hz, 1H), 2.38 (dd, J = 17.0, 4.8 Hz, 1H), 1.49 (s, 2H). 
 
N-(1-(4-chlorophenyl)-5-oxopyrrolidin-3-yl)-3,5-bis(trifluoromethyl)benzamide 
(203606). Compound 28 (0.023 g, 0.109 mmol) was dissolved in DCM (0.218 mL). To 
the stirring solution was added 3,5-bis(trifluoromethyl)benzoyl chloride (0.022 mL, 0.120 
mmol) followed by Triethylamine (0.031 mL, 0.218 mmol). The reaction mixture was 
stirred at room temperature overnight. The mixture was diluted with 10 mL of DCM and 
was washed with 1M aq HCl (5 mL) followed by a wash with sat. aq. NaHCO3 (5 mL) 
and brine (5 mL), and was dried (MgSO4) and concentrated in vacuo. Crude material was 
triturated with DCM to afford 0.021 g (0.047 mmol, 43% yield) of title compound as a 
white solid. TOF MS-ESI m/z [M+H]
+
 451.0; [M+Na] 473.0. HPLC (50-90% 
Acetonitrile/Water over 6 minutes): ret time = 4.20 min; purity = >90%. 
1
H NMR (500 
MHz, DMSO-d6): δ 9. 7 (d, J = 6.7 Hz, 1H), 8.52 (s, 2H), 8.34 (s, 1H), 7.81-7.71 (m, 
2H), 7.51-7.41 (m, 2H), 4.76-4.68 (m, 1H), 4.26 (dd, J = 10.4, 6.9 Hz, 1H), 3.83 (dd, J = 






difluorobenzoic acid (0.014 g, 0.085 mmol) was dissolved in DCM (0.4 mL). DMAP 
(0.217 mg, 1.780 µmol) was added, followed by 28 (0.015 g, 0.071 mmol), and then EDC 
(0.014 g, 0.071 mmol). The solution was stirred at room temperature overnight. DCM (2 
mL) was then added.  The solution was washed with 1N HCl (2 mL) followed by 
saturated NaHCO3 (2 mL). The solvent was concentrated in vacuo. Crude material was 
purified by column chromatography (50-60% EtOAc/Hex) to afford 0.012 g (0.034 
mmol, 48% yield) of title compound as a white solid. TLC Rf (50% EtOAc/Hex): 0.26. 




H NMR (500 MHz, DMSO) δ 9.08 (d, J = 6.6 Hz, 1H), 
7.76-7.69 (m, 2H), 7.63-7.58 (m, 2H), 7.49 (tt, J = 9.3, 2.4 Hz, 1H), 7.46-7.40 (m, 2H), 
4.70-4.61 (m, 1H), 4.25-4.20 (m, 1H), 3.76 (dd, J = 10.4, 3.0 Hz, 1H), 3.01 (dd, J = 17.3, 





 To a stirring solution of 26 (0.050 g, 0.209 mmol) and 3,5-
bis(trifluoromethyl)aniline (0.039 ml, 0.250 mmol) in DMF (0.417 ml) was added EDC 
(0.048 g, 0.250 mmol). The reaction was stirred overnight at room temperature. After 
stirring overnight, the DMF was removed in vacuo. Water was then added (10 mL), and 
the aqueous layer was extracted with EtOAc (3 x 10 mL), and the combined organic 
layers were washed with brine (10 mL), dried (MgSO4), and concentrated in vacuo. 
Crude material was triturated with DCM to afford 0.045 g (0.100 mmol, 48% yield) of 





(500 MHz, DMSO-d6) δ 10.87 (s, 1H), 8.28 (s, 2H), 7.80 (m, 1H), 7.72 (d, J = 8.7 Hz, 






26 was suspended in toluene (17.0 mL) and was treated with benzyl alcohol (0.312 mL, 
3.00 mmol), TEA (0.259 mL, 1.86 mmol), and DPPA (0.209 mL, 0.967 mmol). Reaction 
was refluxed for 6 h, and the solution was concentrated. Crude material was purified by 




to afford title compound as a white solid. TLC Rf (50% EtOAc/Hex): 0.21. 
1
H NMR (500 
MHz, DMSO-d6): δ 7.88 (d, J = 6.4 Hz, 1H), 7.68 (d, J = 8.9 Hz, 2H), 7.46-7.03 (m, 7H), 
5.04 (s, 2H), 4.30-4.23 (m, 1H), 4.13-4.05 (m, 1H), 3.64 (dd, J = 10.1 Hz, 3.6 Hz, 1H), 





Compound 26 (0.030 g, 0.125 mmol) was suspended in toluene (2.09 mL) and to the 
mixture were added 3,5-difluorobenzyl alcohol (0.043 mL, 0.376 mmol), triethylamine 
(0.026 ml, 0.188 mmol), and DPPA (0.032 mL, 0.150 mmol). Reaction mixture was 
refluxed for 6 hours. The reaction was cooled to room temperature and concentrated in 
vacuo. Crude material was purified using a CombiFlash system (18-45% EtOAc/Hex) to 
afford 0.039 g (0.102 mmol, 82% yield) of title compound as a clear oil. TLC Rf (50% 
EtOAc/Hex): 0.19. 
1
H NMR (500 MHz, CDCl3): δ 7.55-7.43 (m, 2H), 7.32-7.20 (m, 2H), 
6.90-6.80 (m, 2H), 6.78-6.68 (m, 1H), 5.77-5.62 (m, 1H), 5.12-5.00 (m, 2H), 4.53-4.35 
(m, 1H), 4.15-4.00 (m, 1H), 3.79-3.59 (m, 1H), 2.96 (dd, J = 17.5, 8.3 Hz, 1H), 2.51 (dd, 





 Compound 26 (0.050 g, 0.209 mmol) was suspended in toluene (3.5 ml) and 
to the mixture were added 3,5-bis(trifluoromethyl)benzyl alcohol (0.154 g, 0.631 mmol), 
triethylamine (0.044 ml, 0.313 mmol), and DPPA (0.054 ml, 0.250 mmol).  Mixture was 
refluxed for 6 hours. The reaction was cooled to room temperature and concentrated in 
vacuo. Crude material was purified using CombiFlash system (25-40% EtOAc/Hex) 
followed by trituration with CHCl3 to afford 0.049 g (0.102 mmol, 49% yield) of title 
compound as an off-white solid. TLC Rf (50% EtOAc/Hex): 0.43. HPLC (gradient A): 
ret time = 7.98 min; purity = 99%. TOF MS-ESI m/z [M+H]
+
 480.9; [M+Na] 502.9. 
1
H 
NMR (500 MHz, CDCl3): δ 7.82 (m, 3H), 7.50 (d, J = 6.2 Hz, 2H), 7.35-7.10 (m, 3H), 
5.64 (s, 1H), 5.21 (s, 2H), 4.48 (s, 1H), 4.18-4.08 (m, 1H), 3.75 (d, J = 8.8 Hz, 1H), 3.03-





3-amino-3-(5-chloro-2-nitrophenyl)propanoic acid  (30).
82
 A mixture of 5-chloro-2-
nitrobenzaldehyde (29) (0.200 g, 1.078 mmol), formic acid (0.165 ml, 4.31 mmol), and 
malonic acid (0.146 g, 1.401 mmol) was heated to 45 °C with stirring and was then 
treated with ammonium formate (0.170 g, 2.69 mmol). The temperature was increased to 
70 °C and held for one hour. The temperature was then increased to 95 °C. After 4 hours, 
concentrated HCl (0.400 mL) was added and heating continued for 1 hour. The mixture 
was then cooled and diluted with water (1 mL), followed by extraction with methyl 
isobutyl ketone (3 x 2 mL). The aqueous layer was separated and its pH was adjusted to 
approximately 4 by addition of 50% KOH solution. The precipitate was collected and 
dried in vacuo to afford 0.098 g (0.401 mmol, 37% yield) of title compound as a yellow 
solid. No further purification was performed. 
1
H NMR (500 MHz, DMSO-d6): δ 7.97 (d, 
J = 2.4 Hz, 1H), 7.93 (d, J = 8.7 Hz, 1H), 7.58 (dd, J = 8.7, 2.3 Hz, 1H), 6.27 (bs, 2H), 
4.61 (dd, J = 8.8, 5.0 Hz, 1H), 2.64-2.56 (m, 1H). 
 
3-(3,5-bis(trifluoromethyl)benzamido)-3-(5-chloro-2-nitrophenyl)propanoic acid 
(31). Compound 30 (0.041 g, 0.168 mmol) was dissolved in 2M NaOH (0.335 ml) and 
then treated with 3,5-bis(trifluoromethyl)benzoyl chloride (0.033 ml, 0.184 mmol). The 
mixture was stirred overnight at room temperature under nitrogen. The basic mixture was 
acidified to pH ~2 using 2M HCl. The acidic mixture was then filtered, and the resulting 
solid was rinsed with water. The solid was dried in vacuo to afford 0.050 g (0.103 mmol, 
62% yield) of title compound as a fluffy white solid. No further purification was 
performed. 
1
H NMR (500 MHz, DMSO-d6) δ 12.62 (s, 1H), 9.55 (d, J = 6.8 Hz, 1H), 
8.49-8.42 (m, 4H), 8.37 (s, 1H), 8.05-8.01 (m, 1H), 7.85-7.83 (m, 1H), 7.66-7.62 (m, 





 Compound 31 (0.021 g, 0.043 mmol) was 
heated with iron(II) sulfate heptahydrate (0.120 g, 0.433 mmol) at 100 °C for 1 hour in 
10% NH4OH (0.722 ml) and Ethanol (0.722 ml). The reaction was cooled and additional 
ethanol was added. The mixture was filtered, then extracted using ethyl acetate (3 x 5 




white residue. The residue was then triturated with chloroform to afford 0.007 g (0.016 





NMR (500 MHz, DMSO-d6) δ 10. 5 (s, 1H), 9. 2 (d, J = 7.4 Hz, 1H), 8.55 (s, 2H), 8.35 





 A mixture of ethyl 1-
cyanocyclopropanecarboxylate (32) (0.186 ml, 1.437 mmol) and 4-chloroaniline (0.183 
g, 1.437 mmol) was heated at 140 °C overnight. The mixture was cooled and the crude 
material was purified using a CombiFlash system (25-50% EtOAc/Hex) to afford 0.034 g 
of title compound as a brown solid. A second purification was performed using a 
CombiFlash system (15% EtOAc/Hex) to afford an additional 0.043 g of title compound 
as a brown solid, totaling 0.077 g (0.349 mmol, 24% yield). TLC Rf (50% EtOAc/Hex): 
0.38. 
1
H NMR (500 MHz, CDCl3): δ 7.58-7.49 (m, 2H), 7.40-7.32 (m, 2H), 3.98-3.85 (m, 




 Compound 33 (0.038 g, 
0.172 mmol) was dissolved in 1M methanolic ammonia (3.5 ml), and to the solution was 
added a spatula tip of Raney nickel catalyst. The mixture was placed on a Parr shaker at 
~34 psi at room temperature for 2 hours. The mixture was filtered through a plug of celite 
topped with MgSO4. The celite was rinsed repeatedly with MeOH, and the filtrate was 
concentrated in vacuo. The compound was then triturated and filtered to afford 0.025 g 
(0.111 mmol, 65% yield) of brown solid.  
 
N-((1-(4-chlorophenyl)-2-oxopyrrolidin-3-yl)methyl)-3,5-
bis(trifluoromethyl)benzamide (203850). Prepared according to Procedure B using 34 
(0.015 g, 0.067 mmol), 3,5-bis(trifluoromethyl)benzoyl chloride (0.014 ml, 0.080 mmol), 
and TEA (0.011 ml, 0.080 mmol). Crude material was purified by column 
chromatography (20-50% EtOAc/Hex) to afford 0.010 g (0.020 mmol, 30% yield) of title 
compound as a crystalline white solid.  TLC Rf (50% EtOAc/Hex): 0.33. TOF MS-ESI 
m/z [M-H]
-
 463.0. HPLC (gradient A): ret time = 8.07 min; purity = 99%. 
1




MHz, CDCl3) δ 8.29 (s, 2H), 8.01 (s, 1H), 7.96-7.91 (m, 1H), 7.62-7.49 (m, 2H), 7.42-
7.30 (m, 2H), 4.20-4.09 (m, 1H), 3.92-3.76 (m, 2H), 3.54-3.47 (m, 1H), 3.00-2.92 (m, 




 DMF (0.878 ml, 11.34 mmol) and 
phosphorus oxychloride (0.061 ml, 0.649 mmol) were heated up to 45 °C using an oil 
bath. 5-Chlorooxindole (0.100 g, 0.597 mmol) was added to the mixture, and the 
temperature was held at 45 °C for 1 hr. The reaction was then cooled to 0 °C, and to the 
cooled mixture was added ammonium hydroxide (17.55 ml, 496 mmol). The mixture was 
warmed to room temperature and allowed to stir for 30 minutes. Reaction mixture was 
then extracted with EtOAc (3 x 20 mL), dried (MgSO4), and concentrated in vacuo. 
Crude oil was triturated with DCM to afford 0.020 g (0.100 mmol, 17% yield) of a 
greenish solid. Filtrate was concentrated and triturated a second time with DCM to yield 
0.030 g (0.154 mmol, 26% yield) of a mustard yellow solid. Filtrate was concentrated and 
triturated a third time with dichloromethane to yield 0.009 g (0.046 mmol, 8% yield) of 
title compound as a mustard yellow solid. NMR showed a mixture of isomers in batch 1 
of solid. Batch 2 appeared to only the E-isomer, as found by NOE. Batch 1: 
1
H NMR 
(500 MHz, DMSO-d6): δ 10.25 (Isomer 2, s, 1H), 10.0  (Isomer 1, s, 1H), 8. 7 (Isomer 2, 
dd, J = 15.1, 4.1 Hz, 1H), 8.22-8.13 (Isomer 2, m, 2H), 7.94 (Isomer 2, dd, J = 15.0, 7.6 
Hz, 1H), 7.86 (Isomer 1, s, 1H), 7.74 (Isomer 1, d, J = 2.0 Hz, 1H), 7.59-7.49 (Isomer 1, 
m, 1H), 7.44 (Isomer 2, d, J = 2.1 Hz, 1H), 7.42-7.34 (Isomer 1, m, 1H), 6.94 (Isomer 1, 
dd, J = 8.2, 2.0 Hz, 1H), 6.89 (Isomer 2, dd, J = 8.1, 2.1 Hz, 1H), 6.74 (Isomers 1 and 2, 
dd, J = 11.4, 8.2 Hz, 2H). Batch 2: 
1
H NMR (500 MHz, DMSO-d6): δ 10.25 (s, 1H), 
8.45-8.30 (m, 2H), 8.24-8.11 (m, 2H), 7.94 (dd, J = 15.1, 7.6 Hz, 1H), 7.44 (d, J = 2.2 
Hz, 1H), 6.89 (dd, J = 8.2, 2.1 Hz, 1H), 6.75 (d, J = 8.2 Hz, 1H). 
 
N-((5-chloro-2-oxoindolin-3-ylidene)methyl)-3,5-bis(trifluoromethyl)benzamide 
(203851). Compound 36 batch 2 (.010 g, 0.051 mmol) was suspended in DCM (0.150 
mL), and to the stirring mixture was added 3,5-bis(trifluoromethyl)benzoyl chloride 
(10.18 µl, 0.057 mmol) followed by TEA (0.010 mL, 0.071 mmol). The reaction mixture 




vacuo and was redissolved in EtOAc (10 mL). The organic layer was washed with 
NaHCO3 (5 mL) followed by 1M HCl (5 mL) and then brine (5 mL). The organic layer 
was then dried (MgSO4) and concentrated in vacuo. The solid was triturated with 
hexanes to yield solid, which was dried and triturated with DCM to afford 0.009 g (0.020 




H NMR (500 
MHz, DMSO-d6): δ 12.   (d, J = 10.5 Hz, 1H), 11.02 (s, 1H), 8.69 (d, J = 10.4 Hz, 1H), 
8.53 (s, 1H), 8.49 (s, 2H), 7.98 (d, J = 2.3 Hz, 1H), 7.21 (dd, J = 8.1, 2.2 Hz, 1H), 6.92 




-(6-chloropyridin-3-yl)propane-1,3-diamine. 2-Chloro-5-aminopyridine (0.088 g, 
0.685 mmol) was dissolved in Toluene (0.700 mL) and treated with 3-Bromopropylamine 
hydrobromide (4) (0.050 g, 0.228 mmol). Mixture was heated at reflux for 40 minutes. 
After cooling, precipitate was collected and treated with aqueous 15% aq NaOH (1 mL), 
and the aqueous layer was extracted with DCM (3 x 2 mL). Combined extracts were 
washed with water (2 mL), dried (MgSO4), and concentrated to afford a purple oil. Crude 
material was purified by flash chromatography (10-14% Methanolic ammonia/DCM) to 
afford 0.013 g (0.070 mmol, 31% yield) of title compound as a yellow oil. TLC Rf (10% 
Methanolic ammonia/DCM): 0.20. 
1
H NMR (500 MHz, CDCl3): δ 7.75 (d, J = 3.0 Hz, 
1H), 7.08 (d, J = 8.6 Hz, 1H), 6.86 (dd, J = 8.6 Hz, 3.1 Hz, 1H), 4.51 (bs, 1H), 3.20 (t, J = 
6.6 Hz, 2H), 2.88 (t, J = 6.5 Hz, 2H), 1.77 (p, J = 6.5 Hz, 2H), 1.35 (bs, 2H). 
 
N-(3-((6-chloropyridin-3-yl)amino)propyl)-3,5-bis(trifluoromethyl)benzamide 
(203059). Compound was prepared using N
1
-(6-chloropyridin-3-yl)propane-1,3-diamine 
(0.013 g, 0.070 mmol) and 3,5-bis(trifluoromethyl)benzoic acid (0.020 g, 0.077 mmol) 
according to Procedure C. Crude material was purified using column chromatography 
(30-50% EtOAc/Hex) to afford 0.018 g (0.042 mmol, 60% yield) of title compound as a 
yellow solid. TLC Rf (50% EtOAc/Hex): 0.37. HPLC (gradient A): ret time = 7.42 min; 
purity = 99%. TOF MS-ESI m/z [M+H]
+
 425.9; [M+Na] 447.9. 
1
H NMR (500 MHz, 














(203063). Compound was prepared using N
1
-(5-chloropyridin-2-yl)propane-1,3-diamine 
(0.025 g, 0.135 mmol) and 3,5-bis(trifluoromethyl)benzoic acid (0.038 g, 0.148 mmol) 
according to Procedure C. Crude material was purified by column chromatography (50% 
EtOAc/Hex) to afford 0.033 g (0.078 mmol, 58% yield) of title compound. TLC Rf (50% 
EtOAc/Hex): 0.38. TOF MS-ESI m/z [M+H]
+
 425.9; [M+Na] 447.9. 
1
H NMR (500 MHz, 
CDCl3): δ 8. 6 (s, 2H), 8.24 (t, J = 6.5 Hz, 1H), 8.04 (s, 1H), 7.96 (d, J = 2.5 Hz, 1H), 
7.40-7.34 (m, 1H), 6.42 (d, J = 8.8 Hz, 1H), 4.82 (t, J = 6.9 Hz, 1H), 3.60-3.55 (m, 4H), 





was prepared according to Procedure C, with slight modification. 3,5-difluorobenzoic 
acid (0.047 g, 0.298 mmol) was dissolved in THF and was treated with HOBt and EDC, 
and was allowed to stir for 20 minutes. DIPEA was added and stirring continued for 10 
minutes. Compound 5 (0.050 g, 0.271 mmol) was then added. Crude material was 
purified using column chromatography (25-36% EtOAc/Hex) to afford 0.032 g (0.099 
mmol, 36% yield) of title compound as an off-white solid. HPLC (gradient A): ret time = 




H NMR (500 MHz, CDCl3): δ 
7.24 (d, J = 5.0 Hz, 2H), 7.18-7.04 (m, 2H), 7.00-6.89 (m, 1H), 6.81-6.69 (m, 1H), 6.61-
6.48 (m, 2H), 4.05 (bs, 1H), 3.55 (q, J = 6.4 Hz, 2H), 3.20 (t, J = 6.4 Hz, 2H), 1.89 (p, J = 
6.5 Hz, 2H). 
 
(3,5-bis(trifluoromethyl)phenyl)(3-(hydroxymethyl)piperidin-1-yl)methanone (38). 
Prepared using 1.05 eq (1.05 mmol) 3,5-bis(trifluoromethyl)benzoic acid according to 
Procedure C. Crude material was purified by flash chromatography (40-50% EtOAc/Hex) 




solid. TLC Rf (50% EtOAc/Hex): 0.18. 
1
H NMR (500 MHz, CDCl3): δ 7.9  (s, 1H), 7.87 
(s, 2H), 4.50-4.15 (m, 1H), 3.76-3.36 (m, 3H), 3.34-3.17 (m, 1H), 3.00 (dt, J = 38.8, 10.3 




 To a stirring 
solution of 38 (0.051 g, 0.144 mmol) and DIPEA (0.163 ml, 0.933 mmol) in DCM (0.167 
ml) at 0 °C was added sulfur trioxide pyridine complex (0.075 g, 0.474 mmol) in 
anhydrous DMSO (0.571 mL). The reaction was stirred at 0 °C for 20 minutes and was 
then warmed to room temperature. Reaction was stirred for 2.5 hours and was quenched 
with water (3 mL). The aqueous layer was extracted with DCM (3 x 3 mL). Combined 
organics were washed with 1N HCl (3 mL) followed by brine (3 mL). Organics were then 
dried (MgSO4) and concentrated in vacuo. Crude material was purified using a 
CombiFlash system (60% EtOAc/Hex) to afford 0.040 g (0.113 mmol, 79% yield) of title 
compound as an off-white solid. TLC Rf (60% EtOAc/Hex): 0.25. 
1
H NMR (500 MHz, 
CDCl3): 1.3:1.0 mixture of rotamers, δ 9.79 (rotamer 1, s), 9.60 (rotamer 2, s, 1H), 7.97-





 4-Chloroaniline (0.004 g, 0.031 mmol) and 39 (0.017 g, 0.047 
mmol) in DCE (0.105 ml) was cooled to 0 °C and was treated with sodium 
triacetoxyborohydride (0.013 g, 0.063 mmol). The reaction was stirred overnight at room 
temperature. The mixture was diluted with EtOAc (2 mL) and was quenched with DI 
water (1 mL). Additional EtOAc (2 mL) was added, and the pH of the aqueous layer was 
adjusted to 10 using saturated NaHCO3 and 2M NaOH. The organic layer was removed, 
dried (MgSO4), and concentrated in vacuo. Crude material was purified by column 
chromatography (15-30% EtOAc/Hex) to afford 0.012 g (0.026 mmol, 82% yield) of title 
compound as a clear oil. TLC Rf (30% EtOAc/Hex): 0.29. TOF MS-ESI m/z [M+H]
+
 
465.1; [M+Na] 487.1. HPLC (gradient A): ret time = 8.39 min; purity = 99%. 
1
H NMR 
(500 MHz, CDCl3): δ 7.9  (s, 1H), 7.8  (d, J = 9.4 Hz, 2H), 7.20-7.00 (m, 2H), 6.56 (d, J 




2.05-1.95 (m, 1H), 1.94-1.78 (m, 1H), 1.77-1.67 (m, 1H), 1.56-1.44 (m, 1H), 1.38 (h, J = 




 A solution of 
racemic BINAP (4.61 mg, 0.016 mmol) and tris(dibenzylideneacetone)dipalladium(0) 
(7.37 mg, 8.05 µmol) in toluene (4.0 mL) was stirred under nitrogen at 90 °C for 10 
minutes and was cooled to 40 °C. 3-(tert-Butoxycarbonylamino)-pyrrolidine (0.075 g, 
0.403 mmol), 1-chloro-4-iodobenzene (0.106 g, 0.443 mmol), and sodium tert-butoxide 
(0.062 g, 0.644 mmol) were added, and the mixture was stirred at 40 °C under nitrogen 
for 18 h. The reaction was then heated to 85 °C for five hours. The reaction mixture was 
cooled to room temperature, diluted with EtOAc (7 mL), and was filtered through a plug 
of celite. The filtrate was then concentrated in vacuo. Crude material was purified using a 
CombiFlash system (10% EtOAc/Hex) to afford 0.007 g (0.024 mmol, 6% yield) of title 
compound as an amber oil. TLC Rf (10% EtOAc/Hex): 0.15. 
1
H NMR (500 MHz, 
CDCl3) δ 7.20-7.12 (m, 1H), 6.51-6.40 (m, 2H), 4.71 (s, 1H), 4.36 (s, 1H), 3.53 (dd, J = 
9.6, 5.9 Hz, 1H), 3.42-3.36 (m, 1H), 3.29 (td, J = 8.8, 5.3 Hz, 1H), 3.18-3.07 (m, 2H), 
2.28 (dq, J = 13.8, 7.0 Hz, 1H), 1.98-1.91 (1, 2H), 1.45 (s, 9H). 
 
1-(4-chlorophenyl)pyrrolidin-3-amine (41). Compound 203854 (0.021 g, 0.071 mmol) 
was dissolved in DCM (0.472 ml) and was cooled 0 °C. TFA (0.236 ml) was slowly 
added and the solution continued to stir at 0 °C. After 45 minutes, crude material was 
added to cooled 2M NaOH (5 mL). The mixture was then extracted with DCM (4 x 5 
mL). The combined organic layers were dried (MgSO4)  and concentrated in vacuo to 
afford 0.012 g (0.061 mmol, 86% yield) of title compound as a yellow solid. No further 
purification was performed. 
1
H NMR (500 MHz, CDCl3): δ 7.18-7.12 (m, 2H), 6.47-6.41 
(m, 2H), 3.71 (p, J = 5.8 Hz, 1H), 3.51-3.39 (m, 2H), 3.33-3.23 (m, 2H), 2.98 (dd, J = 
9.3, 4.7 Hz, 1H), 2.27-2.18 (m, 1H), 1.85-1.76 (m, 1H). 
 
N-(1-(4-chlorophenyl)pyrrolidin-3-yl)-3,5-bis(trifluoromethyl)benzamide (203855). 
Compound 41 (0.012 g, 0.061 mmol) was dissolved in DCM (0.610 mL), and to the 




mmol) followed by TEA (0.026 ml, 0.183 mmol. The reaction was stirred under nitrogen 
at room temperature overnight. The reaction mixture was concentrated in vacuo, and the 
solid was partitioned between saturated aqueous NaHCO3 (5 mL) and EtOAc (10 mL). 
The aqueous layer was extracted a second time with EtOAc (10 mL), and the combined 
organics were washed with brine (10 mL), dried (MgSO4), and concentrated in vacuo. 
Solid was triturated with DCM to afford 0.005 g (0.011 mmol, 18% yield) of title 




H NMR (500 MHz, DMSO-
d6): δ 9.12 (d, J = 6.7 Hz, 1H), 8.52 (s, 2H), 8.33 (s, 1H), 7.23-7.17 (m, 2H), 6.60-6.54 
(m, 2H), 4.71-4.62 (m, 1H), 3.63-3.56 (m, 1H), 3.47-3.23 (m, 1H), 3.29-3.23 (m, 1H), 
2.34-2.27 (m, 1H), 2.16-2.06 (m, 1H). 
 
N-((1-(3,5-bis(trifluoromethyl)benzyl)piperidin-3-yl)methyl)-4-chloroaniline 
(203847). To a stirring solution of JR-1-012 (0.050 g, 0.104 mmol) in anhydrous 
tetrahydrofuran (2.1 ml) was added LAH (0.313 ml, 0.313 mmol), and the reaction was 
stirred at 75 °C overnight. The reaction mixture was cooled to 0 °C and water (0.285 mL) 
was added dropwise, followed by a 15% aqueous NaOH solution (0.285 mL), followed 
by water (0.855 mL). The mixture was then filtered and washed with additional THF. 
The solution was then concentrated in vacuo. Crude material was purified by column 
chromatography (15-25% EtOAc/Hex) to afford 0.014 g (0.031 mmol, 30% yield) of title 





H NMR (500 MHz, CDCl3) δ 7.81-7.75 (m, 3H), 7.12-7.06 (m, 2H), 6.52-6.45 
(m, 2H), 3.76-3.49 (m, 3H), 3.01 (s, 2H), 2.82 (d, J = 6.3 Hz, 1H), 2.72-2.62 (m, 1H), 
2.13-2.05 (m, 1H), 1.99-1.88 (m, 2H), 1.87-1.77 (m, 1H), 1.76-1.66 (m, 1H), 1.63-1.59 
(m, 1H), 1.17-1.03 (m, 1H). 
Chapter 3 
Kinetic solubility assay. Working compound solutions were prepared by dissolving 
compound in DMSO to afford 25 mM solutions. Solubility testing was conducted at room 
temperature in a 96-well NUNC-F plate using pH 7.4 PBS buffer. PBS buffer (199 µL) 
was added to wells A1-A5; B1-12; C1-12; and D1-12. DMSO (1 µL) was added to wells 




and 100 µL of working test compound solution was added to E1; F1; and G1. A series of 
2-fold dilutions was prepared using the working stock solutions in E, F, and G1, 
respectively. Following dilution, 1 µL aliquots were transferred from dilution wells to 
corresponding test wells (E1 to B1, F1 to C1, G1 to D1, etc.) The 96-well plate was then 
loaded into the UV/Vis plate reader and was shaken for 5 cycles. Using SoftMax 
software, wells A1-A5 were labeled as “blank,” and each replicate was given its own 
respective label. Each replicate was plotted logarithmically using concentration versus 
absorbance value. Data from each replicate was combined, averaged, and graphed 
logarithmically. The point at which the absorbance begins to increase was identified, and 
the point of inflection between no absorbance and the point where it begins to rise was 
considered to be the solubility of the compound.  
 
Parallel Artificial Membrane Permeability Assay. The PAMPA assay was conducted 
using the PAMPA Explorer kit from pION at a single pH of 7.4. Due to low compound 
solubility, the system solution was prepared by adding System Solution concentrate (6.75 
mL), followed by Milli-Q water (75 mL), acetonitrile (50 mL), and additional Milli-Q 
water (118.75 mL) while stirring.  The pH of the solution was adjusted to 7.4 using 
freshly prepared 0.5 M NaOH (aq).  
A blank plate was prepared by transferring 150 µL of the pH adjusted system 
solution to a UV plate. The blank was read using pION software to ensure no microbial 
growth was present. A deep well plate containing the working solutions was prepared by 
transferring 5 µL of a 10 mM stock solution of desired compound to a corresponding 
well. This was done in quadruplicate for each compound. Each well was then diluted with 
1000 µL of pH adjusted system solution. A reference plate was then prepared by 
transferring 150 µL of the working solutions from the deep well plate into a UV plate. 
 he plate was then read as the “reference plate” using pION software. 
The PAMPA sandwich plate was then prepared using a donor plate and an 
acceptor plate. The donor plate was prepared by transferring 200 µL of working solutions 
from the deep well plate to the donor plate. The acceptor plate containing the membrane 
was inverted and 5 µL of lipid was dispensed on each membrane. The acceptor plate was 




was added to the top of the donor plate, establishing the sandwich plate, which was 
incubated for 4 hours. 
Following incubation, the sandwich was separated, and 150 µL from the acceptor 
wells were transferred to a UV plate and was read as “acceptor plate” using pION 
software.  he same was performed for the donor plate, which was read as “donor plate” 
using pION software. The pION software then computed permeability, providing a bin of 
low, medium, or high permeability based on the pION standard ranking system.  
 
Scratch Assay. PC-3 prostate cancer cells in 10% FBS DMEM media were plated into a 
12-well plate (~400,000 cells per well) and were incubated for at 37 °C for 24 hours to 
form a confluent monolayer. A vertical scratch was made across the monolayer using a 
200 Lpipette tip. The 10% FBS DMEM buffer was removed and replaced with 0.5% 
FBS DMEM buffer, and an initial image was captured. Compound or control DMSO was 
then added to each well, affording a final 0.1% DMSO concentration. The cells were then 
incubated at 37 °C for 24 hours, and a final image was capture. The scratch area was then 
analyzed using ImageJ software. 
 
2-((3,5-bis(trifluoromethyl)benzamido)oxy)acetic acid (2f). Prepared according to 
Procedure A to afford 0.371 g (1.12 mmol, 95% yield) of title compound as a white solid. 




H NMR (500 MHz, DMSO-d6): δ 8. 9 (s, 2H), 8.   (s, 
1H), 4.55 (s, 2H). 
 
N-(2-((3-chlorophenyl)amino)-2-oxoethoxy)-3,5-bis(trifluoromethyl)benzamide 
(101200).  Prepared using 2f according to Procedure C. Crude material was purified by 
flash chromatography (20-30% EtOAc/hexanes) to afford 0.027 g (0.061 mmol, 5% 
yield) of title compound. Waters TOF MS-ESI m/z [M+H]
+
 441.1; [M+Na] 463.0. HPLC 
(gradient A): ret time = 8.10 min; purity = 99%. 
1
H NMR (500 MHz, DMSO-d6): δ 12.70 
(bs, 1H), 10.61 (s, 1H), 8.42 (s, 1H), 8.34 (s, 1H), 7.86 (s, 1H), 7.52 (d, J = 10 Hz, 1H), 





2-((3-(trifluoromethyl)benzamido)oxy)acetic acid (2g). Prepared according to 
Procedure A to afford 0.228 g (0.866 mmol, 73% yield) of title compound as a white 
solid. TOF MS-ESI m/z [M+H]
+
 263.0; [M+Na] 287.0. 
1
H NMR (500 MHz, DMSO-d6): 
δ 8.25-7.65 (m, 5H), 4.25 (s, 2H). 
 
N-(2-((4-chlorophenyl)amino)-2-oxoethoxy)-3,5-bis(trifluoromethyl)benzamide 
(101202). Prepared using 2g according to Procedure C. Crude material was purified by 
flash chromatography (50-65% EtOAc/Hex) to afford 0.102 g (0.027 mmol, 32% yield) 
of title compound as a yellow solid. TLC Rf (50% EtOAc/Hex): 0.11. Waters TOF MS-
ESI m/z [M+H]
+
 373.1; [M+Na] 395.0. 
 
1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid (43). Nipecotic acid (42) (0.200 g, 
1.549 mmol), and sodium hydroxide (1.703 ml, 1.703 mmol) were stirred in a solution of 
dioxane (3.40 mL) and water (1.70 mL). The solution was cooled to 0 °C and di-tert-
butyl dicarbonate (0.395 ml, 1.703 mmol) was added. The reaction mixture was then 
warmed to room temperature and was stirred overnight. The solution was concentrated in 
vacuo to approximately 2 mL and was cooled in an ice bath, covered with ~3 mL of ethyl 
acetate, and acidified with a dilute solution of KHSO4 (10% solution) to pH~2. The 
aqueous phase was extracted with EtOAc (4 x 15 mL). The organics were combined, 
washed with brine (20 mL), dried (MgSO4), filtered, and concentrated to afford 0.349 g 
(1.52 mmol, 96% yield) of title compound as a white solid. No further purification was 
performed. %. 
1
H NMR (500 MHz, DMSO-d6): δ 12.38 (s, 1H), 4.03-3.76 (m, 1H), 3.75-
3.60 (bs, 1H), 2.87-2.78 (m, 1H), 2.35-2.25 (m, 1H), 1.95-1.85 (m, 1H), 1.66-1.57 (m, 
1H), 1.56-1.46 (m, 1), 1.42-1.28 (m, 11H). 
 
tert-butyl 3-((4-chlorophenyl)carbamoyl)piperidine-1-carboxylate (44). 4-
Chloroaniline (0.179 g, 1.407 mmol) was dissolved in dichloromethane (9.4 mL), and to 
the stirring solution was added EDC (0.270 g, 1.407 mmol) followed by DMAP (0.172 g, 
1.407 mmol) and 43 (0.215, 0.938 mmol). The mixture was stirred at room temperature 
under nitrogen overnight. The dichloromethane layer was removed in vacuo and the 




layer was extracted with ethyl acetate (3 x 10 mL). Combined organics were washed with 
1N HCl (25 mL) followed by saturated NaHCO3 (25 mL), and brine (25 mL). The 
organics were dried (MgSO4), filtered, and concentrated in vacuo to yield 0.440 g of an 
amber oil. Oil was partitioned between 1N HCl (20 mL) and ethyl acetate (20 mL). The 
aqueous layer was extracted with additional ethyl acetate (3 x 10 mL). The organic layers 
were combined, washed with brine (25 mL), dried (MgSO4), filtered, and concentrated to 
afford 0.315 g (0.930 mmol, 99% yield) of title compound an amber oil. No further 
purification was performed. %. 
1
H NMR (500 MHz, DMSO-d6): δ 10.15 (s, 1H), 7.66-
7.60 (m, 2H), 7.38-7.32 (m, 2H), 3.95-3.80 (m, 2H), 2.84-2.70 (m, 1H), 2.49-2.40 (m, 
1H), 1.97-1.90 (m, 1H), 1.75-1.56 (m, 2H), 1.47-1.30 (m, 11H). 
 
N-(4-chlorophenyl)piperidine-3-carboxamide (45). Compound 44 (1.28 g, 3.78 mmol) 
was dissolved in dichloromethane (25 mL), and the solution was cooled to approximately 
-10 °C. To the cooled stirring solution was added TFA (12.5 mL). The reaction mixture 
continued stirring at -10 °C for 1.5 h and then was poured into 100 mL of cooled 2M 
NaOH. The cooled basic solution was extracted with dichloromethane (3 x 30 mL), and 
the combined organics were dried (MgSO4), filtered, and concentrated to afford 0.754 g 
(3.15 mmol, 84% yield) of title compound as a tan solid. No further purification was 
performed. %. 
1
H NMR (500 MHz, CDCl3): δ 10.75 (s, 1H), 7.57-7.51 (m, 2H), 7.27-7.24 
(m, 2H), 3.33-3.23 )m, 1H), 3.15-3.05 (m, 1H), 2.93 (dd, J = 5, 10 Hz, 1H), 2.80-2.70 (m, 
1H), 2.60-2.53 (m, 1H), 2.10-2.03 (m, 1H), 2.00-1.91 (m, 2H), 1.83-1.70 (m, 2H), 1.63-
1.53 (m, 1H). 
 
Ethyl 1-(3,5-bis(trifluoromethyl)benzoyl)piperidine-3-carboxylate (47). Ethyl 
piperidine-3-carboxylate (42) (0.466 ml, 3.00 mmol) was dissolved in dichloromethane 
(12.0 mL) and to the stirring solution was added triethylamine (0.502 ml, 3.60 mmol) 
followed by 3,5-bis(trifluoromethyl)benzoyl chloride (0.595 ml, 3.30 mmol). The 
reaction mixture was stirred overnight at room temperature under nitrogen. The reaction 
was diluted with 50 mL of dichloromethane and was washed with NaHCO3 (2 x 30 mL) 




dried (MgSO4) and concentrated in vacuo to afford 1.44 g of a yellow oil. Crude material 
was purified by to afford 0.990 g (2.49 mmol, 83% yield) of title compound as a clear oil. 
1
H NMR (400 MHz, DMSO-d6): δ 8.22 (s, 1H), 8.18-8.07 (m, 2H), 4.50-3.45 (m, 4H), 
3.4-3.23 (under water peak, 1H), 3.18-3.00 (m, 1H), 2.78-2.63 (m, 1H), 2.15-1.87 (m, 
1H), 1.85-1.40 (m, 3H), 1.28-1.00 (m, 3H). 
 
1-(3,5-bis(trifluoromethyl)benzoyl)piperidine-3-carboxylic acid (48). Prepared 
according to Procedure A to afford 0.310 g (0.840 mmol, 70% yield) of title compound as 
a white solid OR 47 was dissolved in tetrahydrofuran (3.35 mL) and water (6.70 mL) and 
to the stirring solution was added lithium hydroxide hydrate (1.044 g, 24.87 mmol). The 
mixture was stirred at room temperature for 1.5 hours and then was diluted with water 
(20 mL) and washed with diethyl ether (20 mL). The aqueous layer was removed and its 
pH was adjusted to ~2 using 2M HCl (aq). The aqueous layer was then extracted with 
ethyl acetate (3 x 40 mL). The combined organics were washed with brine (40 mL), dried 
(MgSO4), and concentrated to afford 0.817 g of title compound as a white solid. No 





(400 MHz, DMSO-d6): δ 12.50 (s, 1H), 8.21 (s, 1H), 8.1  (s, 2H),  .55-3.73 (m, 1H), 
3.50-3.35 (m, 2H), 3.15-2.95 (m, 1H), 2.65-2.54 (m, 1H), 2.08-1.40 (m, 5H). 
 
General procedure for acid library
95
 
The following procedure was performed in a parallel reaction format. To each 8 
mL vial was added N-(4-chlorophenyl)piperidine-3-carboxamide (0.150 mmol), followed 
by a 0.500 mL of a solution containing EDCI (0.3M) and DMAP (0.3M) in 
dichloromethane, varied carboxylic acid (0.10 mmol), anhydrous DMF (0.150 mL), and 
dichloromethane (0.250 mL). The solution was sonicated between each addition. The 
reaction mixture was capped and allowed to stir 48 hours at room temperature on an 
orbital shaker at 2,500 rpm. The reaction solution was diluted with dichloromethane (5 
mL), and Amberlyst-15 (~300 mg) was added. The reaction mixture was allowed to stir 
on an orbital shaker 3,000 rpm overnight. The mixture was then filtered and concentrated. 
Water (3 mL) and dichloromethane (3 mL) were added to the vial. The vial was shaken 




and the remaining organic layer was washed a second time with water (3 mL), and the 
layers were again allowed to separate for 30 minutes. The dichloromethane layer was 
removed and transferred to a clean vial and concentrated. The water wash and organic 
isolation was repeated. Organics were concentrated to afford title compounds below. 
ESI-MS was performed in positive mode on an Agilent Technologies LC/MS 
system using a 1200 Series LC and 6130 Quadrupole LC/MS (Agilent Technologies, 
Santa Clara, CA, USA) in positive mode with 5–10 L injection volume and a linear 
gradient of 10% Solvent D (0.02% TFA and 0.1% acetic acid in acetonitrile) in Solvent C 
(0.02% TFA and 0.1% acetic acid in water) to 90% Solvent D in Solvent C over 6 min 
with a hold at 90% for 7 min. 
 
N-(4-chlorophenyl)-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide (203971). 32 
mg (0.078 mmol, 78% yield) of title compound as an orange-brown oil. ESI(+) m/z 
[M+H]+ 409.0; [M+Na] 434.0; HPLC (gradient A): ret time = 7.52 min; purity = >95%. 
1
H NMR (500 MHz, DMSO-d6): 1.5:1.0 mixture of rotamers, δ 10.21 (rotamer 1, s), 9.90 
(rotamer 2, s,1H), 7.85-7.24 (m, 9H), 7.05 (s, 1H), 6.62 (s, 1H), 4.63-4.20 (m, 1H), 3.73-
3.49 (m, 1H), 3.17-2.91 (m, 2H), 2.68-2.56 (m, 1H), 2.01 (d, J = 9.1 Hz, 1H), 1.93-1.63 
(m, 2H), 1.46 (s, 1H). 
 
1-(3-benzoylbenzoyl)-N-(4-chlorophenyl)piperidine-3-carboxamide (203972). 31 mg 
(0.069 mmol, 69% yield) of title compound as a light brown oil. ESI(+) m/z [M+H]+ 
447.0; [M+Na] 469.0; HPLC (gradient A): ret time = 7.46 min; purity = >95%. 
1
H NMR 
(500 MHz, DMSO-d6): 1.5:1.0 mixture of rotamers, δ 10.17 (rotamer 1, s), 9.99 (rotamer 
2, s, 1H), 7.88-7.21 (m, 13H), 4.58-4.13 (m, 1H), 3.75-3.53 (m, 1H), 3.19-2.93 (m, 2H), 
2.64-2.54 (m, 1H), 2.01 (s, 1H), 1.89-1.61 (m, 2H), 1.57-1.33 (m, 1H). 
 
1-(2-(3,5-bis(trifluoromethyl)phenyl)acetyl)-N-(4-chlorophenyl)piperidine-3-
carboxamide (203960). 41 mg (0.083 mmol, 83% yield) of title compound as an amber 
glass. ESI(+) m/z [M+H]+ 493.0; [M+23] 515.0; HPLC (gradient A): ret time = 8.19 min; 
purity = >95%. 
1
H NMR (500 MHz, DMSO-d6): δ 10.12 (d, J = 10.2 Hz, 2H), 8.02-7.88 




3.16-3.06 (m, 1H), 2.82-2.70 (m, 1H), 2.45-2.38 (m, 1H), 2.09-1.91 (m, 1H), 1.83-1.63 
(m, 2H), 1.50-1.30 (m, 1H). 
 
N-(4-chlorophenyl)-1-(3-(thiazol-2-yl)benzoyl)piperidine-3-carboxamide (206115). 
40 mg (0.094 mmol, 94% yield) as a light brown oil. ESI(+) m/z [M+H]+ 426.1; [M+23] 
448.1; HPLC (gradient A): ret time = 6.88 min; purity = >95%. 
1
H NMR (500 MHz, 
DMSO-d6): 1.4:1.0 mixture of rotamers, δ 10.27 (rotamer 1, s), 10.07 (rotamer 2, s, 1H), 
8.08-7.91 (m, 3H), 7.85 (s, 1H), 7.74-7.46 (m, 4H), 7.44-7.22 (m, 2H), 4.62-4.15 (m, 
1H), 3.75-3.52 (m, 1H), 3.17-2.95 (m, 2H), 2.69-2.59 (m, 1H), 2.02 (d, J = 10.2 Hz, 1H), 
1.93-1.66 (m, 2H), 1.58-1.36 (m, 1H). 
 
N-(4-chlorophenyl)-1-(3-(3,3-dimethylbutanamido)benzoyl)piperidine-3-
carboxamide (203966). 38 mg (0.083 mmol, 83% yield) of title compound as a light 
brown solid. ESI(+) m/z [M+Na] 456.0; HPLC (gradient A): ret time = 7.35 min; purity = 
>95%. 
1
H NMR (500 MHz, DMSO-d6): δ 10.26-9.86 (m, 2H), 7.75 (s, 1H), 7.70-7.44 (m, 
3H), 7.42-7.20 (m, 4H), 7.03 (d, J = 7.5 Hz, 1H), 4.57-4.23 (m, 1H), 3.77-3.50 (m, 1H), 
3.13-2.89 (m, 2H), 2.19 (s, 2H), 2.01 (s, 1H), 1.89-1.58 (m, 3H), 1.43 (s, 1H), 1.02 (s, 
9H). 
 
N-(4-chlorophenyl)-1-(3-vinylbenzoyl)piperidine-3-carboxamide (203968). 34 mg 
(0.071 mmol, 71% yield) of title compound as an off-white foam. ESI(+) m/z [M+H]+ 
369.0; [M+Na] 391.0; HPLC (gradient A): ret time = 7.31 min; purity = >95%. 
1
H NMR 
(500 MHz, DMSO-d6): 1.5:1.0 mixture of rotamers, δ 10.19 (rotamer 1, s), 10.00 
(rotamer 2, s, 1H), 7.71-7.17 (m, 8H), 6.75 (s, 1H), 5.89 (d, J = 17.6 Hz, 1H), 5.38-5.25 
(m, 1H), 4.60-4.20 (m, 1H), 3.72-3.43 (m, 1H), 3.13-2.90 (m, 2H), 2.62-2.53 (m, 1H), 
2.07-1.57 (m, 4H), 1.43 (s, 1H). 
 
N-(4-chlorophenyl)-1-(3-(2-methylthiazol-4-yl)benzoyl)piperidine-3-carboxamide 
(203975). 17 mg (0.039 mmol, 39% yield) of title compound as an off-white solid. 
ESI(+) m/z [M+H]+ 440.0; [M+Na] 462.0; HPLC (gradient A): ret time = 7.20 min; 
purity = >95%. 
1




(rotamer 1, s), 10.00 (rotamer 2, s, 1H), 8.12-7.24 (m, 9H), 4.67-4.19 (m, 1H), 3.74-3.53 
(m, 1H), 3.18-2.90 (m, 2H), 2.72 (s, 3H), 2.66-2.55 (m, 1H), 2.11-1.94 (m, 1H), 1.93-
1.63 (m, 2H), 1.55-1.35 (m, 1H). 
 
N-(4-chlorophenyl)-1-(3-methylbenzoyl)piperidine-3-carboxamide (203977). 40 mg 
(0.112 mmol, 112% yield). ESI(+) m/z [M+H]+ 357.0; [M+Na] 379.0; HPLC (gradient 
A): ret time = 7.26; purity = >90%. 
1
H NMR (500 MHz, DMSO-d6): 2.0:1.0 mixture of 
rotamers, δ 10.22 (rotamer 1, s), 10.04 (rotamer 2, 1H), 7.80-7.44 (m, 2H), 7.44-7.11 (m, 
5H), 6.60-6.56 (m, 1H), 4.60-4.16 (m, 1H), 3.70-3.50 (m, 1H), 3.13-2.91 (m, 2H), 2.40-
2.24 (m, 3H), 2.07-1.61 (m, 3H), 1.51-1.30 (m, 1H). 
 
N-(4-chlorophenyl)-1-(3-(methylthio)benzoyl)piperidine-3-carboxamide (203963). 32 
mg (0.082 mmol, 82% yield) of title compound as an off-white oil. ESI(+) m/z [M+H]+ 
389.0; [M+Na] 411.0; HPLC (gradient A): ret time = 7.26 min; purity = >95%. 
1
H NMR 
(500 MHz, DMSO-d6): 1.4:1.0 mixture of rotamers, δ 10.20 (rotamer 1, s), 10.02 
(rotamer 2, s, 1H), 7.73-7.06 (m, 8H), 4.60-4.20 (m, 1H), 3.70-3.45 (m, 1H), 3.14-2.90 
(m, 2H), 2.10-1.62 (m, 3H), 1.55-1.35 (m, 1H). 
 
N-(4-chlorophenyl)-1-(3-(oxazol-5-yl)benzoyl)piperidine-3-carboxamide (203973). 28 
mg (0.068 mmol, 68% yield) of title compound as a yellowish solid. ESI(+) m/z [M+H]+ 
410.0; [M+Na] 432.0; HPLC (gradient A): ret time = 6.53 min; purity = >95%. 
1
H NMR 
(500 MHz, DMSO-d6): 1.4:1.0 mixture of rotamers, δ 10.21 (rotamer 1, s), 9.98 (rotamer 
2, s, 1H), 8.53-7.19 (m, 10H), 4.63-4.17 (m, 1H), 3.70-3.48 (m, 1H), 3.17-2.93 (m, 2H), 
2.66-2.54 (m, 1H), 2.01 (d, J = 12.9 Hz, 1H), 1.91-1.61 (m, 2H), 1.46 (s, 1H). 
 
N-(4-chlorophenyl)-1-(3-(N,N-diethylsulfamoyl)benzoyl)piperidine-3-carboxamide 
(203967). 34 mg (0.071 mmol, 71% yield) of title compound as a light brown oily solid. 
ESI(+) m/z [M+H]+ 478.0; [M+Na] 500.0; HPLC (gradient A): ret time = 7.24 min; 
purity = >95%. 
1
H NMR (500 MHz, DMSO-d6): 1.2:1.0 mixture of rotamers, δ 10.02 
(rotamer 1, s), 10.03 (rotamer 2, s, 1H), 7.92-7.81 (m, 1H), 7.78-7.60 (m, 4H), 7.58-7.49 




(m, 6H), 2.67-2.55 (m, 1H), 2.12-1.94 (m, 1H), 1.88-1.64 (m, 2H), 1.59-1.35 (m, 1H), 
1.12-0.85 (m, 6H). 
 
Methyl 3-(3-((4-chlorophenyl)carbamoyl)piperidine-1-carbonyl)benzoate (203969). 
30 mg (0.075 mmol, 75% yield) of title compound as a light brown oil. ESI(+) m/z 
[M+H]+ 401.0; [M+Na] 423.0; HPLC (gradient A): ret time = 6.86 min; purity = >90%. 
1
H NMR (500 MHz, DMSO-d6): 1.4:1.0 mixture of rotamers, δ 10.19 (rotamer 1, s), 9.96 
(rotamer 2, s, 1H), 8.12-7.24 (m, 8H), 4.60-4.13 (m, 1H), 3.87 (s, 3H), 3.65-3.45 (m, 1H), 
3.20-2.95 (m, 2H), 2.13-1.61 (m, 3H), 1.59-1.33 (m, 1H). 
 
N-(4-chlorophenyl)-1-(3-(5-methyl-1,2,4-oxadiazol-3-yl)benzoyl)piperidine-3-
carboxamide (203974). 36 mg (0.085 mmol, 85% yield) of title compound as a light 
brown solid. ESI(+) m/z [M+H]+ 425.0; [M+Na] 447.0; HPLC (gradient A): ret time = 
6.89 min; purity = >95%. 
1
H NMR (500 MHz, DMSO-d6): 1.5:1.0 mixture of rotamers, δ 
10.22 (rotamer 1, s), 9.97 (rotamer 2, s, 1H), 8.17-7.20 (m, 8H), 4.62-4.10 (m, 1H), 3.73-
3.49 (m, 1H), 3.19-2.95 (m, 1H), 2.73-2.55 (m, 4H), 2.05-1.95 (m, 1H), 1.93-1.64 (m, 
2H), 1.58-1.35 (m, 1H). 
 
N-(4-chlorophenyl)-1-(3-methoxybenzoyl)piperidine-3-carboxamide (203979). TOF 
MS-ESI m/z [M+H]
+
 373.0; [M+Na] 395.0. HPLC (gradient A): ret time = 6.99 min; 
purity = >95%.  
1
H NMR (500 MHz, DMSO-d6): 1.6:1.0 mixture of rotamers, δ 10.22 
(rotamer 1, s), 10.03 (rotamer 2, s, 1H) 7.70 (m, 2H), 7.35 (s, 3H), 7.01 (s, 1H), 6.92 (d, J 
= 7.7 Hz, 1H), 6.90-6.87 (m, 1H), 4.59-4.21 (m, 1H), 3.77 (s, 3H), 3.67-3.47 (m, 1H), 
3.12-2.87 (m, 2H), 2.07-1.61 (m, 3H), 1.55-1.31 (m, 1H). 
 
N-(4-chlorophenyl)-1-(3-(methoxymethyl)benzoyl)piperidine-3-carboxamide 
(203962). 37 mg (0.096 mmol, 96% yield) of title compound as an off-white foam. 
ESI(+) m/z [M+H]+ 387.0; [M+Na] 409.0; HPLC (gradient A): ret time = 6.76 min; 
purity = >95%. 
1
H NMR (500 MHz, DMSO-d6): 1.4:1.0 mixture of rotamers, δ 10.20 




(m, 1H), 3.30-3.23 (m, 3H), 3.13-2.88 (m, 2H), 2.63-2.53 (m, 1H), 2.08-1.62 (m, 3H), 
1.55-1.32 (m, 1H). 
 
N-(4-chlorophenyl)-1-(3-(methylsulfonamido)benzoyl)piperidine-3-carboxamide 
(203965). 36 mg (0.083 mmol, 83% yield) of title compound as an off-white solid. 
ESI(+) m/z [M+H]+ 436.0; [M+Na] 458.0; HPLC (gradient A): ret time = 6.2 min; purity 
= >95%. 
1
H NMR (500 MHz, DMSO-d6): 1.2:1.0 mixture of rotamers, δ 10.19 (rotamer 
1, s), 9.99 (s, 1H), 9.93 (rotamer 2, s, 1H), 7.76-7.07 (m, 8H), 4.57-4.23 (m, 1H), 3.75-
3.47 (m, 1H), 3.01 (s, 5H), 2.61-2.54 (m, 1H), 2.02 (s, 1H), 1.88-1.63 (m, 2H), 1.44 (s, 
1H). 
 
N-(4-chlorophenyl)-1-(3-cyanobenzoyl)piperidine-3-carboxamide (203961). 22 mg 
(0.060 mmol, 60% yield) of title compound as an off-white oil. ESI(+) m/z [M+H]+ 
368.0; [M+Na] 390.0; HPLC (gradient A): ret time = 6.68 min; purity = >95%. 
1
H NMR 
(500 MHz, DMSO-d6): 1.2:1.0 mixture of rotamers, δ 10.22 (rotamer 1, s), 9.99 (rotamer 
2, s, 1H), 8.02-7.23 (m, 8H), 4.58-4.14 (m, 1H), 3.60-3.40 (m, 1H), 3.16-2.93 (m, 2H), 
2.65-2.52 (m, 1H), 2.00 (d, J = 8.1 Hz, 1H), 1.91-1.64 (m, 2H), 1.47 (s, 1H). 
 
N-(4-chlorophenyl)-1-(3-(methylsulfonyl)benzoyl)piperidine-3-carboxamide 
(203970). 39 mg (0.093 mmol, 93% yield) of title compound as a yellowish-brown oil. 
ESI(+) m/z [M+H]+ 421.0; [M+Na] 443.0; HPLC (gradient A): ret time = 6.25 min; 
purity = >95%. 
1
H NMR (500 MHz, DMSO-d6): 1.4:1.0 mixture of rotamers, δ 10.20 
(rotamer 1, s), 9.99 (rotamer 2, s, 1H), 8.06-7.87 (m, 2H), 7.79-7.47 (m, 4H), 7.42-7.27 
(m, 2H), 4.59-4.19 (m, 1H), 3.64-3.42 (m, 1H), 3.31 (s, 3H), 3.19-2.95 (m, 2H), 2.67-
2.52 (m, 1H), 2.02 (s, 1H), 1.91-1.37 (m, 3H). 
 
1-(3-acetamidobenzoyl)-N-(4-chlorophenyl)piperidine-3-carboxamide (203964). 27 
mg (0.068 mmol, 68% yield) of title compound as an off-white solid. ESI(+) m/z [M+H]+ 
400.0; [M+Na] 422.0; HPLC (gradient A): ret time = 6.08 min; purity = >95%. 
1
H NMR 




3H), 7.02 (d, J = 7.6 Hz, 1H), 4.60-4.24 (m, 1H), 3.75-3.49 (m, 1H), 3.10-2.89 (m, 2H), 
2.13-1.60 (m, 6H), 1.43 (s, 1H). 
 
General procedure for aniline library
95
 
The following procedure was performed in a parallel reaction format. To each 8 
mL vial was added varied aniline (0.100 mmol), followed by a 0.500 mL of a solution 
containing EDCI (0.3M) and DMAP (0.3M) in dichloromethane, 1-(3,5-
bis(trifluoromethyl)benzoyl)piperidine-3-carboxylic acid (0.055 g, 0.150 mmol), and 
anhydrous dichloromethane (0.500 mL). The solution was sonicated between each 
addition. The reaction mixture was capped and allowed to stir 48 hours at room 
temperature on an orbital shaker at 2,500 rpm. The reaction solution was diluted with 
dichloromethane (3 mL) and washed with saturated NaHCO3 (2 mL). The vial was 
shaken and the layers allowed to separate for 30 minutes. The aqueous layer was then 
removed, and the remaining organic layer was washed 1M aqueous Hydrochloric acid (2 
mL), and the layers were again allowed to separate for 30 minutes. The dichloromethane 
layer was removed and transferred to a clean vial and concentrated. Organics were dried 
(MgSO4) and concentrated to afford title compounds below. 
 
1-(3,5-bis(trifluoromethyl)benzoyl)-N-(3-phenoxyphenyl)piperidine-3-carboxamide 
(206114). 52 mg (0.097 mmol, 97% yield) of title compound as a white solid. ESI(+) m/z 
[M+H]+ 537.2; [M+Na] 559.2. HPLC (gradient A): ret time = 8.44 min; purity = 89%. 
1
H NMR (400 MHz, DMSO-d6): 1.1:1.0 mixture of rotamers, δ 10.1  (rotamer 1, s), 9.90 
(rotamer 2, s, 1H), 8.25-6.59 (m, 12H), 4.55-4.01 (m, 1H), 3.53-3.33 (m, 1H), 3.22-2.89 
(m, 2H), 2.03-1.25 (m, 5H). 
 
N-(3-benzylphenyl)-1-(3,5-bis(trifluoromethyl)benzoyl)piperidine-3-carboxamide 
(206108). 56 mg (0.105 mmol, 105% yield) of title compound as a light purple solid. 
ESI(+) m/z [M+H]+ 535.2; [M+Na] 557.2. HPLC (gradient A): ret time = 8.52 min; 
purity = 91%. 
1
H NMR (400 MHz, DMSO-d6): 1.2:1.0 mixture of rotamers, δ 10.02 




16.7 Hz, 1H), 4.58-4.06 (m, 1H), 3.97-3.81 (m, 2H), 3.55-3.35 (m, 1H), 3.22-2.93 (m, 
2H), 2.06-1.38 (m, 5H). 
 
1-(3,5-bis(trifluoromethyl)benzoyl)-N-(3-(2-(pyridin-2-yl)ethoxy)phenyl)piperidine-
3-carboxamide  (206124). 18 mg (0.032 mmol, 32%) of title compound as a white solid. 
ESI(+) m/z [M+H]+ 566.2; [M+Na] 588.2. HPLC (gradient A): ret time = 6.13 min; 
purity = >95%. 
1
H NMR (400 MHz, DMSO-d6): 1.2:1.0 mixture of rotamers, δ 10.02 
(rotamer 1, s), 9.79 (rotamer 2, s, 1H), 8.54-8.47 (m, 1H), 8.27-8.14 (m, 1H), 8.10 (s, 
2H), 7.73 (t, J = 7.6 Hz, 2H), 7.41-6.95 (m, 6H), 6.68-6.53 (m, 1H), 4.58-4.05 (m, 3H), 
3.57-3.36 (m, 2H), 3.23-2.98 (m, 4H), 2.70-2.53 (m, 1H), 2.06-1.95 (m, 1H), 1.86-1.64 
(m, 2H), 1.59-1.39 (m, 1H). 
 
1-(3,5-bis(trifluoromethyl)benzoyl)-N-(3-(pyrrolidin-1-ylsulfonyl)phenyl)piperidine-
3-carboxamide (206109). 54 mg (0.094 mmol, 94% yield) of title compound as a yellow 
solid. ESI(+) m/z [M+H]+ 578.2; [M+Na] 600.2. HPLC (gradient A): ret time = 7.65 
min; purity = 94%. 
1
H NMR (400 MHz, DMSO-d6): 1.1:1.0 mixture of rotamers, δ 10. 4 
(rotamer 1, s), 10.22 (rotamer 2, s, 1H), 8.37-7.39 (m, 7H), 4.59-4.01 (m, 1H), 3.71-3.37 
(m, 2H), 3.13 (s, 5H), 2.78-2.53 (m, 2H), 2.14-1.98 (m, 1H), 1.92-1.42 (m, 6H). 
 
1-(3,5-bis(trifluoromethyl)benzoyl)-N-(3-(2-methylthiazol-4-yl)phenyl)piperidine-3-
carboxamide (206244). 22 mg (0.041 mmol, 41% yield) of title compound as a white 
solid. ESI(+) m/z [M+H]+ 542.0; [M+Na] 564.0. HPLC (gradient A): ret time = 7.63 
min; purity = >95%. 
1
H NMR (400 MHz, DMSO-d6): 1.1:1.0 mixture of rotamers, δ 
10.17 (rotamer 1, s), 9.94 (rotamer 2, s, 1H), 8.28-8.02 (m, 4H), 7.87-7.75 (m, 1H), 7.64-
7.44 (m, 2H), 7.38-7.22 (m, 1H), 4.58-4.04 (m, 1H), 3.57-3.34 (m, 1H), 3.21-2.96 (m, 
2H), 2.76-2.52 (m, 4H), 2.01 (d, J = 10.9, 1H), 1.87-1.35 (m, 3H). 
 
1-(3,5-bis(trifluoromethyl)benzoyl)-N-(3-ethylphenyl)piperidine-3-carboxamide 
(206102). 51 mg (0.108 mmol, 70% yield) of title compound as a light brown solid. 
ESI(+) m/z [M+H]+ 473.2; [M+Na] 495.1. HPLC (gradient A): ret time = 8.15 min; 
purity = 92%. 
1




(rotamer 1, s), 9.80 (rotamer 2, s, 1H), 8.27-8.16 (m, 1H), 8.12 (s, 2H), 7.55-7.25 (m, 
2H), 7.18 (dt, J = 29.5, 7.9 Hz, 1H), 6.95-6.82 (m, 1H), 4.58-4.05 (m, 1H), 3.55-3.38 (m, 
1H), 3.25-2.99 (m, 2H), 2.68-2.52 (m, 3H), 2.06-1.97 (m, 1H), 1.73-1.38 (m, 3H), 1.15 
(dq, J = 15.0, 7.4 Hz, 3H). 
 
1-(3,5-bis(trifluoromethyl)benzoyl)-N-(3-vinylphenyl)piperidine-3-carboxamide 
(206248). ESI(+) m/z [M+H]+ 471.0; [M+Na] 493.0. HPLC (gradient A): ret time = 6.05 
min; purity = 82%. 
1
H NMR (400 MHz, DMSO-d6): 1.2:1.0 mixture of rotamers, δ 10.07 
(rotamer 1, s), 9.85 (rotamer 2, s, 1H), 8.26-7.91 (m, 3H), 7.76-7.06 (m, 4H), 6.75-6.57 
(m, 1H), 5.80-5.60 (m, 1H), 5.30-5.13 (m, 1H), 4.55-4.00 (m, 1H), 3.52-3.34 (m, 1H), 
3.21-2.94 (m, 2H), 2.66-2.51 (m, 1H), 2.05-1.93 (m, 1H), 1.81-1.40 (m, 3H). 
 
1-(3,5-bis(trifluoromethyl)benzoyl)-N-(3-(oxazol-5-yl)phenyl)piperidine-3-
carboxamide (206243). ESI(+) m/z [M+H]+ 512.0; [M+Na] 534.0. HPLC (gradient A): 
ret time = 7.19 min; purity = >95%. 
1
H NMR (400 MHz, DMSO-d6): 1.2:1.0 mixture of 
rotamers, δ 10.23 (rotamer 1, s), 10.09 (rotamer 2, s, 1H), 8.47-7.28 (m, 9H), 4.59-3.98 
(m, 1H), 3.55-3.35 (m, 1H), 3.25-2.96 (m, 2H), 2.68-2.52 (m, 1H), 2.07-1.94 (m, 1H), 
1.86-1.61 (m, 2H), 1.59-1.38 (m, 1H). 
 
1-(3,5-bis(trifluoromethyl)benzoyl)-N-(3-(methylthio)phenyl)piperidine-3-
carboxamide (206241). 19 mg (0.039 mmol, 39% yield) of title compound as a clear oil. 
ESI(+) m/z [M+H]+ 491.0; [M+Na] 512.9. HPLC (gradient A): ret time = 7.93 min; 
purity = 81%. 
1
H NMR (400 MHz, CDCl3): 8.20-7.60 (m, 4H), 7.30-7.20 (m, 2H), 7.01 
(d, J = 6.3 Hz, 1H), 4.60-4.20 (m, 1H), 3.82 (s, 1H), 3.70-3.25 (m, 2H), 2.67 (s, 1H), 2.48 
(s, 3H), 2.25-1.50 (m, 4H). 
 
Methyl 3-(1-(3,5-bis(trifluoromethyl)benzoyl)piperidine-3-carboxamido)benzoate 
(206110). 36 mg (0.072 mmol, 72% yield) of title compound as a light purple solid. 
ESI(+) m/z [M+H]+ 503.1; [M+Na] 525.2. HPLC (gradient A): ret time = 7.63 min; 
purity = 90%. 
1
H NMR (400 MHz, DMSO-d6): 1.1:1.0 mixture of rotamers, δ 10.   




1H), 7.70-7.57 (m, 1H), 7.44 (dq, J = 14.3, 7.6 Hz, 1H), 4.60-4.00 (m, 1H), 3.90-3.79 (m, 
3H), 3.51-3.38 (m, 1H), 3.29-2.97 (m, 2H), 2.76-2.60 (m, 1H), 2.10-1.98 (m, 1H), 1.88-
1.65 (m, 2H), 1.63-1.43 (m, 1H). 
 
1-(3,5-bis(trifluoromethyl)benzoyl)-N-(3-methoxyphenyl)piperidine-3-carboxamide 
(206242). 29 mg (0.061 mmol, 61% yield) of title compound as an amber oil. ESI(+) m/z 
[M+H]+ 475.0; [M+Na] 497.0. HPLC (gradient A): ret time = 7.59 min; purity = 80%. 
1
H NMR (400 MHz, DMSO-d6): 1.1:1.0 mixture of rotamers, δ 10.07 (rotamer 1, s), 9.85 
(rotamer 2, s, 1H), 8.30-8.17 (m, 1H), 8.11 (s, 2H), 8.09-7.96 (m, 1H), 7.38-6.97 (m, 3H), 
6.61 (dd, J = 18.4, 6.8 Hz, 1H), 4.58-4.06 (m, 1H), 3.77-3.66 (m, 3H), 3.56-3.38 (m, 1H), 
3.24-2.97 (m, 2H), 2.08-1.95 (m, 1H), 1.86-1.26 (m, 3H). 
 
1-(3,5-bis(trifluoromethyl)benzoyl)-N-(3-cyanophenyl)piperidine-3-carboxamide 
(206104). 62 mg (0.132 mmol, 132% yield) of title compound as a light brown foam. 
ESI(+) m/z [M+H]+ 470.1; [M+Na] 492.1. HPLC (gradient A): ret time = 7.43 min; 
purity = 93%. 
1
H NMR (500 MHz, DMSO-d6): 1.0:1.0 mixture of rotamers, δ 10. 8 
(rotamer 1, s), 10.25 (rotamer 2, s, 1H), 8.31-7.44 (m, 7H), 4.60-3.97 (m, 1H), 4.02 (s, 
1H), 3.62-3.39 (m, 2H), 3.17-3.03 (m, 1H), 2.73-2.55 (m, 1H), 2.08-1.97 (m, 1H), 1.88-
1.66 (m, 2H), 1.63-1.42 (m, 1H). 
1-(3,5-bis(trifluoromethyl)benzoyl)-N-(3-(morpholinomethyl)phenyl)piperidine-3-
carboxamide (206247). 31 mg (0.057 mmol, 57% yield) of title compound as a white 
solid. ESI(+) m/z [M+H]+ 544.1; [M+Na] 566.1. HPLC (gradient A): ret time = 5.96 
min; purity = >95%. 
1
H NMR (400 MHz, DMSO-d6): 1.1:1.0 mixture of rotamers, δ 
10.08 (rotamer 1, s),  9.85 (rotamer 2, s, 1H), 8.30-8.16 (m, 1H), 8.12 (s, 2H), 7.64-7.37 
(m, 2H), 7.22 (dt, J = 15.7, 7.4 Hz, 1H), 6.96 (dd, J = 17.8, 6.7 Hz, 1H), 4.59-4.05 (m, 
1H), 3.56 (bs, 4H), 3.40 (d, J = 17.6 Hz, 3H), 3.25-2.97 (m, 2H), 2.74-2.59 (m, 1H), 2.45-
2.23 (m, 4H), 2.09-1.95 (m, 4H), 1.89-1.63 (m, 1H), 1.63-1.38 (m, 1H). 
 
1-(3,5-bis(trifluoromethyl)benzoyl)-N-(3-nitrophenyl)piperidine-3-carboxamide 
(206103). 59 mg, (0.121 mmol, 121% yield) of title compound as an amber oil. ESI(+) 






H NMR (500 MHz, DMSO-d6): 1.1:1.0 mixture of rotamers, δ 10.60 (rotamer 1, 
s), 10.35 (rotamer 2, s, 1H), 8.73-8.53 (m, 1H), 8.28-8.16 (m, 1H), 8.12 (s, 2H), 7.99-7.77 
(m, 2H), 7.59 (dt, J = 30.8, 7.7 Hz, 1H), 4.60-3.95 (m, 1H), 3.62-3.38 (m, 2H), 3.17-3.04 
(m, 1H), 2.73-2.56 (m, 1H), 2.11-1.97 (m, 1H), 1.88-1.64 (m, 2H), 1.64-1.43 (m, 1H). 
 
N-(3-acetylphenyl)-1-(3,5-bis(trifluoromethyl)benzoyl)piperidine-3-carboxamide 
(206105). 57 mg (0.117 mmol, 117% yield) of title compound as a light brown foam. 
ESI(+) m/z [M+H]+ 487.1; [M+Na] 509.1. HPLC (gradient A): ret time = 7.25 min; 
purity = 92%. 
1
H NMR (500 MHz, DMSO-d6): 1.1:1.0 mixture of rotamers, δ 10. 1 
(rotamer 1, s), 10.07 (rotamer 2, s, 1H), 8.47-8.07 (m, 5H), 7.93-7.60 (m, 2H), 7.50-7.38 
(m, 1H), 4.60-4.05 (m, 1H), 3.58-3.38 (m, 1H), 3.27-3.02 (m, 2H), 2.71-2.52 (m, 4H), 
2.09-2.00 (m, 1H), 1.87-1.41 (m, 4H). 
 
1-(3,5-bis(trifluoromethyl)benzoyl)-N-(3-(pyrrolidin-1-ylmethyl)phenyl)piperidine-
3-carboxamide (206123). ESI(+) m/z [M+H]+ 528.2; [M+Na] 550.2. HPLC (gradient 
A): ret time = 6.05 min; purity = >95%. 
1
H NMR (400 MHz, DMSO-d6): 1.2:1.0 mixture 
of rotamers, δ 10.01 (rotamer 1, s, 1H), 9.79 (rotamer 2, s), 8.21 (rotamer 1, s, 1H), 8.15 
(rotamer 2, s), 8.08 (s, 2H), 7.65-7.33 (m, 2H), 7.25-7.10 (m, 1H), 7.00-6.88 (m, 1H), 
4.60-4.00 (m, 1H), 3.60-3.35 (m, 4H), 3.20-2.95 (m, 2H), 2.70-2.55 (m, 1H), 1.98 (d, J = 
9.5, 1H), 1.85-1.60 (m, 6H), 1.60-1.35 (m, 1H).  
 
Methyl 5-(3-(1-(3,5-bis(trifluoromethyl)benzoyl)piperidine-3-
carboxamido)phenyl)furan-2-carboxylate (206112). 25 mg (0.044 mmol, 44% yield) 
of title compound as a white solid. ESI(+) m/z [M+H]+ 569.2; [M+Na] 591.2. HPLC 
(gradient A): ret time =8.00 min; purity = >95%. 
1
H NMR (400 MHz, DMSO-d6): 1.0:1.0 
mixture of rotamers, δ 10. 1 (rotamer 1, s), 10.07 (rotamer 2, s, 1H), 8.28-7.06 (m, 9H), 
4.61-4.07 (m, 1H), 3.85 (s, 7H), 3.58-2.99 (m, 3H), 2.77-2.56 (m, 1H), 2.11-1.98 (m, 
1H), 1.92-1.66 (m, 2H), 1.64-1.46 (m, 1H). 
 
N-(3-(allyloxy)phenyl)-1-(3,5-bis(trifluoromethyl)benzoyl)piperidine-3-carboxamide 




[M+H]+ 501.0; [M+Na] 523.0. HPLC (gradient A): ret time = 7.96 min; purity = 79%. 
TOF MS-ESI m/z [M+H]
+
 501.0; [M+Na] 523.0. 
1
H NMR (400 MHz, DMSO-d6): 
1.2:1.0 mixture of rotamers, δ 10.0  (rotamer 1, s), 9.81 (rotamer 2, s, 1H), 8.28-7.93 (m, 
3H), 7.41-6.93 (m, 3H), 6.64-6.52 (m, 1H), 6.08-5.90 (m, 1H), 5.43-5.28 (m, 1H), 5.26-
5.16 (m, 1H), 4.53-4.40 (m, 2H), 4.15-3.33 (m, 2H), 3.21-2.94 (m, 2H), 1.97 (m, 1H), 
1.82-1.40 (m, 3H). 
N-(3-benzoylphenyl)-1-(3,5-bis(trifluoromethyl)benzoyl)piperidine-3-carboxamide 
(206111). 41 mg (0.075 mmol, 75% yield) of title compound as a light brown solid. 
ESI(+) m/z [M+H]+ 549.2; [M+Na] 571.2. HPLC (gradient A): ret time = 8.13 min; 
purity = 90%. 
1
H NMR (400 MHz, DMS)-d6) 1.2:1.0 mixture of rotamers, δ 10.   
(rotamer 1, s), 10.10 (rotamer 2, s, 1H), 8.29-7.33 (m, 12H), 4.60-4.05 (m, 1H), 3.48-3.35 
(m, 1H), 3.24-2.98 (m, 2H), 2.75-2.60 (m, 1H), 2.08-1.97 (m, 1H), 1.88-1.65 (m, 2H), 
1.65-1.40 (m, 1H). 
 
1-(3,5-bis(trifluoromethyl)benzoyl)-N-(3-(4-methyl-4H-1,2,4-triazol-3-
yl)phenyl)piperidine-3-carboxamide (206245). ESI(+) m/z [M+H]+ 526.0; [M+Na] 
548.0. HPLC (gradient A): ret time = 6.00 min; purity = >95%. 
1
H NMR (500 MHz, 
DMSO-d6): 1.1:1.0 mixture of rotamers, δ 10.28 (rotamer 1, s), 10.06 (rotamer 2, s, 1H), 
8.58-8.51 (m, 1H), 8.26-8.14 (m, 1H), 8.09 (s, 2H), 8.05-7.89 (m, 1H), 7.79-7.59 (m, 
1H), 7.51-7.33 (m, 2H), 4.52-4.05 (m, 1H), 3.82-3.61 (m, 2H), 3.47-3.35 (m, 1H), 3.22-




carboxamide (206113). 29 mg (0.055 mmol, 55% yield) of title compound as a white 
solid. ESI(+) m/z [M+H]+ 528.2; [M+Na] 550.2. HPLC (gradient A): ret time = 7.02 
min; purity = 94%. 
1
H NMR (500 MHz, DMSO-d6): 1.1:1.0 mixture of rotamers, δ 10.28 
(rotamer 1, s), 10.06 (rotamer 2, s, 1H), 8.25-8.13 (m, 1H), 8.11-7.88 (m, 3H), 7.77-7.58 








yl)oxy)phenyl)piperidine-3-carboxamide (206125). 42 mg (0.066 mmol, 66% yield) of 
title compound as a white solid. ESI(+) m/z [M+H]+ 640.1. HPLC (gradient A): ret time 
= 8.70 min; purity = >95%. 
1
H NMR (400 MHz, DMSO-d6): 1.1:1.0 mixture of rotamers, 
δ 10.27 (rotamer 1, s), 10.05 (rotamer 2, s, 1H), 8.59 (s, 1H), 8.55-8.46 (m, 1H), 8.27-
8.15 (m, 1H), 8.13-8.07 (m, 2H), 7.67-7.53 (m, 1H), 7.47-7.23 (m, 4H), 6.92 (dd, J = 
18.2, 6.1 Hz, 1H), 4.58-3.95 (m, 1H), 3.55-3.36 (m, 3H), 3.29-2.97 (m, 4H), 2.69-2.53 
(m, 1H), 2.07-1.96 (m, 2H), 1.84-1.39 (m, 7H). 
 
tert-butyl 3-(1-(3,5-bis(trifluoromethyl)benzoyl)piperidine-3-carboxamido)benzoate 
(206107). 47 mg (0.086 mmol, 86% yield) of title compound as a white solid. ESI(+) m/z 
[M+Na] 567.2. HPLC (gradient A): ret time = 8.52 min; purity = 87%. 
1
H NMR (400 
MHz, DMSO-d6): 1.1:1.0 mixture of rotamers, δ 10.28 (rotamer 1, s), 10.05 (rotamer 2, s, 
1H), 8.30-7.96 (m, 4H), 7.91-7.73 (m, 1H), 7.64-7.32 (m, 2H), 4.60-4.03 (m, 1H), 3.60-
3.37 (m, 1H), 3.24-3.01 (m, 2H), 2.72-2.54 (m, 1H), 2.12-1.19 (m, 13H). 
 
N-(4-chlorophenyl)-1-(3-(thiophen-2-yl)benzoyl)piperidine-3-carboxamide (206455). 
29 mg (0.068 mmol, 93% yield) as an amber glass. ESI(+) m/z [M+H]+ 425.0; [M+23] 
447.0; HPLC (gradient A): ret time = 7.66 min; purity = >95%. 
1
H NMR (500 MHz, 
DMSO-d6): 1.4:1.0 mixture of rotamers, δ 10.25 (rotamer 1, s), 10.06 (rotamer 2, s, 1H), 
7.99-7.11 (m, 11H), 4.64-4.19 (m, 1H), 3.75-3.51 (m, 1H), 3.18-2.93 (m, 2H), 2.68-2.54 
(m, 1H), 2.12-1.64 (m, 3H), 1.59-1.36 (m, 1H). 
 
N-(4-chlorophenyl)-1-(4-(furan-2-yl)benzoyl)piperidine-3-carboxamide (206119). 31 
mg (0.076 mmol, 76% yield). ESI(+) m/z [M+H]+ 409.1; [M+23] 431.1; HPLC (gradient 
A): ret time = 7.38 min; purity = 99%. 
1
H NMR (500 MHz, DMSO-d6): 1.4:1.0 mixture 




= 8.3 Hz, 2H), 7.35 (bs, 2H), 7.04 (s, 1H), 6.63 (s, 1H), 4.60-4.20 (m, 1H), 3.78-3.53 (m, 
1H), 3.15-2.90 (m, 2H), 2.63-2.53 (m, 1H), 2.01 (s, 1H), 1.89-1.62 (m, 2H), 1.46 (s, 1H). 
 
1-(3,5-bis(trifluoromethyl)benzoyl)-N-(3-(furan-2-yl)phenyl)piperidine-3-
carboxamide (206122). 23 mg (0.045 mmol, 45% yield) of title compound as a white 
solid. ESI(+) m/z [M+H]+ 511.1; [M+Na] 533.1. HPLC (gradient A): ret time = 8.10 
min; purity = 91%. 
1
H NMR (400 MHz, CDCl3): δ 8.40-7.76 (m, 5H), 7.55-7.30 (m, 4H), 
6.67 (s, 1H), 6.46 (s, 1H), 4.30-4.20 (m, 1H), 3.85-3.25 (m, 3H), 2.70 (s, 1H), 2.27-1.50 
(m, 4H). 
 
tert-butyl 3-((3-(methylthio)phenyl)carbamoyl)piperidine-1-carboxylate. Prepared 
using 43 according to Procedure D to afford 0.030 g (0.086 mmol, 86% yield) of title 
compound. No further purification was performed. 
 
N-(3-(methylthio)phenyl)piperidine-3-carboxamide. tert-butyl 3-((3-
(methylthio)phenyl)carbamoyl)piperidine-1-carboxylate (0.028 g, 0.080 mmol) was 
dissolved in DCM (0.540 mL) and the solution was cooled to -10 °C. TFA (0.270 mL) 
was added to the cooled, stirring solution. The reaction mixture continued stirring at -10 
°C for 45 minutes. The solution was added to a cooled 2M NaOH solution (10 mL). The 
mixture was then extracted with DCM (3 x 5 mL). The combined organics were dried 
(MgSO4) and concentrated in vacuo to afford 0.010 g (0.040 mmol, 50% yield) of title 
compound as a brown oil. No further purification was performed. 
 
1-(3-(furan-2-yl)benzoyl)-N-(3-(methylthio)phenyl)piperidine-3-carboxamide 
(206683). Prepared using N-(3-(methylthio)phenyl)piperidine-3-carboxamide according 
to Procedure B to afford 0.013 g (0.031 mmol, 77% yield) of title compound as a tan 
solid. No further purification was performed. ESI(+) m/z [M+H]+ 421.0; [M+Na] 442.9. 
HPLC (gradient A): ret time = 7.35 min; purity = >90%. 
1
H NMR (400 MHz, DMSO-d6): 
1.4:1.0 mixture of rotamers, δ 10.08 (rotamer 1, s), 9.88 (rotamer 2, s, 1H), 7.80-7.15 (m, 




2.96 (m, 2H), 2.64-2.54 (s, 1H), 2.44 (bs, 3H), 2.07-1.95 (m, 1H), 1.91-1.66 (m, 2H), 
1.47 (s, 1H). 
1-(3,5-bis(trifluoromethyl)benzoyl)-N-(3-(pyridin-2-yloxy)phenyl)piperidine-3-
carboxamide. (206681). Prepared using 3-(pyridin-2-yloxy)aniline and 48 according to 
Procedure D. Crude material was purified using a Biotage FlashMaster Personal
+
 system 
(2.5% Methanolic ammonia/DCM) to afford 0.007 g (0.013 mmol, 13% yield) of title 
compound as a clear glass. ESI(+) m/z [M+H]+ 537.9; [M+Na] 559.8. HPLC (gradient 
A): ret time = 7.51 min; purity = >95%. 
1
H NMR (400 MHz, DMSO-d6): 1.1:1.0 mixture 
of rotamers, δ 10.17 (rotamer 1, s), 9.95 (rotamer 2, s, 1H), 8.27-8.12 (m, 2H), 8.10 (s, 
2H), 7.90-7.81 (m, 1H), 7.56-7.22 (m, 3H), 7.14 (s, 1H), 7.07-6.95 (m, 1H), 6.87-6.72 
(m, 1H), 4.58-4.07 (m, 1H), 3.55-3.35 (m, 1H), 3.21-2.96 (m, 2H), 2.69-2.53 (m, 1H) 








 2-((3-nitrophenoxy)methyl)pyridine (0.050 g, 0.217 
mmol), iron powder (0.050 g, 0.890 mmol), and ammonium chloride (0.014 g, 0.261 
mmol) were combined in a solution of methanol (1.41 mL), tetrahydrofuran (1.41 mL), 
and water (0.470 mL), and was refluxed for 3 hours. The resulting mixture was cooled to 
room temperature, diluted with methanol (5 mL), and filtered through a pad of celite. The 
filtrate was concentrated and triturated with dichloromethane. The triturated solid was 
discarded, and the filtrate was concentrated in vacuo to afford 0.035 g of title compound 
as a brown oil. No further purification was performed. 
1
H NMR (400 MHz, DMSO-d6): δ 
8.56 (d, J = 4.5 Hz, 1H), 7.82 (t, J = 7.7 Hz, 1H), 7.46 (d, J = 7.9 Hz, 1H), 7.38-7.28 (m, 




carboxamide (208798). Prepared using 3-(pyridin-2-ylmethoxy)aniline and 48 according 






system (1-15% Methanolic ammonia/DCM) to afford 0.019 g (0.034 mmol, 27% yield) 
of title compound as an orangish-brown solid. ESI(-) m/z [M-H]- 550.0. HPLC (gradient 
A): ret time = 6.36 min; purity = >95%. 
1
H NMR (400 MHz, DMSO-d6): 1.1:1.0 mixture 
of rotamers, δ 10.06 (rotamer 1, s), 9.8  (rotamer 2, s, 1H), 8.57 (s, 1H), 8.27-8.15 (m, 
1H), 8.10 (s, 2H), 7.83 (t, J = 6.4, 1H), 7.54-7.00 (m, 5H), 6.70 (d, J = 7.2, 1H), 5.13 (d, J 
= 13.8, 2H), 4.55-4.05 (m, 1H), 3.55-2.95 (m, 3H), 2.65-2.55 (m, 1H), 2.06-1.95 (m, 1H), 
1.88-1.38 (m, 3H). 
 
1-(3,5-bis(trifluoromethyl)benzoyl)-N-(5-chloropyridin-2-yl)piperidine-3-
carboxamide (206101). Only base wash was performed. The crude material was purified 
using Biotage with 1% Methanolic ammonia in DCM to afford 19 mg (0.040 mmol, 40% 
yield) of title compound as a white solid. TLC Rf (5% Methanolic ammonia/DCM): 0.63. 
ESI(+) m/z [M+H]+ 480.1; [M+Na] 502.1. HPLC (gradient A): ret time = 7.81 min; 
purity = >95%. 
1
H NMR (500 MHz, DMSO-d6): 1.1:1.0 mixture of rotamers, δ 10.86 
(rotamer 1, s), 10.62 (rotamer 2, s, 1H), 8.47-7.99 (m, 5H), 7.97-7.82 (m, 1H), 4.55-3.98 
(m, 1H), 3.63-3.37 (m, 2H), 3.31-3.05 (m, 2H), 2.89-2.66 (m, 1H), 2.10-1.93 (m, 1H), 
1.90-1.63 (m, 2H), 1.58-1.37 (m, 1H). 
 
1-(3,5-bis(trifluoromethyl)benzoyl)-N-(6-chloropyridin-3-yl)piperidine-3-
carboxamide (206106). 28 mg (0.058 mmol, 58% yield) of title compound. ESI(+) m/z 
[M+H]+ 480.1. HPLC (gradient A): ret time = 7.40 min; purity = >95%. 
1
H NMR (500 
MHz, DMSO-d6) 1.1:1.0 mixture of rotamers, δ 10.46 (rotamer 1, s), 10.22 (rotamer 2, s, 
1H), 8.70-8.48 (m, 1H), 8.31-7.91 (m, 4H), 7.46 (dd, J = 28.4, 8.7 Hz, 1H), 4.61-4.00 (m, 
1H), 3.61-3.00 (m, 1H), 2.75-2.55 (m, 2H), 2.10-2.00 (m, 1H), 1.88-1.65 (m, 2H), 1.61-
1.41 (m, 1H). 
 
1-(3,5-bis(trifluoromethyl)benzoyl)-N-(pyridin-4-yl)piperidine-3-carboxamide 
(206682). Pyridin-4-amine (0.021 g, 0.220 mmol) was dissolved in DCM (2.00 mL) and 
was treated with EDC (0.058 g, 0.300 mmol), followed by DMAP (0.037 g, 0.300 mmol) 
and 48 (0.074 g, 0.200 mmol). The suspension was stirred overnight at room temperature. 




saturated NaHCO3 (5 mL). Organics were dried (MgSO4) and concentrated in vacuo. 
Crude material was purified using a CombiFlash Retrieve system (0-5% Methanolic 
ammonia/DCM) to afford 0.028 g (0.063 mmol, 31% yield) of title compound as a clear 
glass. TLC Rf (5% Methanolic ammonia/DCM): 0.23. ESI(+) m/z [M+H]
+ 445.9. HPLC 
(gradient A): ret time = 5.70 min; purity = >90%. 
1
H NMR (400 MHz, DMSO-d6): 
1.0:1.0 mixture of rotamers, δ 10. 5 (rotamer 1, s), 10.21 (rotamer 2, s, 1H), 8. 7-8.33 
(m, 2H), 8.27-8.15 (m, 1H), 8.10 (s, 2H), 7.59 (s, 1H), 7.46 (s, 1H), 4.60-3.97 (m, 1H), 
3.60-3.36 (m, 1H), 3.29-3.00 (m, 2H), 2.62-2.54 (m, 1H), 2.09-1.99 (m, 1H), 1.90-1.64 
(m, 2H), 1.61-1.40 (m, 1H). 
 
N-(6-chloropyridin-3-yl)-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide 
(206460). 42 mg (0.102 mmol, 44% yield) of title compound as a light brown solid. 
Agilent ESI(+) m/z [M+Na] 432.0. HPLC (gradient A): ret time = 6.75 min; purity = 
>95%. 
1
H NMR (400 MHz, DMSO-d6): 1. :1.0 mixture of rotamers, δ 10.   (rotamer 1, 
s), 10.21 (rotamer 2, s, 1H), 8.75-8.43 (m, 1H), 8.20-7.93 (m, 1H), 7.77 (bs, 2H), 7.67 (s, 
1H), 7.48 (bs, 2H), 7.28 (d, J = 7.4 Hz, 1H), 7.04 (s, 1H), 6.62 (s, 1H), 4.65-4.15 (m, 1H), 
3.75-3.49 (m, 1H), 3.21-2.89 (m, 2H), 2.70-2.55 (m, 1H), 2.09-2.00 (m, 1H), 1.92-1.65 
(m, 2H), 1.47 (s, 1H). 
 
tert-butyl 3-((3-chloro-4-methoxyphenyl)carbamoyl)piperidine-1-carboxylate 
(206120). Prepared using 28 according to Procedure D. Crude material was triturated 
with DCM to afford 0.009 g (0.024 mmol, 22% yield) of title compound as a white solid. 
ESI(+) m/z [M+H]+ 381.1; [M+Na] 403.1. HPLC (gradient A): ret time = 7.11; purity = 
>95%. 
1
H NMR (400 MHz, DMSO-d6: δ 9.0  (s, 1H), 8.17 (s, 1H), 7.97-7.38 (m, 8H), 
7.03 (s, 1H), 6.63 (s, 1H), 4.70 (s, 1H), 4.23 (t, J = 8.6 Hz, 1H), 3.80 (d, J = 10.8 Hz, 1H), 
3.01 (dd, J = 17.8, 8.5 Hz, 1H), 2.64 (d, J = 17.9 Hz, 1H). 
 
1-(3-(furan-2-yl)benzoyl)-N-(3-phenoxyphenyl)piperidine-3-carboxamide (206451). 
20 mg (0.043 mmol, 67% yield) of title compound as a white solid. Agilent ESI(+) m/z 
[M+H]+ 467.1. HPLC (gradient A): ret time = 8.00 min; purity = >90%. 
1
H NMR (400 




1H), 7.77 (s, 2H), 7.67 (s, 1H), 7.53-6.94 (m, 12H), 6.75-6.58 (m, 2H), 4.65-4.18 (m, 
1H), 3.70-3.48 (m, 1H), 3.15-2.88 (m, 2H), 2.65-2.53 (m, 1H), 2.07-1.93 (m, 1H), 1.89-
1.63 (m, 2H), 1.44 (bs, 1H). 
 
N-(3-benzylphenyl)-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide (206450). 15 
mg (0.032 mmol, 67% yield) of title compound as a white solid. Agilent ESI(+) m/z 
[M+H]+ 465.1; [M+Na] 487.1. HPLC (gradient A): ret time = 8.04 min; purity = >90%. 
1
H NMR (400 MHz, DMSO-d6): 1.6:1.0 mixture of rotamers, δ 10.00 (rotamer 1, s), 9.80 
(rotamer 2, s, 1H), 7.82-7.65 (m, 3H), 7.54-7.11 (m, 10H), 7.05 (s, 1H), 6.92 (s, 1H), 6.61 
(s, 1H), 4.62-4.20 (m, 1H), 3.98-3.80 (m, 2H), 3.71-3.48 (m, 1H), 3.15-2.85 (m, 2H), 





2-one 49a (0.102 g, 1.01 mmol) was added to a pressure tube containing Copper(I) iodide 
(0.032 g, 0.168 mmol), potassium phosphate (0.356 g, 1.68 mmol), and a stir bar. 1-
chloro-4-iodobenzene (0.200 g, 0.839 mmol) dissolved in 1,4-dioxane (8.4 mL) was 
added, and the tube was purged with nitrogen. trans-1,2-diaminocyclohexane (0.030 mL, 
0.252 mmol) was added to the pressure tube, and the tube was purged with nitrogen. The 
pressure tube was capped and stirred at 110 °C overnight. Crude material was combined 
with a two additional reactions and was purified by column chromatography (75-100% 
EtOAc/Hex) to afford 0.444 g (2.10 mmol, 63% yield) of title compound as a brown 
solid. TLC Rf (80% EtOAc/Hex): 0.23. 
1
H NMR (400 MHz, DMSO-d6): δ 7.70 (m, 2H), 
7.42 (m, 2H), 5.37 (d, J = 3.8, 1H), 4.42-4.35 (m, 1H), 4.04 (dd, J = 10.5, 5.1, 1H), 3.61-
3.55 (m, 1H), 2.84 (dd, J = 17.1, 6.1, 1H), 2.30 (dd, J = 17.1, 1.4, 1H). 
 
(R)-1-(4-chlorophenyl)-5-oxopyrrolidin-3-yl 4-methylbenzenesulfonate (51a). 
Compound 50a (0.410 g, 1.94 mmol), pyridine (3.13 mL, 38.7 mmol), and p-
toluenesulfonyl chloride (1.11 g, 5.81 mmol) were mixed, and the reaction was allowed 
to stir overnight at room temperature under nitrogen. Water (30 mL) was added, and the 
water layer was extracted with ether (3 x 30 mL). The combined ether layers were then 




brine (30 mL). The ether layer was dried (MgSO4) and concentrated in vacuo to afford 
0.643 g (1.76 mmol, 91% yield) of title compound as a brown solid. No further 
purification was performed. 
1
H NMR (400 MHz, DMSO-d6): δ 7.90-7.82 (m, 2H), 7.68-
7.59 (m, 2H), 7.55-7.47 (m, 2H), 7.48-7.39 (m, 2H), 5.25 (ddt, J = 6.8, 5.4, 1.7 Hz, 1H), 
4.21 (dd, J = 11.9, 5.2 Hz, 1H), 3.92-3.84 (m, 1H), 3.01 (dd, J = 17.9, 6.4 Hz, 1H), 2.54-
2.46 (m, 1H), 2.44 (s, 3H). 
 
(S)-4-azido-1-(4-chlorophenyl)pyrrolidin-2-one (52a). Compound 51a (0.641 g, 1.75 
mmol) was dissolved in DMSO (2.19 mL), and to the stirring solution was added sodium 
azide (0.570 g, 8.76 mmol). The mixture was stirred at room temperature for 5 hours. The 
mixture was diluted with water (25 mL) and was extracted with DCM (3 x 25 mL). 
Combined organics were washed with water (25 mL), dried (MgSO4), and concentrated 
in vacuo. Crude material was purified using a Biotage SP1 system (7-40% EtOAc/Hex) 
to afford 0.073 g (0.308 mmol, 18% yield) of title compound as an amber oil. TLC Rf 
(30% EtOAc/Hex): 0.18. 
1
H NMR (400 MHz, DMSO-d6): δ 7.71-7.64 (m, 2H), 7.48-7.41 
(m, 2H), 4.59 (tt, J = 5.9, 2.6 Hz, 1H), 4.17 (dd, J = 10.9, 5.8 Hz, 1H), 3.77 (dd, J = 10.9, 
2.1 Hz, 1H), 3.00 (dd, J = 17.3, 7.0 Hz, 1H). 
 
(S)-4-amino-1-(4-chlorophenyl)pyrrolidin-2-one (53a). Compound 52a (0.071 g, 0.300 
mmol) and Pd-C (6.39 mg, 6.00 µmol) were added to a flask, and the flask was evacuated 
and backfilled with nitrogen 3 times. Sparged methanol (1.50 mL) was then slowly 
added. A blanket of hydrogen was provided, and the reaction was stirred for 5 h. The 
reaction was then filtered through a plug of celite and was flushed using additional 
methanol. Organics were concentrated in vacuo to afford 0.059 g (0.280 mmol, 93% 
yield) of title compound as a brown opaque oil. No further purification was performed. 
1
H NMR (400 MHz, DMSO-d6): δ 7.71-7.64 (m, 2H), 7.48-7.40 (m, 2H), 4.59 (tt, J = 
5.6, 2.6 Hz, 1H), 4.17 (dd, J = 10.9, 5.9 Hz, 1H), 3.77 (dd, J = 10.9, 2.1 Hz, 1H), 3.00 
(dd, J = 17.3, 7.1 Hz, 1H), 2.54-2.47 (m, 1H). 
 
(S)-N-(1-(4-chlorophenyl)-5-oxopyrrolidin-3-yl)-3,5-bis(trifluoromethyl)benzamide 




and was treated with DIPEA (0.025 ml, 0.142 mmol) followed by 3,5-
bis(trifluoromethyl)benzoyl chloride (0.019 mL, 0.104 mmol). Upon treatment with the 
acid chloride, a sample was removed for HPLC, and the reaction appeared to have 
completed instantaneously. Therefore, the solution was diluted with DCM to a volume of 
5 mL, and the organic layer was washed with 1 N HCl (5 mL) followed by NaHCO3 (5 
mL) and was then dried (MgSO4) and concentrated in vacuo to afford 0.028 g of title 
compound as a white solid. No further purification was performed. ESI(+) m/z [M+H]+ 
450.9; [M+Na] 472.8. HPLC (gradient A): ret time = 7.84 min; purity = >95%. 
1
H NMR 
(400 MHz, DMSO-d6): δ 9. 6 (d, J = 6.6 Hz, 1H), 8.51 (s, 2H), 8.33 (s, 1H), 7.78-7.69 
(m, 2H), 7.49-7.40 (m, 2H), 4.72 (qt, J = 7.0, 3.8 Hz, 1H), 4.25 (dd, J = 10.4, 7.0 Hz, 
1H), 3.83 (dd, J = 10.4, 2.8 Hz, 1H), 3.06 (dd, J = 17.4, 8.5 Hz, 1H), 2.64 (dd, J = 17.4, 
3.4 Hz, 1H). 
 
(S)-1-(4-chlorophenyl)-4-hydroxypyrrolidin-2-one (50b). (S)-4-hydroxypyrrolidin-2-
one (49b) (0.102 g, 1.01 mmol) was added to a pressure tube containing copper(I) iodide 
(0.032 g, 0.168 mmol), potassium phosphate (0.356 g, 1.68 mmol), and a stir bar. 1-
chloro-4-iodobenzene (0.200 g, 0.839 mmol) dissolved in 1,4-dioxane (8.4 mL) was 
added, and the tube was purged with nitrogen. trans-1,2-diaminocyclohexane (0.030 mL, 
0.252 mmol) was added to the pressure tube, and the tube was purged with nitrogen. The 
pressure tube was capped and stirred at 110 °C overnight. Crude material was combined 
with a two additional reactions and was purified using a Biotage SP1 system (60-82% 
EtOAc/Hex) to afford 0.427 g (2.02 mmol, 60% yield) of title compound as a brown 
solid. TLC Rf (80% EtOAc/Hex): 0.23.
 1H NMR (400 MHz, DMSO-d6): δ 7.70-7.63 (m, 
2H), 7.42-7.35 (m, 2H), 5.34 (d, J = 3.8 Hz, 1H), 4.34 (dtt, J = 5.7, 3.8, 1.8 Hz, 1H), 4.00 
(dd, J = 10.5, 5.1 Hz, 1H), 3.54 (d, J = 10.6 Hz, 1H), 2.79 (dd, J = 17.1, 6.1 Hz, 1H), 
2.31-2.23 (m, 1H). 
 
(S)-1-(4-chlorophenyl)-5-oxopyrrolidin-3-yl 4-methylbenzenesulfonate (51b). 
Compound 50b (0.425 g, 2.01 mmol), Pyridine (3.25 mL, 40.2 mmol), and p-
toluenesulfonyl chloride (1.15 g, 6.02 mmol) were mixed, and the reaction was allowed 




water layer was extracted with ether (3 x 35 mL). The combined ether layers were then 
washed with water (2 x 35 mL), followed by saturated NaHCO3 (2 x 35 mL), and then 
brine (35 mL). The ether layer was dried (MgSO4), filtered, and concentrated in vacuo. 
Crude material was purified using a Biotage SP1 system (12-45% EtOAc/Hex) to afford 
0.244 g (0.667 mmol, 33% yield) of title compound as an amber oil. TLC Rf (50% 
EtOAc/Hex): 0.36. 
1
H NMR (400 MHz, DMSO-d6): δ 7.90-7.82 (m, 2H), 7.68-7.59 (m, 
2H), 7.51 (d, J = 7.9 Hz, 2H), 7.48-7.39 (m, 2H), 5.29-5.20 (m, 1H), 4.21 (dd, J = 11.9, 
5.2 Hz, 1H), 3.88 (d, J = 11.9 Hz, 1H), 3.01 (dd, J = 17.9, 6.3 Hz, 1H), 2.54-2.65 (m, 
1H), 2.44 (s, 3H). 
 
(R)-4-azido-1-(4-chlorophenyl)pyrrolidin-2-one (52b). Compound 51b (0.242 g, 0.662 
mmol) was dissolved in DMSO (0.827 mL), and to the stirring solution was added 
sodium azide (0.215 g, 3.31 mmol). The mixture was stirred at room temperature for 5 h. 
The mixture was diluted with water (20 mL) and was extracted with DCM (3 x 20 mL). 
Combined organics were washed with water (20 mL), dried (MgSO4), and concentrated 
in vacuo. Crude material was purified using a Biotage SP1 system (7-40% EtOAc/Hex) 
to afford 0.073 g (0.308 mmol, 47% yield) of title compound as an amber oil. TLC Rf 
(30% EtOAc/Hex): 0.18. 
1
H NMR (400 MHz, DMSO-d6): δ 7.68-7.59 (m, 2H), 7.45-7.36 
(m, 2H), 4.55 (ddt, J = 7.0, 5.5, 2.6 Hz, 1H), 4.13 (dd, J = 10.9, 5.9 Hz, 1H), 2.97 (dd, J = 
17.3, 7.0 Hz, 1H), 2.51-2.43 (m, 1H). 
 
(R)-4-amino-1-(4-chlorophenyl)pyrrolidin-2-one (53b). Compound 52b (0.071 g, 
0.300 mmol) and Pd-C (6.39 mg, 6.00 µmol) were added to a flask, and the flask was 
evacuated and backfilled with nitrogen 3 times. Sparged methanol (1.50 mL) was then 
slowly added. A blanket of hydrogen was provided, and the reaction was stirred for 5 h. 
The reaction was then filtered through a plug of celite and was flushed using additional 
methanol. Organics were concentrated in vacuo to afford 0.059 g (0.280 mmol, 93% 
yield) of title compound as a brown opaque oil. No further purification was performed. 
1




3.76 (m, 1H), 3.45-3.31 (m, 2H), 3.11-2.90 (m, 1H), 2.58-2.50 (m, 1H), 2.03-1.84 (m, 
1H), 1.78-1.43 (m, 3H). 
 
(R)-N-(1-(4-chlorophenyl)-5-oxopyrrolidin-3-yl)-3,5-bis(trifluoromethyl)benzamide 
(206685). Compound 53b (0.011 g, 0.052 mmol) was suspended in DCM (0.525 mL) and 
was treated with DIPEA (0.014 mL, 0.078 mmol) followed by 3,5-
bis(trifluoromethyl)benzoyl chloride (10.35 µl, 0.057 mmol). Upon treatment with the 
acid chloride, a sample was removed for HPLC, and the reaction appeared to have 
completed instantaneously. Therefore, the solution was diluted with DCM to a volume of 
5 mL, and the organic layer was washed with 1 N HCl (5 mL) followed by NaHCO3 (5 
mL) and was then dried (MgSO4) and concentrated in vacuo to afford 0.015 g of title 
compound as a white solid. No further purification was performed. ESI(+) m/z [M+H]+ 
450.9; [M+Na] 472.8. HPLC (gradient A): ret time = 7.85 min; purity = >90%. 
1
H NMR 
(400 MHz, DMSO-d6): δ 9. 6 (d, J = 6.7 Hz, 1H), 8.51 (s, 2H), 8.33 (s, 1H), 7.79-7.69 
(m, 2H), 7.49-7.40 (m, 2H), 4.78-4.66 (m, 1H), 4.25 (dd, J = 10.4, 6.9 Hz, 1H), 3.83 (dd, 





 Compound 53a (0.017 g, 0.081 mmol) was suspended 
in DCM (0.805 mL) and was treated with DIPEA (0.021 ml, 0.121 mmol) followed by 
(R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl chloride (0.015 ml, 0.081 mmol). A 
sample was removed for HPLC, and the reaction appeared to have completed 
instantaneously. Therefore, the solution was diluted with DCM to a volume of 5 mL and 
the organic layer was washed with 1 N HCl (5 mL) followed by NaHCO3 (5 mL) and 
was dried (MgSO4) and concentrated in vacuo to afford 0.015 g (0.035 mmol, 44% yield) 
of title compound as a white solid. HPLC (gradient A): ret time = 7.44 min; purity = 
>90%. ESI(+) m/z [M+H]+ 426.9; [M+Na] 448.9. 
1
H NMR (400 MHz, DMSO-d6): δ 
8.98 (d, J = 7.4 Hz, 1H), 7.69 (d, J = 9.0 Hz, 2H), 7.56-7.37 (m, 7H), 4.62 (s, 1H), 4.17 
(dd, J = 10.1, 7.6 Hz, 1H), 3.71 (dd, J = 10.3, 3.7 Hz, 1H), 3.43 (s, 3H), 2.89 (dd, J = 
17.3, 8.8 Hz, 1H), 2.44 (dd, J = 17.3, 4.5 Hz, 1H). 
19







 Prepared identically to 208802 using 53b. ESI(+) m/z 
[M+H]+ 426.9; [M+Na] 448.9. HPLC (gradient A): ret time = 7.41 min; purity = >90%. 
1
H NMR (400 MHz, DMSO-d6): δ 8.98 (d, J = 7.1, 1H), 7.73-7.67 (m, 2H), 7.55-7.40 (m, 
7H), 4.63 (qt, J = 8.4, 4.3, 1H), 4.18 (dd, J = 10.2, 7.7 Hz, 1H), 3.72 (dd, J = 10.2, 3.9 
Hz, 1H), 3.44 (s, 3H), 2.90 (dd, J = 17.3, 8.7 Hz, 1H), 2.45 (dd, J = 17.4, 4.6 Hz, 1H). 
19
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(S)-tert-butyl 3-((4-chlorophenyl)carbamoyl)piperidine-1-carboxylate. Prepared 
according to Procedure C, but using 1.0 eq of (S)-1-(tert-butoxycarbonyl)piperidine-3-
carboxylic acid and 1.1 eq of 4-chloro aniline to afford 0.054 g (0.159 mmol, 61% yield) 
of title compound. No further purification was performed. 
1
H NMR (500 MHz, DMSO-
d6): δ 10.1  (s, 1H), 7.66-7.59 (m, 2H), 7.38-7.31 (m, 2H), 3.86 (d, J = 12.7 Hz, 1H), 
3.12-2.72 (m, 1H), 2.43 (tt, J = 10.9, 3.9 Hz, 1H), 1.96-1.89 (m, 2H), 1.70 (d, J = 12.7 
Hz, 1H), 1.61 (qd, J = 11.9, 3.6 Hz, 1H), 1.43-1.28 (m, 10H). 
 
(S)-N-(4-chlorophenyl)piperidine-3-carboxamide, TFA salt. (S)-tert-butyl 3-((4-
chlorophenyl)carbamoyl)piperidine-1-carboxylate (0.054 g, 0.159 mmol) was dissolved 
in DCM (1.30 mL), and to the stirring solution was added TFA (0.325 mL). Reaction was 
stirred for 45 minutes. Solution was concentrated in vacuo to afford 0.066 g (0.187 mmol, 
117% yield) of title compound as a yellow oil. No further purification was performed. 
1
H 
NMR (500 MHz, DMSO-d6): δ 10. 1 (s, 1H), 8.60 (s, 2H), 7.65-7.59 (m, 2H), 7.41-7.34 
(m, 2H), 3.33 (d, J = 12.3 Hz, 1H), 3.20 (d, J = 12.4 Hz, 1H), 3.06 (tt, J = 11.6, 5.8 Hz, 
1H), 2.98-2.87 (m, 1H), 2.85-2.75 (m, 1H), 2.08-1.97 (m, 1H), 1.89-1.78 (m, 1H), 1.72-
1.59 (m, 2H). 
 
(S)-N-(4-chlorophenyl)-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide (206116, 
Lot 380445). Prepared using (S)-N-(4-chlorophenyl)piperidine-3-carboxamide, TFA salt 




material was purified using a CombiFlash system (35-50% EtOAc/Hex) to afford 0.021 g 
(0.051 mmol, 27% yield) of title compound as a yellow oil. TLC Rf (50% EtOAc/Hex): 
0.29. ESI(+) m/z [M+H]+ 409.1; [M+23] 431.1. HPLC (gradient A): ret time = 7.50; 
purity = >95%. 
1
H NMR (400 MHz, DMSO-d6): 1.6:1.0 mixture of rotamers, δ 10.22 
(rotamer 1, s), 10.01 (rotamer 2, s, 1H), 7.85-7.20 (m, 9H), 7.05 (s, 1H), 6.62 (s, 1H), 
4.62-4.18 (m, 1H), 3.73-3.48 (m, 1H), 3.18-2.89 (m, 2H), 2.59 (s, 1H), 2.08-2.01 (m, 






(R)-tert-butyl 3-((4-chlorophenyl)carbamoyl)piperidine-1-carboxylate. Prepared 
according to Procedure C, but using 1.0 eq of (R)-1-(tert-butoxycarbonyl)piperidine-3-
carboxylic acid and 1.1 eq of 4-chloro aniline to afford 0.054 g (0.159 mmol, 61% yield) 
of title compound. No further purification was performed. 
1
H NMR (500 MHz, DMSO-
d6): δ 10.13 (s, 1H), 7.66-7.60 (m, 2H), 7.38-7.32 (m, 2H), 3.95-3.80 (m, 2H), 2.84-2.70 
(m, 1H), 2.49-2.38 (m, 1H), 1.97-1.88 (m, 1H), 1.75-1.56 (m, 2H), 1.45-1.27 (m, 11H). 
 
(R)-N-(4-chlorophenyl)piperidine-3-carboxamide, TFA salt. (R)-tert-butyl 3-((4-
chlorophenyl)carbamoyl)piperidine-1-carboxylate (0.056 g, 0.165 mmol) was dissolved 
in DCM (1.30 mL), and to the stirring solution was added TFA (0.325 mL). Reaction was 
stirred for 45 minutes. Solution was concentrated in vacuo to afford 0.059 g (0.167 mmol, 
101% yield) of title compound as a yellow oil. No further purification was performed. 
1
H 
NMR (500 MHz, DMSO): δ 10. 1 (s, 1H), 8.6  (bs, 2H), 7.65-7.57 (m, 2H), 7.41-7.35 
(m, 2H), 3.33 (d, J = 12.5 Hz, 1H), 3.20 (d, J = 12.2 Hz, 1H), 3.11-3.02 (m, 1H), 2.92 (d, 




Lot 380439). Prepared using (R)-N-(4-chlorophenyl)piperidine-3-carboxamide, TFA salt 
and 3-(furan-2-yl)benzoic acid according to Procedure C, but using 2.1 eq DIPEA. Crude 




(0.015 mmol, 9% yield) of title compound as an opaque oil. TLC Rf (50% 
EtOAc/Hex):0.29. ESI(+) m/z [M+H]+ 409.1; [M+23] 431.1. HPLC (gradient A): ret 
time = 7.50; purity = >90%. 
1
H NMR (400 MHz, CDCl3): δ 9.2  (s, 1H), 7.79-7.13 (m, 
9H), 6.67 (d, J = 3.3 Hz, 1H), 6.49 (dd, J = 3.2, 1.8 Hz, 1H), 4.06 (s, 1H), 3.61-3.39 (m, 
2H), 2.75-2.65 (m, 1H), 2.35-2.20 (m, 1H), 1.89 (s, 2H), 1.67-1.45 (m, 2H). 
 
(S)-1-(3,5-bis(trifluoromethyl)benzoyl)piperidine-3-carboxylic acid. Prepared 
according to Procedure A to afford 0.402 g (1.09 mmol, 70% yield) of title compound as 
a white solid. 
1
H NMR (400 MHz, DMSO-d6): δ 12.   (s, 1H), 8.17 (s, 1H), 8.09 (s, 2H), 
4.50-3.70 (m, 1H), 3.45-3.31 (m, 2H), 3.11-2.90 (m, 1H), 2.58-2.50 (m, 1H), 2.03-1.84 
(m, 1H), 1.78-1.43 (m, 3H). 
  
(S)-1-(3,5-bis(trifluoromethyl)benzoyl)-N-(3-phenoxyphenyl)piperidine-3-
carboxamide (206686). (S)-1-(3,5-bis(trifluoromethyl)benzoyl)piperidine-3-carboxylic 
acid (0.074 g, 0.200 mmol) was dissolved in THF (0.667 mL) and was treated with EDC 
(0.042 g, 0.220 mmol) followed by HOBt (0.034 g, 0.220 mmol), and was then stirred for 
10 minutes. 3-phenoxyaniline (0.037 g, 0.200 mmol) was then added and stirring 
continued overnight at room temperature. The reaction was then diluted with EtOAc (10 
mL) and was washed with saturated NaHCO3 (5 mL), followed by a wash with 1N HCl 
(5 mL) and then brine (5 mL). Organics were dried (MgSO4) and concentrated in vacuo. 
Crude material was purified using a Biotage Flashmaster Personal
+
 system (25% 
EtOAc/Hex) to afford 0.021 g (0.039 mmol, 20% yield) of title compound as an off-white 
solid.  TLC Rf (50% EtOAc/Hex): 0.43. ESI(+) m/z [M+H]
+ 536.9; [M+Na] 558.8. 
HPLC (gradient A): ret time = 8.36 min; purity = >95%. 
1
H NMR (400 MHz, DMSO-d6): 
1.1:1.0 mixture of rotamers, δ 10.1  (rotamer 1, s), 9.91 (rotamer 2, s, 1H), 8.26-8.15 (m, 
1H), 8.09 (s, 2H), 7.49-7.18 (m, 5H), 7.15 (t, J = 6.6 Hz, 1H), 7.08-6.92 (m, 2H), 6.75-
6.63(m, 1H), 4.59-4.04 (m, 1H), 3.57-3.34 (m, 1H), 3.20-2.93 (m, 2H), 2.65-2.55 (s, 1H), 
2.05-1.94 (m, 1H), 1.85-1.60 (m, 2H), 1.48 (s, 1H). 
 
(R)-1-(3,5-bis(trifluoromethyl)benzoyl)piperidine-3-carboxylic acid. Prepared using 




compound as a white solid. 
1
H NMR (400 MHz, DMSO-d6) δ 12.   (s, 1H), 8.17 (s, 1H), 
8.09 (s, 2H), 4.50-3.70 (m, 1H), 3.49-3.30 (m, 2H), 3.10-2.90 (m, 1H), 2.60-2.50 (m, 
1H), 2.03-1.83 (m, 1H), 1.80-1.48 (m, 3H). 
 
(R)-1-(3,5-bis(trifluoromethyl)benzoyl)-N-(3-phenoxyphenyl)piperidine-3-
carboxamide (206687). (R)-1-(3,5-bis(trifluoromethyl)benzoyl)piperidine-3-carboxylic 
acid (0.074 g, 0.200 mmol) was dissolved in THF (0.670 mL) and was treated with EDC 
(0.042 g, 0.220 mmol) followed by HOBt (0.034 g, 0.220 mmol) and was then stirred for 
10 minutes. 3-phenoxyaniline (0.037 g, 0.200 mmol) was then added and stirring 
continued overnight at room temperature. The reaction was then diluted with EtOAc (10 
mL) and was washed with saturated NaHCO3 (5 mL) followed by a wash with 1N HCl (5 
mL) and then brine (5 mL). Organics were dried (MgSO4) and concentrated in vacuo. 
Crude material was purified using a Biotage Flashmaster Personal
+
 system (25% 
EtOAc/Hex) to afford 0.027 g (0.050 mmol, 25% yield) of title compound as a white 
solid. TLC Rf (50% EtOAc/Hex): 0.43. ESI(+) m/z [M+H]
+ 536.9; [M+Na] 558.9. HPLC 
(gradient A): ret time = 8.35 min; purity = >95%. 
1
H NMR (400 MHz, DMSO-d6): 
1.1:1.0 mixture of rotamers, δ 10.1  (rotamer 1, s), 9.91 (rotamer 2, s, 1H), 8.27-8.15 (m, 
1H), 8.09 (s, 2H), 7.47-7.20 (m, 5H), 7.15 (t, J = 7.1 Hz, 1H), 7.09-6.92 (m, 2H), 6.77-
6.62 (m, 1H), 4.59-4.05 (m, 1H), 3.59-3.35 (m, 1H), 3.21-2.94 (m, 2H), 2.65-2.55 (m, 
















(3R,5S)-5-((tert-butoxycarbonyl)amino)piperidine-3-carboxylic acid (60). To a Parr 




and ammonia (2.33 mL, 1.08 mmol) was 59 (0.279 g, 1.18 mmol). The mixture was 
placed on the Parr shaker at room temperature at ~40 psi for ~72 hours. The reaction was 
then filtered through a plug of celite and rinsed with water. The solvent was then 
removed in vacuo to afford 0.255 g (1.04 mmol, 89% yield) of title compound as a white 
solid. 
1
H NMR (400 MHz, D2O): δ 3.96-3.77 (m, 1H), 3.63-3.45 (m, 1H), 3.42-3.04 (m, 
1H), 3.00-2.83 (m, 1H), 2.80-2.65 (m, 1H), 2.40-2.90 (m, 1H), 1.98-1.87 (m, 1H), 1.70-
1.35 (m, 10H). 
Chapter 4 
1-(3,5-bis(trifluoromethyl)benzoyl)-N-(3-chloro-4-methoxyphenyl)piperidine-3-
carboxamide (101331). Prepared using 48 according to Procedure C. Crude material was 
triturated using EtOAc to afford 0.201 g (0.413 mmol, 36% yield) of title compound as a 
light yellow solid. TOF MS-ESI m/z [M+H]
+
 509.0; [M+Na] 531.0. HPLC (gradient A): 
ret time = 7.72 min; purity = 99%. 
1
H NMR (500 MHz, DMSO-d6) 1.2:1.0 mixture of 
rotamers, δ 10.08 (rotamer 1, s), 9.85 (rotamer 2, s, 1H), 8.26-8.17 (m, 1H), 8.11 (s, 2H), 
7.85-7.67 (m, 1H), 7.51-7.30 (m, 1H), 7.52-7.28 (m, 1H), 7.17-7.04 (m, 1H), 4.58-4.05 
(m, 1H), 3.87-3.76 (m, 3H), 3.65-3.38 (m, 2H), 3.29-2.97 (m, 1H), 2.68-2.56 (m, 1H), 
2.06-2.00 (m, 1H), 1.93-1.63 (m, 2H), 1.62-1.39 (m, 1H). 
 
5-(3,5-bis(trifluoromethyl)benzamido)pentanoic acid. Prepared according to 
Procedure A to afford 0.392 g (1.10 mmol, 93% yield) of title compound as a white 




H NMR (500 MHz, DMSO-d6): δ 
12.05 (bs, 1H), 8.97 (s, 1H), 8.50 (s, 2H), 8.31 (s, 1H), 3.40-3.28 (m, 2H), 2.35-2.23 (m, 
2H), 1.57 (s, 4H). 
 
N-(5-((3-chloro-4-methoxyphenyl)amino)-5-oxopentyl)-3,5-
bis(trifluoromethyl)benzamide (101339). Prepared using 5-(3,5-
bis(trifluoromethyl)benzamido)pentanoic acid according to Procedure C. Crude material 
was triturated using EtOAc to afford 0.179 g (0.360 mmol, 34% yield) of title compound 
as a solid. TOF MS-ESI m/z [M+Na] 518.9. HPLC (gradient A): ret time = 7.62 min; 
purity = 99%. 
1
H NMR (500 MHz, DMSO-d6): δ 9.90 (s, 1H), 8.98 (t, J = 5.4 Hz, 1H), 




7.08 (d, J = 9.0 Hz, 1H), 3.80 (s, 3H), 3.38-3.31 (m, 2H), 2.33 (t, J = 7.1 hz, 2H), 1.74-
1.53 (m, 4H). 
 
1-(3,5-bis(trifluoromethyl)benzoyl)-N-(4-chloro-3-methoxyphenyl)piperidine-3-
carboxamide (101341). Prepared using 48 according to Procedure C. Crude material was 
purified Combiflash (25-60% EtOAc/Hex) to afford 0.207 g (0.407 mmol, 49% yield) of 
title compound. TLC Rf (50% EtOAc/Hex): 0.23. TOF MS-ESI m/z [M-H]
-
 375.9. HPLC 
(gradient A): ret time = 7.93 min; purity = 99%. 
1
H NMR (500 MHz, DMSO-d6): 1.1:1.0 
mixture of rotamers, δ 10.23 (rotamer 1, s), 10.00 (rotamer 2, s, 1H), 8.28-8.18 (m, 1H), 
8.12 (s, 2H), 7.60-7.46 (m, 1H), 7.40-7.00 (m, 2H), 4.60-4.00 (m, 1H), 3.90-3.75 (m, 
3H), 3.55-3.00 (m, 3H), 2.72-2.58 (m, 1H), 2.09-2.00 (m, 1H), 1.90-1.64 (m, 2H), 1.62-
1.42 (m, 1H). 
 
N-(5-((4-chloro-3-methoxyphenyl)amino)-5-oxopentyl)-3,5-
bis(trifluoromethyl)benzamide (101337). Prepared using 5-(3,5-
bis(trifluoromethyl)benzamido)pentanoic acid according to Procedure C. Crude material 
was triturated using EtOAc to afford 0.104 g (0.209 mmol, 20% yield) of title compound 
as a light brown solid. TOF MS-ESI m/z [M+Na] 518.9. HPLC (gradient A): ret time = 
7.78 min; purity = 99%. 
1
H NMR (500 MHz, DMSO-d6): δ 10.0  (s, 1H), 8.99 (t, J = 5.4 
Hz, 1H), 8.51 (s, 2H), 8.32 (s, 1H), 7.53 (d, J = 2.1 Hz, 1H), 7.31 (d, J = 8.6 Hz, 1H), 
7.16 (dd, J = 8.6 Hz, 2.2 Hz, 1H), 3.81 (s, 3H), 3.39-3.35 (m, 2H), 2.37 (t, J = 7.1 Hz, 







carboxamide (67). N,N-Carbonyldiimidazole (CDI) (0.102 g, 0.627 mmol) was 
dissolved in dry THF (0.780 mL) with stirring at room temperature under nitrogen. 
Compound 48 (0.231 g, 0.627 mmol) was carefully added and the reaction mixture was 
stirred for 10 minutes.  After CO2 evolution stopped, 4-amino-2-chlorophenol (0.075 g, 




and was then heated to 62 °C. Upon reaching temperature, nitrogen was removed and 
tube was capped. Heating continued overnight. 
1
H NMR (500 MHz, MeOD): δ 8.15-8.03 
(m, 3H), 7.70-7.46 (m, 1H), 7.31-7.06 (m, 1H), 6.90-6.78 (m, 1H), 4.65-4.15 (m, 1H), 









 Compound 68 (0.019 g, 
0.058 mmol) was dissolved in DMF (1.05 mL) and to the stirring solution were added 67 
(0.026 g, 0.053 mmol) and cesium carbonate (0.094 g, 0.289 mmol). The purple mixture 
was heated at 75 °C for 8 hours. Cesium carbonate was filtered off and rinsed with 
dichloromethane. Filtrate was concentrated in vacuo to afford 0.033 g (0.045 mmol, 85% 





 To a stirring solution 5-(3,5-
bis(trifluoromethyl)benzamido)pentanoic acid (0.357 g, 1.00 mmol) and 4-amino-2-
chlorophenol (0.172 g, 1.20 mmol) in DMF (2.00 mL) was added EDC (0.230 g, 1.200 
mmol).  The mixture was allowed to stir overnight at room temperature. After stirring, 
DMF was removed in vacuo, and ten milliliters of water were added.  The water layer 
was then extracted with EtOAc (3 x 30 mL). Combined organics were washed with brine 
(30 mL), dried (MgSO4), and concentrated to afford 0.566 g of an oil. The oil was 
triturated with dichloromethane, and the solid was filtered and dried in vacuo to afford 
0.263 g (0.545 mmol, 55% yield) of title compound as an off-white solid. 
1
H NMR (500 
MHz, MeOD): δ 8.44 (s, 2H), 8.15 (s, 1H), 7.61-7.59 (m, 1H), 7.24-7.21 (m, 1H), 6.86-








and cesium carbonate (0.059 g, 0.182 mmol) were added to N-(5-((3-chloro-4-
hydroxyphenyl)amino)-5-oxopentyl)-3,5-bis(trifluoromethyl)benzamide (0.016 g, 0.033 
mmol) in DMF (0.663 mL). The mixture was heated at 75 °C overnight. The cesium 
carbonate was filtered off and the DMF was removed in vacuo to afford 0.035 g (0.049 
mmol, 151% yield) of title compound. Compound was used without further purification. . 
1
H NMR (500 MHz, MeOD) δ 8.   (s, 2H), 8.1  (s, 1H), 7.98 (s, 1H), 7.69 (d, J = 2.6 
Hz, 1H), 7.37 (dd, J = 8.8, 2.6 Hz, 1H), 7.02 (d, J = 8.9 Hz, 1H), 4.19-4.14 (m, 2H), 3.89-
3.84 (m, 2H), 3.76-3.71 (m, 2H), 3.65-3.61 (m, 2H), 3.54-3.50 (m, 2H), 3.49-3.44 (m, 
2H), 3.24-3.19 (m, 2H), 2.45-2.39 (m, 2H), 1.83-1.66 (m, 4H), 1.41 (s, 9H). 
 
N-(5-((4-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)-3-chlorophenyl)amino)-5-oxopentyl)-
3,5-bis(trifluoromethyl)benzamide (203882). A solution of DCM (0.327 mL) and TFA 
(0.163 mL) (2:1) was added to a vial containing tert-butyl (2-(2-(2-(4-(5-(3,5-
bis(trifluoromethyl)benzamido)pentanamido)-2-
chlorophenoxy)ethoxy)ethoxy)ethyl)carbamate (0.035 g, 0.049 mmol). The mixture was 
stirred for 1 hour and 45 minutes at room temperature and was concentrated in vacuo. 
Crude material was purified using a CombiFlash system (5-10% Methanolic 
ammonia/DCM) to afford 0.016 g (0.026 mmol, 69% yield) of title compound as a white 
solid. TLC Rf (10% Methanolic ammonia/DCM): 0.20. 
1
H NMR (500 MHz, MeOD) δ 
8.44 (s, 2H), 8.14 (s, 2H), 7.75-7.65 (m, 1H), 7.45-7.29 (m, 1H), 7.09-6.95 (m, 1H), 4.23-
4.07 (m, 2H), 3.96-3.85 (m, 2H), 3.82-3.62 (m, 8H), 3.50-3.42 (m, 2H), 3.17-3.03 (m, 
2H), 2.47-2.37 (m, 2H), 1.84-1.63 (m, 4H). 
 
N-(4-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)-3-chlorophenyl)-1-(3,5-
bis(trifluoromethyl)benzoyl)piperidine-3-carboxamide (203883). A solution of DCM 
(0.716 ml) and TFA (0.358 ml) were added to a vial containing 69 (0.078 g, 0.107 
mmol). The mixture was stirred for 1.5 h at room temperature and was then concentrated. 
Crude material was purified using a CombiFlash system (5% Methanolic 
ammonia/DCM) to afford 0.034 g (0.046 mmol, 43% yield) of title compound as a 
yellow gummy solid. TLC Rf (10% Methanolic ammonia/DCM): 0.43. 
1
H NMR (500 




1H), 8.27-8.16 (m, 1H), 8.11 (s, 2H), 7.84-7.68 (m, 1H), 7.49-7.26 (m, 1H), 7.17-7.04 
(m, 1H), 4.51 (d, J = 13.2 Hz, 1H), 4.12 (d, J = 15.6 Hz, 2H), 3.80-3.71 (m, 2H), 3.65-
3.57 (m, 2H), 3.54-3.40 (m, 4H), 3.37 (s, 2H), 3.23-2.97 (m, 2H), 2.64 (s, 2H), 2.06-1.99 




carboxamide (203602). Compound 203883 (0.018 g, 0.024 mmol) was dissolved in 
anhydrous DMF (0.600 mL), and the clear solution was stirred for 10 minutes at room 
temperature. Biotin-OSu (0.010 g, 0.029 mmol) was added, and the reaction solution 
continued stirring overnight at room temperature. The reaction was concentrated in vacuo 
and crude material was purified using a CombiFlash system (5-10% MeOH/DCM) to 
afford 0.020 g (0.023 mmol, 96% yield) of title compound as a white solid. TLC Rf (10% 
Methanolic ammonia/DCM): 0.31. TOF MS-ESI m/z [M+H]
+
 851.9; [M+Na] 873.9. 
NMR was difficult to decipher due to rotamers, therefore heat experiment was conducted, 
increasing temperature to 30, 40, and then 50 °C. Rotamers coalesced to show desired 
product. 1H NMR (500 MHz, DMSO-d6, 50 °C): δ 9.80 (s, 1H), 8.15 (s, 1H), 8.07 (s, 
2H), 7.73 (s, 1H), 7.61 (s, 1H), 7.38 (s, 1H), 7.10 (d, J = 8.9 Hz, 1H), 6.21 (d, J = 11.1 
Hz, 2H), 4.34-4.27 (m, 1H), 4.18-4.09 (m, 3H), 3.80-3.73 (m, 2H), 3.66-3.60 (m, 2H), 
3.58-3.52 (m, 2H), 3.47-3.40 (m, 3H), 3.35-3.05 (under water peak, 2H), 2.84 (dd, J = 
12.4, 5.2 Hz, 2H), 2.12-2.05 (m, 4H), 1.85-1.72 (m, 3H), 1.69-1.59 (m, 2H), 1.58-1.43 




 Cesium carbonate (0.186 g, 0.570 
mmol) and N-(5-((3-chloro-4-hydroxyphenyl)amino)-5-oxopentyl)-3,5-
bis(trifluoromethyl)benzamide (0.050 g, 0.104 mmol) were added to a solution of 68 
(0.037 g, 0.114 mmol) in DMF (2.08 ml).  The mixture was stirred for 18 h at room 
temperature under nitrogen. After stirring overnight, the reaction was checked by TLC, 
which indicated the reaction had not completed.  Therefore it was heated at 75 °C for 3 




carbonate was filtered off and resulting filtrate was concentrated in vacuo to afford 0.070 
g (0.098 mmol, 95% yield) of title compound. Compound was used without further 
purification. 
1
H NMR (500 MHz, MeOD) δ 8.   (s, 2H), 8.1  (s, 1H), 7.98 (s, 1H), 7.69 
(d, J = 2.6 Hz, 1H), 7.37 (dd, J = 8.8, 2.6 Hz, 1H), 7.02 (d, J = 8.9 Hz, 1H), 4.19-4.14 (m, 
2H), 3.89-3.84 (m, 2H), 3.76-3.71 (m, 2H), 3.65-3.61 (m, 2H), 3.54-3.50 (m, 2H), 3.49-
3.44 (m, 2H), 3.24-3.19 (m, 2H), 2.45-2.39 (m, 2H), 1.83-1.66 (m, 4H), 1.41 (s, 9H). 
 
N-(5-((4-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)-3-chlorophenyl)amino)-5-oxopentyl)-
3,5-bis(trifluoromethyl)benzamide. A solution of dichloromethane (0.327 ml) and TFA 
(0.163 mL) was added to a vial containing tert-butyl (2-(2-(2-(4-(5-(3,5-
bis(trifluoromethyl)benzamido)pentanamido)-2-
chlorophenoxy)ethoxy)ethoxy)ethyl)carbamate (0.035 g, 0.049 mmol).  The mixture was 
stirred for 1 hour and 45 minutes at room temperature. The reaction was concentrated and 
dried using high vacuum to yield 0.035 g (0.048 mmol, 98% yield) of title compound as a 
yellow oil.  Compound was used without further purification. 
1
H NMR (500 MHz, 
MeOD) δ 8.   (s, 2H), 8.1  (s, 2H), 7.75-7.65 (m, 1H), 7.45-7.29 (m, 1H), 7.09-6.95 (m, 
1H), 4.23-4.07 (m, 2H), 3.96-3.85 (m, 2H), 3.82-3.62 (m, 8H), 3.50-3.42 (m, 2H), 3.17-






bis(trifluoromethyl)benzamide (0.037 g, 0.051 mmol) was dissolved in anhydrous DMF 
(1.3 mL) and DIPEA (0.009 mL, 0.051 mmol) was added to the stirring solution. The 
solution continued for 10 minutes and Biotin-OSu (0.017 g, 0.051 mmol) was added.  
The mixture continued stirring overnight at room temperature under nitrogen. The 
solution was concentrated in vacuo. Crude material was purified by column 
chromatography (10-15% MeOH/DCM) followed by trituration with CHCl3 to afford 
0.017 g (0.020 mmol, 39% yield) of title compound as an off-white solid. TLC Rf (10% 
MeOH/DCM): 0.32. TOF MS-ESI m/z [M+H]
+
 839.9; [M+Na] 861.9. 
1




MHz, DMSO-d6): δ 9.91 (s, 1H), 8.98 (t, J = 5.4 Hz, 1H), 8.50 (s, 2H), 8.31 (s, 1H), 7.83 
(t, J = 5.6 Hz, 1H), 7.80-7.77 (m, 1H), 7.41-7.36 (m, 1H), 7.11-7.08 (m, 1H), 6.42 (s, 
1H), 6.36 (s, 1H), 4.32-4.27 (m, 1H), 4.14-4.08 (m, 3H), 3.77-3.73 (m, 2H), 3.63-3.59 
(m, 2H), 3.55-3.50 (m, 2H), 3.42-3.38 (m, 2H), 3.18 (q, J = 6.0 Hz, 2H), 3.11-3.05 (m, 
1H), 2.84-2.77 (m, 1H), 2.59-2.53 (m, 1H), 2.36-2.29 (m, 2H), 2.08-2.02 (m, 2H), 1.70-
1.19 (m, 12H). HPLC (gradient A): ret time = 6.55 min; purity = 99%. 
 
tert-butyl 3-((4-chloro-3-methoxyphenyl)carbamoyl)piperidine-1-carboxylate. 
Prepared using 43 according to Procedure D, but using 1.5 eq of aniline. Crude material 
was purified using a CombiFlash system (35% EtOAc/Hex) to afford 0.139 g (0.377 
mmol, 86% yield) of title compound as a clear oil. TLC Rf (50% EtOAc/Hex): 0.48. 
1
H 
NMR (500 MHz, CDCl3): δ 8.61 (bs, 1H), 7.62 (d, J = 2.4 Hz, 1H), 7.28-7.23 (m, 1H), 
6.93 (s, 1H), 3.89 (s, 3H), 3.83-3.18 (m, 1H), 2.52 (s, 1H), 2.12 (s, 1H), 1.90 (s, 1H), 1.63 
(s, 1H), 1.47 (s, 10H). 
 
N-(4-chloro-3-methoxyphenyl)piperidine-3-carboxamide. tert-butyl 3-((4-chloro-3-
methoxyphenyl)carbamoyl)piperidine-1-carboxylate (134 mg, 0.363 mmol) was 
dissolved in DCM (2.40 mL) and placed in an ice bath at approximately -5 °C. TFA (1.20 
mL) was slowly added and the solution continued to stir at -5 °C for 1 hour. The solution 
was poured into 20 mL of cooled 2M NaOH. The mixture was extracted with DCM (3 x 
20 mL), and the combined organic layers were dried (MgSO4) and concentrated in vacuo 
to afford 0.073 g (0.272 mmol, 75% yield) of title compound as a yellow solid. No 
further purification was performed. 
1
H NMR (500 MHz, CDCl3): δ 10.75 (s, 1H), 7.67 (d, 
J = 2.4 Hz, 1H), 7.28-7.23 (m, 1H), 6.94-6.82 (m, 1H), 3.92 (s, 3H), 3.36-3.22 (m, 1H), 
3.13-3.05 (m, 1H), 2.95 (dd, J = 12.0, 3.2 Hz, 1H), 2.81-2.72 (m, 1H), 2.59-2.53 (m, 1H), 
2.20-1.99 (m, 2H), 1.85-1.71 (m, 2H), 1.65-1.52 (m, 1H). 
 
N-(3-chloro-4-methoxyphenyl)piperidine-3-carboxamide (206117). Prepared using N-
(4-chloro-3-methoxyphenyl)piperidine-3-carboxamide according to Procedure D, but 
using 1.1 eq of EDC and DMAP. Crude material was triturated with DCM to afford 0.011 




477.2; [M+23] 499.1. HPLC (gradient A): ret time = 7.36; purity = >95%. 
1
H NMR (400 
MHz, DMSO-d6): 1. :1.0 mixture of rotamers, δ 10.21 (rotamer 1, s), 10.01 (rotamer 2, s, 
1H), 7.91-7.00 (m, 12H), 4.62-4.13 (m, 1H), 3.89-3.72 (m, 3H), 3.72-3.53 (m, 1H), 3.20-
2.91 (m, 2H), 2.66-2.55 (m, 1H), 2.01 (s, 1H), 1.92-1.64 (m, 2H), 1.59-1.32 (m, 1H). 
 
tert-butyl 3-((3-chloro-4-methoxyphenyl)carbamoyl)piperidine-1-carboxylate. 
Prepared using 43 according to Procedure D, but using 1.5 eq of aniline. Crude material 
was purified using a CombiFlash system (35% EtOAc/Hex) to afford 0.139 g (0.377 
mmol, 86% yield) of title compound as a clear oil. TLC Rf (50% EtOAc/Hex): 0.48. 
1
H 
NMR (500 MHz, CDCl3): δ 8. 1 (s, 1H), 7.67 (s, 1H), 7.   (dd, J = 8.8, 2.6 Hz, 1H), 
6.85 (d, J = 8.8 Hz, 1H), 3.90-3.10 (m, 7H), 2.49 (s, 1H), 2.11 (s, 1H), 1.89 (s, 1H), 1.63 
(s, 1H), 1.54-1.43 (m, 10H). 
 
N-(3-chloro-4-methoxyphenyl)piperidine-3-carboxamide. tert-butyl 3-((3-chloro-4-
methoxyphenyl)carbamoyl)piperidine-1-carboxylate (134 mg, 0.363 mmol) was 
dissolved in DCM (2.40 mL) and placed in an ice bath at approximately -5 °C. TFA (1.20 
mL) was slowly added and the solution continued to stir at -5 °C for 1 hour. The solution 
was poured into 20 mL of cooled 2M NaOH. The mixture was extracted with DCM (3 x 
20 mL), and the combined organic layers were dried (MgSO4) and concentrated in vacuo 
to afford 0.063 g (0.234 mmol, 64% yield) of title compound as a light brown solid. No 
further purification was performed. 
1
H NMR (500 MHz, CDCl3): δ 10.60 (s, 1H), 7.60 (d, 
J = 2.5 Hz, 1H), 7.50-7.48 (m, 1H), 6.87 (d, J = 8.8 Hz, 1H), 3.88 (s, 3H), 3.29-3.23 (m, 
1H), 3.11-3.05 (m, 1H), 2.92 (dd, J = 11.9, 3.3 Hz, 1H), 2.73 (td, J = 10.9, 3.1 Hz, 1H), 




(206118). Prepared using N-(3-chloro-4-methoxyphenyl)piperidine-3-carboxamide 
according to Procedure D, but using 1.1 eq of EDC and DMAP. Crude material was using 
a CombiFlash system (65% EtOAc/Hex) to afford 0.040 g (0.084 mmol, 73% yield) of 




(gradient A): ret time = 7.17; purity = >95%. 
1
H NMR (400 MHz, DMSO-d6): 1.3:1.0 
mixture of rotamers, δ 10.06 (rotamer 1, s), 9.87 (rotamer 2, s, 1H), 7.90-7.29 (m, 11H), 
7.16-7.00 (m, 1H), 4.60-4.15 (m, 1H), 3.81 (s, 3H), 3.70-3.50 (m, 1H), 3.21-2.90 (m, 






tert-butyl (4-chloro-3-(prop-2-yn-1-yloxy)phenyl)carbamate (82). To a mixture of 81 
(0.144 g, 0.591 mmol) and potassium carbonate (0.245 g, 1.773 mmol) in dioxane (1.45 
mL) was added 3-bromoprop-1-yne (0.111 ml, 1.477 mmol). The reaction mixture was 
then heated to 80 °C for 48 h in a sealed tube. The reaction mixture was concentrated and 
was diluted with water (10 mL). The aqueous layer was extracted with dichloromethane 
(3 x 10 mL). The organics were washed with water (2 x 10 mL), dried (MgSO4) and 
concentrated. Crude material was purified using a 12 g SiliaSep cartridge and was 
separated using a Biotage unit. Eight milliliter fractions were collected  at 20 mL/min 
using a threshold of 20 mAU for collection. Gradient employed 100% Hexanes for 3 
CVs; ramping 0-20% over 15 CVs; and holding at 20% for 5 CVs. Fractions 4-8 (Rf: 0.35 
in 20% Ethyl acetate in Hexanes) were combined and concentrated to yield 0.108 g of 
title compound as a white solid. 
1
H NMR (400 MHz, DMSO-d6): δ 9.51 (s, 1H), 7.   (d, 
J = 1.9 Hz, 1H), 7.29 (d, J = 8.7 Hz, 1H), 7.06 (dd, J = 8.7, 1.9 Hz, 1H), 4.81 (d, J = 2.3 
Hz, 2H), 3.63 (t, J = 2.3 Hz, 1H), 1.47 (s, 9H). 
 
4-chloro-3-(prop-2-yn-1-yloxy)aniline (83). Compound 82 (0.105 g, 0.373 mmol) was 
dissolved in dichloromethane (2.50 mL) and cooled to -10 °C. TFA (1.25 mL) was added 
slowly to the cooled solution. The solution was stirred at -5 °C for 45 minutes and was 
then poured into 10 mL of cooled 2M NaOH. The cooled basic solution was extracted 
with dichloromethane (3 x 10 mL), and the combined organics were dried (MgSO4) and 
concentrated to afford 0.064 g (0.352 mmol) of title compound as a yellow solid. No 
further purification was performed. 
1
H NMR (400 MHz, DMSO-d6): δ 6.99 (d, J = 8.5 
Hz, 1H), 6.38 (d, J = 2.1 Hz, 1H), 6.17 (dd, J = 8.5, 2.2 Hz, 1H), 5.29 (s, 2H), 4.75 (d, J = 






carboxylate (84). Compound 83 (0.061 g, 0.336 mmol) was dissolved in 
dichloromethane (3.36 mL), and to the stirring solution was added EDC (0.097 g, 0.504 
mmol) followed by DMAP (0.062 g, 0.504 mmol) and 43 (0.085 g, 0.369 mmol). The 
mixture was stirred at room temperature under nitrogen overnight. Additional 
dichloromethane (6.7 mL) was added to the solution, and it was washed with saturated 
aqueous NaHCO3 (10 mL), 1M HCl (10 mL), and then brine (10 mL) and was dried 
(MgSO4) and concentrated to afford 0.109 g (0.277 mmol, 83% yield) of title compound 
as a white solid. No further purification was performed. 
1
H NMR (400 MHz, DMSO-d6): 
δ 10.16 (s, 2H), 7.60 (d, J = 1.7 Hz, 3H), 7.34 (d, J = 8.6 Hz, 2H), 7.23 (dd, J = 8.7, 1.8 
Hz, 3H), 4.84 (d, J = 1.7 Hz, 6H), 4.15-3.80 (m, 2H), 3.66-3.63 (m, 1H), 3.10-2.70 (m, 
2H), 2.44 (tt, J = 10.8, 3.8 Hz, 1H), 1.97-1.87 (m, 1H), 1.77-1.53 (m, 2H), 1.43-1.30 (m, 
10H). 
 
N-(4-chloro-3-(prop-2-yn-1-yloxy)phenyl)piperidine-3-carboxamide (85). Compound 
84 (0.107 g, 0.272 mmol) was dissolved in dichloromethane (1.82 mL) and cooled to -5 
°C. TFA (0.910 mL) was added slowly to the cooled solution. Solution was stirred at -5 
°C. After 1 hour, the solution was poured into 5 mL of cooled 2M NaOH. The cooled 
basic solution was extracted with dichloromethane (3 x 5 mL), and the organic layers 
were combined, dried (MgSO4), and concentrated to afford 0.050 g (0.171 mmol, 63% 
yield) of title compound as a white solid. No further purification was performed. 
1
H 
NMR (400 MHz, DMSO-d6): δ 10.11 (s, 1H), 7.65-7.57 (m, 1H), 7.33 (d, J = 8.6 Hz, 
1H), 7.22 (dd, J = 8.6, 1.7 Hz, 1H), 4.83 (d, J = 1.8 Hz, 2H), 3.64 (s, 1H), 3.06-2.99 (m, 
1H), 2.90-2.83 (m, 1H), 2.66-2.57 (m, 6H), 2.48-2.38 (m, 2H), 1.92-1.83 (m, 1H), 1.68-
1.50 (m, 2H), 1.45-1.33 (m, 1H). 
 
1-(3-benzoylbenzoyl)-N-(4-chloro-3-(prop-2-yn-1-yloxy)phenyl)piperidine-3-
carboxamide (206454). Prepared using 43 and 85 according to Procedure D. Crude 
material was purified using a Biotage FlashMaster Personal
+
 system (30-100% 




solid. TLC Rf (50% EtOAc/Hex): 0.18. Agilent ESI(+) m/z [M+H]
+ 501.0; [M+Na] 
523.0. HPLC (gradient A): ret time = 7.40 min; purity = >95%.  
1
H NMR (400 MHz, 
DMSO-d6): 1. :1.0 mixture of rotamers, δ 10.22 (rotamer 1, s), 10.02 (rotamer 2, s, 1H), 
7.98-7.44 (m, 10H), 7.40-7.03 (m, 2H), 4.87-4.75 (m, 1H), 4.58-4.14 (m, 1H), 3.76-3.49 
(m, 2H), 3.17-2.83 (m, 2H), 1.98 (s, 1H), 1.89-1.60 (m, 2H), 1.57-1.31 (m, 1H). 
 
1-(3-benzoylbenzoyl)-N-(4-chloro-3-(2-(prop-2-yn-1-yloxy)ethoxy)phenyl)piperidine-
3-carboxamide (206558). Agilent ESI(+) m/z [M+H]+ 545.0; [M+Na] 567.0. HPLC 
(gradient A): ret time = 7.46 min; purity = >95%. 
1
H NMR (400 MHz, DMSO-d6): 
1.4:1.0 mixture of rotamers, δ 10.16 (rotamer 1, s), 9.97 (rotamer 2, s, 1H), 7.92-7.02 (m, 
12H), 4.52 (d, J = 9.5 Hz, 1H), 4.32-4.20 (m, 2H), 4.13 (bs, 2H), 3.81 (s, 3H), 3.73-3.53 
(m, 1H), 3.48-3.44 (m, 1H), 3.21-2.88 (m, 2H), 2.65-2.55 (m, 1H), 2.09 (s, 1H), 1.90-
1.65 (m, 2H), 1.60-1.32 (m, 1H). 
 
N-(3-benzoylphenyl)-1-(3-methoxy-5-(trifluoromethyl)benzoyl)piperidine-3-
carboxamide (206448). Waters ESI(+) m/z [M+H]+ 511.3; [M+Na] 533.3. HPLC 
(gradient A): ret time = 7.71 min; purity = >95%. 
1
H NMR (400 MHz, DMSO-d6): 
1.3:1.0 mixture of rotamers, δ 10. 1 (rotamer 1, s), 10.10 (rotamer 2, s, 1H), 8.10-7.18 
(m, 12H), 4.58-4.10 (m, 1H), 3.93-3.75 (m, 3H), 3.63-3.40 (m, 1H), 3.17-2.93 (m, 2H), 
2.70-2.55 (m, 1H), 2.08-1.97 (m, 1H), 1.90-1.65 (m, 2H), 1.57-1.35 (m, 1H). 
 
N-(3-benzoylphenyl)-1-(3-(prop-2-yn-1-yloxy)-5-
(trifluoromethyl)benzoyl)piperidine-3-carboxamide (206559). Agilent ESI(+) m/z 
[M+H]+ 535.1; [M+Na] 557.0. HPLC (gradient A): ret time = 7.74 min; purity = 95%. 
1
H NMR (400 MHz, DMSO-d6): 1.6:1.0 mixture of rotamers, δ 10.28 (rotamer 1, s), 
10.06 (rotamer 2, s, 1H), 8.11-7.22 (m, 12H), 5.00-4.85 (m, 1H), 4.55-4.08 (m,1H), 3.71-
3.34 (m, 2H), 3.17-2.88 (m, 2H), 2.62-2.51 (m, 1H), 2.02-1.97 (m, 1H), 1.87-1.60 (m, 






carboxamide (206449). Agilent ESI(+) m/z [M+H]+ 482.0; [M+Na] 504.0. HPLC 
(gradient A): ret time = 8.01 min; purity = >95%. 
1
H NMR (400 MHz, DMSO-d6): 
1.3:1.0 mixture of rotamers, δ 10. 5 (rotamer 1, s), 10.1  (rotamer 2, s, 1H), 8.00-7.66 
(m, 1H), 7.50-7.12 (m, 5H), 4.58-4.00 (m, 1H), 3.90-3.77 (m, 3H), 3.63-3.69 (m, 1H), 
3.09 (d, J = 37.6 Hz, 2H), 2.70-2.55 (m, 1H), 2.07-1.96 (m, 1H), 1.91-1.65 (m, 2H), 1.60-
1.37 (m, 1H). 
Methyl 3-hydroxy-5-(trifluoromethyl)benzoate (96). 3-hydroxy-5-
(trifluoromethyl)benzoic acid (95) (0.220 g, 1.067 mmol) was dissolved in methanol 
(1.60 mL) and was cooled to 0 °C. Thionyl chloride (0.117 ml, 1.601 mmol) was added 
slowly. Following addition, the bath was allowed to warm to room temperature. The 
reaction continued stirring at room temperature overnight. The reaction was concentrated 
in vacuo and was dissolved in ethyl acetate (5 mL). The organic layer was then washed 
with saturated NaHCO3 (5 mL), followed by brine (5 mL). The organic layer was then 
dried (MgSO4), filtered, and concentrated to afford 0.193 g (0.877 mmol, 82% yield) of 
title compound as an off-white solid. No further purification was performed. 
1
H NMR 
(400 MHz, DMSO-d6): δ 10.61 (s, 1H), 7.61-7.54 (m, 2H), 7.28 (t, J = 2.0 Hz, 1H), 3.84 
(s, 3H). 
 
Methyl 3-(prop-2-yn-1-yloxy)-5-(trifluoromethyl)benzoate (97). To a mixture of 96 
(0.181 g, 0.822 mmol) in dioxane (2.05 mL) was added 3-bromoprop-1-yne (0.155 ml, 
2.06 mmol). The reaction mixture was then heated to 80 °C in a sealed tube. After stirring 
overnight, the reaction mixture was concentrated and was diluted with water (10 mL). 
The aqueous layer was extracted with DCM (3 x 10 mL). The combined organics were 
washed with water (10 mL), dried (MgSO4), and concentrated in vacuo to afford 0.154 g 
(0.596 mmol, 73% yield) of title compound as a yellow oil. No further purification was 
performed. 
1
H NMR (400 MHz, DMSO-d6): δ 7.85-7.76 (m, 2H), 7.63 (t, J = 2.0 Hz, 





3-(prop-2-yn-1-yloxy)-5-(trifluoromethyl)benzoic acid (98). A solution of sodium 
hydroxide (0.061 g, 1.521 mmol), Methanol (1.20 mL), and Water (0.400 mL) was added 
to a vial containing 97 (0.151 g, 0.585 mmol). The reaction was stirred for 3 hours and 
was then concentrated in vacuo. Residue was acidified using 2N HCl (5 mL). The 
aqueous layer was extracted with DCM (3 x 5 mL). The combined organics were dried 
(MgSO4) and concentrated to afford 0.107 g (0.438 mmol, 75% yield) of title compound 
as a white solid. No further purification was performed. 
1
H NMR (400 MHz, DMSO-d6): 
δ 1 .59 (s, 1H), 7.8 -7.75 (m, 2H), 7.59 (t, J = 2.0 Hz, 1H), 5.01 (d, J = 2.3 Hz, 3H), 3.66 


















Compound 110 (0.075 g, 0.445 mmol) was dissolved in dichloromethane (4.45 mL), and 
to the stirring solution was added EDC (0.128 g, 0.667 mmol) followed by DMAP (0.082 
g, 0.667 mmol) and 43 (0.112 g, 0.489 mmol). The mixture was stirred at room 
temperature under nitrogen overnight. Additional dichloromethane (5.55 mL) was added 
to the solution, and it was washed with saturated aqueous NaHCO3 (10 mL), 1M HCl (10 
mL), and then brine (10 mL). Organics were dried (MgSO4) and concentrated to afford 
0.149 g (0.392 mmol, 88% yield) of title compound as a fluffy yellow solid. No further 
purification was performed. 
1
H NMR (400 MHz, DMS)-d6): δ 10.28 (s, 1H), 7.86 (d, J = 
2.0 Hz, 1H), 7.42 (d, J = 8.7 Hz, 1H), 7.33 (dd, J = 8.8, 2.1 Hz, 1H), 4.15-3.77 (m, 2H), 
3.12-2.73 (m, 2H), 2.44 (tt, J = 10.5, 3.6 Hz, 1H), 1.97-1.88 (m, 1H), 1.77-1.54 (m, 2H), 





N-(3-azido-4-chlorophenyl)piperidine-3-carboxamide (112). Compound 111 (0.148 g, 
0.390 mmol) was dissolved in dichloromethane (2.60 mL) and cooled to -5 °C. TFA 
(1.30 mL) was added slowly to the cooled solution. Solution was stirred at -5 °C for 1 
hour and was then poured into 10 mL of cooled 2M NaOH. The cooled basic solution 
was extracted with dichloromethane (3 x 10 mL), and the organic layers were combined, 
dried (MgSO4), and concentrated in vacuo to afford 0.094 g (0.336 mmol, 86% yield) of 
title compound as an orange solid. No further purification was performed. 
1
H NMR (400 
MHz, DMSO-d6): δ 10.21 (s, 1H), 7.87 (d, J = 1.4 Hz, 1H), 7.40 (d, J = 8.7 Hz, 1H), 7.33 
(dd, J = 8.8, 2.0 Hz, 1H), 3.06-2.98 (m, 1H), 2.89-2.81 (m, 1H), 2.65-2.54 (m, 1H), 2.50-
2.35 (m, 2H), 1.93-1.83 (m, 1H), 1.66-1.49 (m, 2H), 1.45-1.30 (m, 1H). 
 
N-(3-azido-4-chlorophenyl)-1-(3-(prop-2-yn-1-yloxy)-5-
(trifluoromethyl)benzoyl)piperidine-3-carboxamide (206569). Prepared using 112 and 
98 according to Procedure D. Crude material was purified using a Biotage FlashMaster 
Personal+ (40% EtOAc/Hex) to afford 0.055 g (0.109 mmol, 42% yield) of title 
compound as a pale yellow solid HPLC (gradient A): ret time = 8.01 min; purity = >95%. 
ESI(+) m/z [M+Na] 527.9. 
1
H NMR (400 MHz, DMSO-d6): 1.5:1.0 mixture of rotamers, 
δ 10. 6 (rotamer 1, s), 10.1  (rotamer 2, s, 1H), 7.90-7.72 (m, 1H), 7.51-7.12 (m, 5H), 
5.06-4.88 (m, 2H), 4.63-4.06 (m, 1H), 3.73-3.35 (m, 2H), 3.20-2.92 (m, 2H), 2.65-2.52 
(m, 1H), 2.09-1.99 (m, 1H), 1.90-1.64 (m, 2H), 1.47 (s, 1H). 
 
1-(3-azido-5-(trifluoromethyl)benzoyl)-N-(4-chloro-3-(prop-2-yn-1-
yloxy)phenyl)piperidine-3-carboxamide (206452). Agilent ESI(+) m/z [M+H]+ 506.0; 
[M+Na] 528.0. HPLC (gradient A): ret time = 7.75 min; purity = >90%. 
1
H NMR (400 
MHz, DMSO-d6): 1.2:1.0 mixture of rotamers, δ 10.2  (rotamer 1, s), 10.02 (rotamer 2, s, 
1H), 7.68-6.99 (m, 6H), 4.90-4.75 (m, 2H), 4.58-4.07 (m, 1H), 3.58-3.40 (m, 2H), 3.21-
2.89 (m, 2H), 2.74-2.54 (m, 1H), 2.03 (s, 1H), 1.88-1.64 (m, 2H), 1.46 (bs, 1H). 
 
tert-butyl (5-((3-benzoylphenyl)amino)-5-oxopentyl)carbamate (115). 5-((tert-
butoxycarbonyl)amino)pentanoic acid (0.050 g, 0.230 mmol)was dissolved in 




DMAP (0.042 g, 0.345 mmol) then (3-aminophenyl)(phenyl)methanone (0.045 g, 0.230 
mmol). The reaction was stirred overnight at room temperature. The reaction was then 
diluted with additional DCM to a volume of 5 mL. Organics were washed with 1N HCl 
(5 mL) followed by saturated NaHCO3 (5 mL) and was dried (MgSO4) and concentrated 
in vacuo to afford 0.080 g of light brown solid. No further purification was performed. 
1
H 
NMR (400 MHz, CDCl3): δ 7.80-7.15 (m, 9H), 3.03-2.87 (m, 2H), 2.26-2.11 (m, 2H), 
1.60-1.45 (m, 2H), 1.40-1.25 (m, 2H). 
 
5-amino-N-(3-benzoylphenyl)pentanamide (116). Compound 115 was dissolved in 
dichloromethane (1.35 mL) and the solution was cooled to approximately -10 °C. To the 
cooled stirring solution was added TFA (0.675 mL). The reaction mixture continued 
stirring at -7 °C for 45 minutes. The solution was added to a cooled 2M NaOH solution 
(10 mL). The mixture was then extracted with additional dichloromethane (3 x 5 mL). 
The organics were combined, dried (MgSO4), and concentrated in vacuo to afford 0.039 
g (0.132 mmol, 65% yield) of title compound. 
1
H NMR (400 MHz, DMSO-d6): δ 10.2  
(s, 1H), 8.07 (s, 1H), 7.90 (d, J = 8.2, 1H), 7.76-7.65 (m, 3H), 7.60-7.33 (m, 4H), 2.72-
2.60 (m, 2H), 2.38-2.29 (m, 2H), 1.68-1.57 (m, 2H), 1.54-1.40 (m, 2H). 
 
5-amino-N-(3-benzoylphenyl)pentanamide (117). Compound 116 (0.080 g, 0.202 
mmol) was dissolved in DCM (1.35 mL) and the solution was cooled to approximately -
10 °C. To the cooled stirring solution was added TFA (0.675 mL). The reaction mixture 
continued stirring at -7 °C and the reaction's progression was monitored by TLC, which 
indicated completion after 45 minutes. Therefore, the solution was added to a cooled 2M 
NaOH solution (10 mL). The mixture was then extracted with additional DCM (3 x 5 
mL). The combined organics were dried (MgSO4) and concentrated in vacuo to afford 
0.039 g (0.132 mmol, 65% yield) of title compound. 
1
H NMR (400 MHz, DMSO-d6): δ 
10.23 (s, 1H), 8.07 (s, 1H), 7.90 (d, J = 8.2, 1H), 7.76-7.65 (m, 3H), 7.60-7.33 (m, 4H), 
2.72-2.60 (m, 2H), 2.38-2.29 (m, 2H), 1.68-1.57 (m, 2H), 1.54-1.40 (m, 2H). 
 
N-(5-((3-benzoylphenyl)amino)-5-oxopentyl)-3-(prop-2-yn-1-yloxy)-5-




Procedure D, but using 0.10 mmol of each to afford 0.017 g (0.033 mmol, 40% yield) of 
title compound as a white solid. No further purification was performed. ESI(+) m/z 
[M+H]+ 522.9; [M+Na] 544.9. HPLC (gradient A): ret time = 7.53 min; purity = >90%. 
1
H NMR (400 MHz, DMSO-d6): δ 10.1  (s, 1H), 8.70 (t, J = 5.5 Hz, 1H), 8.01 (t, J = 1.7 
Hz, 1H), 7.94-7.87 (m, 1H), 7.80 (s, 1H), 7.76-7.71 (m, 3H), 7.71-7.65 (m, 1H), 7.60-
7.54 (m, 2H), 7.52-7.44 (m, 1H), 7.39 (dt, J = 7.7, 1.2 Hz, 1H), 4.98 (d, J = 2.4 Hz, 2H), 
3.64 (t, J = 2.3 Hz, 1H), 3.30-3.27 (m, 2H), 3.22 (s, 2H), 2.36 (t, J = 7.1 Hz, 2H), 1.69-
1.52 (m, 4H). 
 
(3,5-bis(trifluoromethyl)phenyl)(4-((4-chlorophenyl)amino)piperidin-1-
yl)methanone (102441). Compound 22 (0.124 g, 0.366 mmol) was dissolved in 1,2-
dichloroethane (1.3 mL) and was treated with 4-chloroaniline (0.047 g, 0.366 mmol) 
followed by Sodium triacetoxyborohydride (0.109 g, 0.512 mmol) and Acetic acid (0.021 
mL, 0.366 mmol). The mixture was stirred overnight at room temperature. Reaction was 
then basified to pH ~9 using 2M NaOH and the aqueous layer was extracted with ether (3 
x 10 mL). Combined extracts were washed with brine (20 mL), dried, and concentrated. 
Crude material was purified using flash chromatography (5-80% EtOAc/Hex) to afford 
0.044 g (0.098 mmol, 27% yield) of title compound as a clear oil. TLC Rf (50% 
EtOAc/Hex): 0.74. TOF MS-ESI m/z [M+H]
+
 451.1; [M+Na] 473.1. HPLC (gradient A): 
ret time = 7.96 min; purity = 99%. 
1
H NMR (500 MHz, d6-DMSO): δ 8.22 (s, 1H), 8.12 
(s, 2H), 7.08 (d, J = 8.7 Hz, 2H), 6.61 (d, J = 8.8 Hz, 2H), 5.74 (d, J = 7.8 Hz, 1H), 4.34 
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